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Abstract 
 
Oxidised forms of low-density lipoprotein (LDL) are widely belived to be involved in the 
pathogenesis of atherogenesis, but large clinical trials have not shown protection of 
cardiovascular disease by antioxidants. Recently, it has been shown that LDL can be 
oxidised by iron in the lysosomes of macrophages. We hypothesised that antioxidants 
would protect  LDL against oxidation less well at lysosomal pH than at pH 7.4. 
LDL was enriched with α-tocopherol by incubating plasma with α-tocopherol and isolating 
the LDL. This enrichment inhibited LDL oxidation by copper ions (Cu2+) at pH 7.4 ,but not 
at pH 4.5, as shown  by spectrophotometry at 234 nm to measure conjugated dienes  and 
by HPLC to measure individual oxidised lipids. α-Tocopherol enrichment did not inhibit LDL 
oxidation by Fe3+ (2, 5 or 20 µM) at pH 4.5 , but  inhibite it by 5 or 20 µM Fe2+, but not 2 
µM Fe2+. This might help to explain why α-tocopherol did not inhibit cardiovascular 
diseases in the large clinical trials.  
The antioxidant tempol and probucol inhibited the late phase of LDL oxidation by Fe2+  and 
Cu2+ at pH 4.5 more than the early phase, possibly because they were located mainly in 
the phospholipid monolayer of LDL, rather than in the cholesteryl ester of the LDL particle. 
There is a suggestion that lysosomal dysfunction plays an important role in atherosclerosis. 
The lysosomal oxidation of  LDL aggregated by sphingomelinase resulted in the production 
of the advanced lipid peroxidation product (ceroid). 
α-Tocopherol enrichment of macrophages did not protect them against apoptosis induced 
by H2O2. The work presented here also demonstrated LDL oxidised Fe2+ at pH 4.5, 
decreased endothelium-dependent vasodilatation of rat aortic rings. This suggests that 
 VI 
lysosomally oxidised LDL released from dead cells in atherosclerotic lesions might damage 
the endothelium. Taken togather, these results suggest that inhibiting the oxidation of 
LDLin lysosomes might be a therapy of atherosclerosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   VII 
Contents 
Acknowledgements ............................................................................................................................... III 
Posters and Publications ....................................................................................................................... IV 
Chapter 1 ................................................................................................................................................ 1 
Introduction ........................................................................................................................................... 1 
1. Atherosclerosis ................................................................................................................................... 2 
1.1 The scale of the problem .............................................................................................................. 2 
1.2 Pathogenesis of Atherosclerosis .................................................................................................. 4 
1.2.1 Histology of normal arteries .................................................................................................. 4 
1.2.1.2 Endothelial cells structure ...................................................................................................... 5 
1. 3 Atherosclerosis process ........................................................................................................... 8 
1. 3.1 Modification of LDL within Atherosclerotic lesion ............................................................. 11 
1. 3.2 Endocytosis of oxidised LDL by macrophages .................................................................... 14 
1.3.3 LDL oxidation by transition metals and heme ..................................................................... 18 
1.3.5 Lipid peroxidation ................................................................................................................... 23 
1.3.6 LDL uptake within acidification environment ...................................................................... 26 
1.3.7 LDL oxidation inside lysosomes ........................................................................................... 28 
1.4 Lysosomes .................................................................................................................................. 30 
1.4.4 The role of lysosomes in atherosclerosis ............................................................................ 34 
1.5 Transition metals in atherosclerosis ............................................................................................... 36 
1.5.1 Iron Homeostasis and Regulation ........................................................................................... 36 
1.5.2 Iron and atherosclerosis ...................................................................................................... 38 
1.5.3 Studies of stored iron level and CVD effects ........................................................................... 39 
1.5.4 Mechanisms of iron toxicity in atherosclerosis ....................................................................... 41 
1.5.5 Copper concentration in atherosclerotic plaque .................................................................... 42 
1.6.1 Mechanisms of antioxidant protection in the body ............................................................ 44 
1.6.2 EDTA .................................................................................................................................... 46 
1.6.3   Vitamin E (α -tocopherol) ...................................................................................................... 48 
1.6.3.1 Biological Functions of Vitamin E ......................................................................................... 52 
1.6.3.3 Improvement of Endothelial Function by VitaminE ......................................................... 53 
1.6.3.5 Antioxidant actions by Vitamin E ..................................................................................... 55 
 VIII 
1.6.4 Tempol .................................................................................................................................... 55 
1.6.5 Probucol .................................................................................................................................. 58 
1.7 Thesis aims and hypothesis ............................................................................................................ 60 
Chapter 2 .............................................................................................................................................. 61 
Materials and methods ........................................................................................................................ 61 
2.1.1 Laboratory reagents ................................................................................................................ 62 
General laboratory reagents and companies from which they were purchased are listed below
 ...................................................................................................................................................... 62 
1.2.2 Laboratory equipments ........................................................................................................... 64 
1.2.3 General solutions .................................................................................................................... 65 
HPLC oxidation mobile phase ........................................................................................................... 67 
2.2. LDL ................................................................................................................................................. 68 
2.2.1 Isolation of LDL ........................................................................................................................ 68 
2.2.2 Measuring LDL protein concentration ..................................................................................... 69 
2.2.3 Aggregation of LDL with sphingomyelinase ............................................................................ 70 
2.2.4 Enrichment of LDL with α-tocopherol ..................................................................................... 70 
2.2.5 Measurement of α- tocopherol in oxidised LDL ...................................................................... 71 
2.2.6 Cuvette preparation ................................................................................................................ 72 
2.2.7 Removing EDTA from LDL by dialysis ...................................................................................... 73 
2.2.8 Monitoring LDL oxidation by the formation of conjucated dienes ......................................... 73 
2.2.9 Preparation of Lipoprotein -Deficient fetal calf serum ........................................................... 74 
2.3 Monitoring of ferrous iron levels ............................................................................................... 75 
2.4 Monitoring of cuprous copper levels ......................................................................................... 75 
2.5 Measurement of lipid hydroperoxide ........................................................................................ 76 
2.5.2 HPLC analysis ........................................................................................................................... 78 
Table2.1 Target lipid species and analysis conditions for HPLC ....................................................... 79 
2.6 Cell culture ................................................................................................................................. 81 
2.6.1 Human THP-1 cells .................................................................................................................. 81 
2.6.2 Cryopreservation of THP-1 cells .............................................................................................. 82 
2.6.3 Differentiation of THP-1 cell into macrophages ...................................................................... 83 
2.6.4 Culturing THP-1 cells to detect ceroid ..................................................................................... 83 
2.6.5 Enriching THP-1 cells with α-tocopherol ................................................................................. 84 
2.7.1 Measuring apoptosis and necrosis of THP-1 cells ................................................................... 85 
2.8 Human microvascular endothelial cells ...................................................................................... 86 
   IX 
2.9 Human aortic endothelial cells ................................................................................................... 87 
2.10 Effect of LDL oxidised at lysosomal pH on endothelial cells ..................................................... 88 
2.10.1 Rat aorta Vasoreactivity assessment ..................................................................................... 88 
2.10.1 Histological analysis and immunohistochemistry ................................................................. 90 
2.10.3 Measurement of reactive oxygen species in endothelial cells exposed to oxidised LDL ...... 90 
2.10.4 Western blot analysis ............................................................................................................ 91 
2.11 Statistical analysis ..................................................................................................................... 92 
Chapter 3 .............................................................................................................................................. 93 
Effect of α-tocopherol enrichment on LDL oxidation by transition metals at lysosomal pH ............... 93 
3.1 Introduction ................................................................................................................................... 94 
3.2 Methods ......................................................................................................................................... 97 
3.3 Results ............................................................................................................................................ 98 
3.3.1 Monitoring oxidised LDL with iron at pH 4.5 and 7.4 .............................................................. 98 
3.3.2 Effect of EDTA on LDL oxidation by iron at lysosomal pH. .................................................... 100 
3.3.3 Effect of α-tocopherol on LDL oxidation at lysosomal pH. .................................................... 103 
3.3.3.2 Effect of α -tocopherol on LDL oxidation  by ferric ion at lysosomal pH. ........................... 107 
3.3.3.3 Effect of α-tocopherol does not inhibit LDL oxidation  by  copper at  lysosomal pH. ........ 111 
3.3.3.4 α- Tocopherol inhibit LDL oxidation by copper at pH 7.4 ................................................... 115 
3.4 Measurement of ferrous ion levels during LDL oxidation by ferric chloride. ........................... 119 
3.5 Measurement of Cu+ levels during LDL oxidation by copper at lysosomal pH. ........................ 121 
3.6 Monitoring α-tocopherol Content of LDL particles during the oxidation process ................... 123 
3.7  Total lipid hydroperoxides in oxidised LDL .............................................................................. 125 
3.8 HPLC analysis of oxidised lipids in LDL ..................................................................................... 127 
3.9 Discussion ..................................................................................................................................... 129 
Chapter 4 ............................................................................................................................................ 135 
Effect of tempol and probucol on low density lipoprotein oxidation at lysosomal pH ...................... 135 
4.2 Material and Methods ................................................................................................................. 139 
4.3 Results .......................................................................................................................................... 140 
4.3.1 Effect of α-tocopherol and tempol on LDL oxidation by 5μM ferrous iron at pH 4.5 ........... 140 
4.3.2 Effect of tempol on LDL oxidation by 5μM Ferric ion at pH 4.5 ............................................ 143 
4.3.3 Effect of α-tocopherol and tempol on LDL oxidation by 5μM copper at pH 4.5 ................... 146 
4.3.4 Effect of α-tocopherol and tempol on LDL oxidation by 5 µM copper ion at pH 7.4 ............ 149 
4.3.5 Effect of Probucol on LDL oxidation by 5μM Fe 2+ at pH 4.5 ................................................. 152 
4.3.6 Effect of probucol on LDL oxidation by 5μM Fe 3+ at pH 4.5 ................................................. 155 
 X 
4.3.7 Effect of probucol on α-tocopherol-enriched LDL oxidation by 5μM Cu2+ at pH 4.5 ............ 158 
4.3.8 Effect of probucol on α-tocopherol-enriched LDL oxidation by 5μM Cu2+ at pH 7.4 ............ 161 
The effect of LDL oxidised at lysosomal pH on cultured macrophages. ............................................. 167 
5.1 Introduction ................................................................................................................................. 168 
5.2 Material and Methods ................................................................................................................. 170 
5.3 Results .......................................................................................................................................... 171 
5.3.1 Measurement of intracellular lipid accumulation in macrophages ...................................... 171 
5.3.2 Intracellular lipid accumulation in presences of probucol in macrophages .......................... 174 
5.3.3 Measurement of ceroid formation in macrophages ............................................................. 177 
5.3.3.2 Measurement of intracellular ceroid formation in macrophages with the presence of 
probucol ......................................................................................................................................... 180 
5.3.4 Monitoring of ROS production with the use of DHE ............................................................. 183 
5.3.5 Effect of α-tocopherol  and tempol on apoptosis of macrophages ...................................... 190 
5.4 Discussion ..................................................................................................................................... 196 
Chapter 6 ............................................................................................................................................ 200 
Effect of LDL oxidised under lysosomal conditions on nitric oxide synthesis by endothelial cells ..... 200 
6.1 Introduction ................................................................................................................................. 201 
6.2 Material and Methods ................................................................................................................. 204 
6.3 Results .......................................................................................................................................... 205 
6.3.1 Effect of oxidised LDL on the relaxation of aortic rings ......................................................... 205 
6.3.2 Evaluation of aortic wall structure ........................................................................................ 207 
6.3.3 Measurement  of endothelial integrity of aortic rings exposed to with oxidised LDL .......... 209 
6.3.4 Effect of oxidised LDL on reactive oxygen species in aortic ring ........................................... 210 
6.3.5 Effect of oxidised LDL on reactive oxygen species formation by cultured endothelial cells . 212 
6.3.6 Effect of oxidised LDL on eNOS phosphorylation in cultured endothelial cells measured by 
western blotting ............................................................................................................................. 215 
6.3.7 Effect of oxidised LDL on eNOS phosphorylation in cultured endothelial cells  measured by 
immunocytochemistry ................................................................................................................... 218 
6.4 Discussion ..................................................................................................................................... 221 
Chapter 7 ............................................................................................................................................ 224 
General discussion ............................................................................................................................. 224 
7.1 Suggestions for future experiments ............................................................................................. 232 
References ......................................................................................................................................... 233 
 
 
   XI 
 
 
Figures and Tables 
Figure Title page 
Figure 1.1 An illustration associating a normal blood vessel and 
incompletely blocked vessel 
5 
Figure 1. 2 Atherogenesis mechanism 8 
Figure 1.3A Diagram shows the free radical chain reaction mechanism 
of lipid peroxidation of a polyunsaturated fatty acid (PUFA).  
24 
Figure 1.3B Major products of free radical attack 25 
Figure 1.4  Diagram of agLDL macrophage interfaces 27 
Figure 1.5 An illustration shows LDL oxidation in lysosomes 29 
Figure 1.6 Diagram of role lysosomes in apoptosis 33 
Figure 
1.7A&B 
EDTA structure 48 
Figure 1.8 The chemical structure of vitamin E family 50 
Figure 1.9 4-Hydroxy-tempol 57 
Figure 1.10 Probucol 59 
Table 2.1 Target lipid species and analysis conditions for HPLC 79 
Figure 2.1 Example chromatogram of standard 80 
Figure 2.2 Tension traces showing responses of rat arteries rings 89 
Figure 3.1 The different phases of LDL oxidation with or without the 
addition of 5 µM FeSO4  at pH 4.5 and 7.4. 
99 
Figure 3.2 Comparison of LDL oxidation with 5 µM FeSO4  1, 2, 5 or 10 
µM EDTA additions. 
101 
Figure 3.3 Effect of EDTA on LDL oxidation by iron at pH 4.5. 102 
Figure 3.4 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a sodium chloride /sodium acetate buffer (pH 
4.5) incubated with 2 µM Fe2+ at 37 0C in capped quartz 
cuvettes. 
104 
Figure 3.5 Control LDL (50 µg LDL protein/ml) and LDL enriched with α- 
tocopherol in sodium chloride /sodium acetate buffer (pH4.5) 
incubated with 5 µM Fe 2+ at 37 0C in capped quartz cuvettes 
in quadruplicate. 
105 
Figure 3.6 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a sodium chloride /sodium acetate buffer 
(pH4.5) incubated with 20 µM Fe2+ at 37 0C in capped quartz 
cuvettes. 
106 
Figure 3.7 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in sodium chloride /sodium acetate buffer (pH 4.5) 
incubated with 2 µM Fe3+ at 37 0C in capped quartz cuvettes. 
108 
Figure 3.8 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a sodium chloride /sodium acetate buffer 
(pH4.5) incubated with 5µM Fe3+  at 37 0C in capped quartz 
cuvettes. 
109 
Figure 3.9 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a sodium chloride /sodium acetate buffer 
110 
 XII 
(pH4.5) incubated with 20 µM Fe 3+ at37 0C in capped quartz 
cuvettes. 
Figure 3.10 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a sodium chloride /sodium acetate buffer pH 4.5 
incubated with 2 µM Cu 2+ at 37 0C in capped quartz cuvettes. 
112 
Figure 3.11. Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a sodium chloride /sodium acetate buffer (pH 
4.5) incubated with 5 µM CuSO4 at 37 0C in capped quartz 
cuvettes. 
113 
Figure 3.12 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a sodium chloride /sodium acetate buffer (pH 
4.5) incubated with 20 µM CuSO4 at 37 0C in capped quartz 
cuvettes. 
114 
Figure 3.13 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a buffer (pH 7.4) incubated with 2 µM CuSO4 at 
37 0C in capped quartz cuvettes. 
116 
Figure 3.14 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a buffer (pH 7.4) incubated with 5µM CuSO4 at 
37 0C in capped quartz cuvettes. 
117 
Figure 3.15 Control LDL (50 µg LDL protein/ml) and LDL enriched with α-
tocopherol in a buffer (pH 7.4) incubated with 20 µM CuSO4 at 
37 0C in capped quartz cuvettes. 
118 
Figure 3.16 Kinetics of ferrous ion formation during LDL oxidation by FeCl3 
at pH 4.5 
120 
Figure 3.17 Kinetics of cuprous ion levels during LDL oxidation by CuSO4 at 
pH 4.5 
122 
Figure 3.18 The depletion of α-tocopherol in LDL during oxidation. Control 
and LDL enriched with α- tocopherol (50 μg protein/ml) was 
incubated in NaCl/sodium acetate buffer (pH 4.5) with 5 μM 
FeSO4 in plastic tubes maintained at 37 °C. α-Tocopherol 
content in LDL was measured periodically. 
124 
Figure 3.19 Effect of enrichment of LDL with α-tocopherol on total lipid 
hydroperoxides during LDL oxidation by 5 μM FeSO4 . Control 
LDL and LDL enriched with α- tocopherol were oxidised by 5 
μM FeSO4 at 37 oC at pH 4.5 and then evaluated for the 
presence of lipid hydroperoxides by a tri-iodide assay at 
different time points. 
126 
Figure 3.20 Effect of α- tocopherol enrichment on LDL oxidation products 
during oxidation by FeSO4 (5 μM) at pH 4.5. 
128 
Figure 4.1 Effect of α-tocopherol and tempol on LDL oxidation by ferrous 
ion.  LDL or α-tocopherol supplemented LDL (50µg protein/ml) 
was oxidised by 5µM FeSO4 at pH 4.5 and 37 
o
C with or 
without 10 µM tempol. 
141 
Figure 4. 2 Effect of α-tocopherol and tempol on LDL oxidation by ferrous 
ion in the presence or absence of 10 µM tempol. LDL or α-
tocopherol supplemented LDL (50 µg LDL protein/ml) was 
oxidised by 5 µM FeSO4 at pH 4.5 and 37 
o
C. 
142 
Figure 4. 3 Effect of α-tocopherol and tempol on LDL oxidation by ferric 
ion. LDL or LDL supplemented with α-tocopherol (50 µg 
144 
   XIII 
protein/ml) was oxidised by 5 µM FeCl3 at pH 4.5 and 37 
o
C in 
the presence or absence of 10 µM tempol. 
Figure 4.4 Effect of α-tocopherol and tempol on LDL oxidation by ferric 
ion. LDL or LDL supplement with α-tocopherol (50 µg 
protein/ml) was oxidised by 5 µM FeCl3 at pH 4.5 and 37 
o
C in 
the presence or absence of 10 µM tempol. 
145 
Figure 4.5 Effect of α-tocopherol and tempol on LDL oxidation by copper 
ion at lysosomal pH. LDL and LDL enriched with α-tocopherol 
(50 µg protein/ml) was oxidised by 5µM CuSO4 at pH 4.5 and 
37 
o
C. 
147 
Figure 4.6 Effect of α-tocopherol and tempol on LDL oxidation by copper 
ion at lysosomal pH. LDL and α-tocopherol (50 µg protein/ml) 
was oxidised by 5 µM CuSO4 at pH 4.5 and 37 
o
C. 
148 
Figure 4.7 Effect of α-tocopherol and tempol on LDL oxidation by copper 
ion at pH7.4. LDL and LDL enriched with α-tocopherol (50 µg 
protein/ml) was oxidised by 5µM CuSO4 at pH 7.4 and 37 
o
C  
with or without tempol (10 μM). 
150 
Figure 4.8 Effect of α-tocopherol and tempol on LDL oxidation by copper 
ion at pH 4.7. LDL and LDL enriched with α-tocopherol (50 µg 
protein/ml) was oxidised by 5 µM CuSO4 at pH 7.4 and 37 
o
C   
with or without tempol 10 μM. 
151 
Figure 4.9 Graph showing the effect of probucol (5 µM) on LDL enriched 
with α-tocopherol (50 µg LDL protein/ml) oxidation by 5 µM 
FeSO4 at pH 4.5 and 37
o
C. 
153 
Figure 4.10 Effect of α-tocopherol and probucol on LDL oxidation by 
ferrous ion. LDL (50µg protein/ml) was oxidised by 5µM FeSO4 
at pH 4.5 and 37
o
C in the presence or absence of probucol (5 
µM). At different time points, the oxidation was stopped by 
adding EDTA (final concentration 4μM) and BHT (80μM). 
154 
Figure 4.11 The effect of probucol (5 µM) on LDL enriched with α-
tocopherol (50µg LDL protein/ml) oxidation by 5µM Fe3+ at pH 
4.5 and 37oC. 
156 
Figure 4.12 Effect of α-tocopherol and probucol on LDL oxidation by ferric 
ion. (50 µg LDL protein/ml) was oxidised by 5µM FeCl3 at pH 
4.5 and 37
o
C in the presence or absence of probucol (5 µM). 
157 
Figure 4.13 Graph showing the effect of probucol (5µM) on LDL enriched 
with α-tocopherol (50 µg LDL protein/ml) oxidation by 5 µM 
Cu2+ at pH 4.5 and 37oC.   
159 
Figure 4.14 Effect of α-tocopherol and probucol on LDL oxidation by 
copper ion at pH 4.5. 
160 
Figure 4.15 Effect of α-tocopherol and probucol (5µM) on LDL oxidation 
by copper ion at pH 7.4.  LDL (50µg LDL protein/ml) was 
oxidised by 5 µM CuSo4 at pH 7.4 and 37
o
C. 
162 
Figure 4.16 Effect of α-tocopherol and probucol on LDL oxidation by 
copper ion at pH 7.4. 
163 
Figure 5.1  Measuring intracellular lipid accumulation in macrophages 
with or without tempol. 
173 
 XIV 
Figure 5.2  Measuring intracellular lipid accumulation in macrophages 
with or without probucol.  
176 
Figure 5.3  Measuring ceroid formation in macrophages  with or without 
tempol 
179 
Figure 5.4  Measuring ceroid formation  in macrophages with or without 
probucol 
182 
Figure 5.5 Detection (ROS) formation in macrophages  185 
Figure 5.6 Detection (ROS) formation in macrophages  with or without 
tempol 
187 
Figure 5.7 Detection (ROS) formation  in macrophages with or without 
probucol 
189 
Figure 5.8 Apoptosis detection in THP-1 cells by flow cytometry. 195 
Figure 6.1 Effect of LDL oxidised under lysosomal conditions on 
vasodilatation 
206 
Figure6.2 Effect of LDL oxidised under lysosomal conditions on aortic 
structure 
208 
Figure 6.3 Immunohistochemical staining for CD31, in rat aortic 
segments. 
209 
Figure 6.4 Effects of oxidised LDL on ROS formation from rat aorta. 211 
Figure 6.5 Detection ROS formation in Human microvascular endothelial 
cells were treated for 1 h with control LDL or LDL (50µg 
protein/ml) 
213 
Figure 6.6 Detection ROS formation in Humane aortic endothelial cells 
were treated for 1 h with control LDL or LDL (50µg/ml) which 
previously been oxidised with 5µM Fe
2+  
 for 24 h at pH. 4.5 
214 
Figure 6.7 Representative western blot analysis, showing effect of 
oxidised LDL by iron at lysosomal pH on different type of 
endothelial cells.  
217 
Figure 6.8  Representative e NOS immunofluorescences staining on 
HMEC& HMEC. 
220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   XV 
 
List of Abbreviations 
ACAT                  AcylCoA:cholesterol acyltransferase 
ABCA1                 ATP binding cassette transporter-1 
ANOVA                 One-way analysis of variance 
ApoB-100             Apolipoprotein B-100 
ApoE                      Apolipoprotein E 
BHT                        Butylated hydroxytoluene 
BP                           Bathophenanthrolinedisulfonic acid 
BSA                         Bovine serum albumin 
CE                            Cholesteryl esters 
CHD                        Coronary heart disease 
CLOOH                   Cholesteryl linoleate hydroperoxide 
CVD                        Cardiovascular disease 
DMSO                    Dimethyl sulphoxide 
DTPA                     Diethylenetriaminepentacetate 
DHE                       Dihydroxyethidium  
EDTA                     Ethylenediaminetetraacetic acid 
EC                          Endothelial cells 
ER                          Endoplasmic reticulum 
FCS                        Fetal calf serum 
FH                         Familial hypercholesterolaemia 
 XVI 
FITC                       Fluorescein isothiocyanate 
FGF                           Fibroblast growth factor 
PDGF                        Platelet derived growth factor 
HEPES                      N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] 
HDL                          High density lipoprotein 
HPLC                        High performance liquid chromatography 
IDL                            Intermediate density lipoprotein 
IL                              Interleukin 
LAL                           Lysosomal acid lipase 
LCAT                        Lecithin: cholesterol acyltransferase 
LDL                          Low density lipoprotein 
LPL                         Lipoprotein lipase 
LOOH                    Lipid hydroperoxide 
LOX-1                    Lectin-like oxidised LDL receptor-1 
LPS                        Lipopolysaccharide 
MI                          Myocardial infarction 
MMP                      Matrix metalloproteinase 
NF-κB                      Nuclear factor-kappa of activated B cells 
oxLDL                       Oxidized LDL 
PBS                            Phosphate buffered saline 
PLA2                         Phospholipase A2 
PMA                         Phorbol 12-myristate 13-acetate 
   XVII 
PUFA                        Polyunsaturated fatty acid 
RPMI                        Roswell Park Memorial Institute 
SDS                           Sodium dodecyl sulphate 
SR-A                          Scavenger receptor A 
SR-B1                        Scavenger receptor B1 
SREBP                        Sterol regulatory element binding protein 
TNF-α                         Tumour necrosis factor-alpha 
VCAM-1                     Vascular cell adhesion molecule-1 
VLDL                           Very low density lipoprotein 
VSMC                          Vascular smooth muscle cell 
 
 
 
  

                                                                                                                                                                                      I 
 
 
 
Chapter 1 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 2 
 
1. Atherosclerosis 
 
1.1 The scale of the problem 
 
Cardiovascular disorder (CVD) is the effective reason of mortality within the world (Garcia 
et al., 2016, Barnhart et al., 1989). Atherosclerosis is the main cause of CVD and it is the 
second leading source of death in England (Yang et al., 2015). The World Health 
Organization (WHO) report that in 2012 globally 17.5 million people died because of 
cardiovascular diseases and that is responsible for one-third of all deaths worldwide (6.2 
million died due to interrupted blood flow in a carotid artery or other artery supplying the 
brain  (stroke) (Natori et al., 2016). In 2011, the British Heart Foundation estimated more 
than 159,000 people died due to CVDs in the UK  with 74,000 of them related to coronary 
heart disease while strokes caused approximately 42,000 deaths in the UK (Wang and 
Bennett, 2012). In 2010 the global cost of cardiovascular disease has been evaluated at 
nearly 863 billion USD. This cost is not just related to the health care system but also 
national economic growth (Herrington et al., 2016). According to the American Heart 
Association, the total cost of cardiovascular diseases in the U.S.  2010 was nearly 503.2 
billion USD yearly. The typical cost in the year of this disease in Europe was approximately 
153 billion USD. In China, the cost of CVD has been determined to be greater than 40 billion 
USD (Ohsfeldt et al., 2010).  
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Atherosclerosis is an inflammatory disease of the arteries associated with lipids. 
The term atherosclerosis refers to the progression of the atheromatous lesion, which 
forms a plaque in the arterial wall (Gaudio et al., 2006). This plaque can lead to clinical 
signs, depending on its size and location, by restricting the blood flow in arteries causing 
ischaemia or by inducing thrombi that may interfere with blood flow. An embolus can 
settle in a distal artery (Stary et al., 1995). In the United States, 2004, the early clinical 
manifestation of atherosclerosis is a heart attack for 66% and 74% men and women, 
respectively. Sudden cardiac death generally occurs when an artery narrows due to a 
plaque by about 75% or more (Pipitone et al., 2007). Most clinical manifestations appear 
after excessive narrowing of arteries or completely closing blood flow to each organ. 
Peripheral arterial lesion symptoms are numbness and pain within legs from severe 
narrowing from atherosclerotic plaque in leg arteries (Korneva et al., 2014). Lack of blood 
amount reached to the brain due to bulky plaque in the carotid and other arteries can 
produce strokes and symptoms such as difficulty in speaking, weakness, blurred vision, 
headache, numbness in the face and loss of consciousness (Xu et al., 2016)  Another 
common location of plaque formation is in the coronary arteries, which can result in 
several symptoms such as chest pain (angina due to myocardial ischaemia), shortness of 
breath, sweating, dizziness, nausea, arrhythmia and ischaemia (Aboyans et al., 2007).  
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Several significant factors raise the risk of atherosclerosis, such as high blood pressure, 
hyperlipidemia, diabetes Mellitus, overweight, smoking, lack of physical activity, fatty 
diets, and genetic history of early heart disease (Rocha and Libby, 2009). 
	
	
	
	
1.2 Pathogenesis of Atherosclerosis 
 
1.2.1 Histology of normal arteries 
 
The healthy artery wall comprises of three layers. The deepest layer facing the 
bloodstream named tunica intima, which has a monolayer of endothelial cells that stand 
on a subendothelial layer of extracellular matrix and proteoglycans. The internal elastic 
lamina provides a barrier between the endothelial layer and the middle layer of the artery 
wall, which is called the tunica media. It consists of many layers of smooth muscle cells 
enclosed with a matrix comprising mostly of different type of fibres like elastic collagen.  
The exterior elastic member also provides a barrier splits the muscular layers of tunica 
media and the outer layer, named tunica adventitia. It composed of a network community 
of fibroblasts cells, collagen fibres and elastin (Spicer et al., 2015, Libby et al., 2010).  The 
structure of the normal and abnormal artery (atherogenic) is displayed in Figure 1. 
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1.2.1.2 Endothelial cells structure 
 
Both blood vessels and lymphatics are fully lined by endothelial cells. These cells were 
thought to be simple coating cells with few functions than to preserve the blood from 
leaking out of the vessels (Rajendran et al., 2013). However, recent research on endothelial 
cells has shown that they have an incredible range of functions (McCarron, 2019). 
Furthermore, they are the vital factor to determines the health of blood vessels and have 
remarkable effects in pathogenesis cardiovascular disease. These cells are flat, with a 
central nucleus, with a thickness of around 1-2 µm with a diameter roughly 10-20 µm. The 
intersections between cells, overlapping areas recognised which lid the vessel. The 
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intercellular junctions are critical for the health of the vessel. Toxic elements open these 
intersections and let large particles pass out of the wall (Goncharova , 2017). 
Consequently, such toxins can possibly damage the blood vessels and cause serious 
disease (recognised as vascular disease). The cytoplasm is quite simple with few 
organelles, typically concentrated around the nuclear area. The most apparent feature is 
the presence of small vesicles (pinocytotic vesicles) bordering the endothelial cell 
membranes.  
This is a mechanism for transporting substances, particularly fluid, transversely from the 
bloodstream to the underlying tissues. Gases diffuse through swiftly, and this is illustrated 
in the lung capillaries where there is a very effective transfer of gases, such as oxygen, and 
anaesthetics. Endothelial cells appear the dynamic impact on the health stability in the 
body tissue like cartilage, all cell is about 25 µm of a capillary. It is merely 10-15 µm 
diameter and comprises simply of endothelial cells and attached material named the basal 
lamina. Endothelial cells also contain Weibel- Palade bodies (WPBs), which have von 
Willebrand factor (VWF), which is released under many stimulators.  VWF has a remarkable 
role in clinical mechanism such as vascular damage repair and inflammation (Valentijn, 
2011). 
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1.2.2 Lesion-prone area 
 
Atherosclerotic lesion builds up inside the internal curve of the arteries and at the division 
zone (Chistiakov et al., 2017). The progression of lesions throughout these positions is 
believed of a reduction in or disrupted shear stress, whereas high shear stress is protective 
(Davies, 1997). Shear stress is a blood flow forces in endothelial cells that regulate the 
principle of vascular endothelium function by targeting receptors, that recognise flow and 
stimulate mechanical signals via mechanosensitive signalling pathways resulting in 
morphologic and role modifications.It modifies endothelial cell regeneration and their role 
by the mechanical transduction mechanism by low shear stress initial the stimulation of 
transcription factors like nuclear factor–kappa B (NF-kB) (Tzima et al., 2005). NF- KB  
stimulation promote transcription of genes encoding proteins, which implicated in 
atherosclerosis, like vascular cell adhesion molecule-1 (VCAM-1) that bind with 
monocytes, assisting their penetration throughout the endothelial junction (Monaco and 
Paleolog, 2004). Endothelial cells in regions appear higher shear stress, acclimatise to the 
stream with downregulate response, while low shear stress, NF-kB are triggered in a 
continual way (Mohan et al., 1999). The expression of these genes is believed early events 
that happen at the lesion before further indicators of atherosclerosis are obvious (Monaco 
and Paleolog, 2004). 
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1. 3 Atherosclerosis process 
 
Atherosclerosis is a pathological disorder that is life-threatening and may initiate growth 
during childhood life (McGill et al., 2000). This condition is identified by the gathering of 
lipids in sub inner layer of the artery wall, forming a plaque that reduces blood flow to the 
target organ (Vitruk, 2013). Atherosclerosis proceeds through steps (Figure 1.2), including: 
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a) Many scientists believe endothelial cell injury is an initial factor of plaque formation 
starting with damage or dysfunction to the endothelium layer of the artery intima (Mudau 
et al., 2012, Gimbrone and Garcia-Cardena, 2016). This damage leads to increased 
permeability and decreases the release of anticoagulant agents, such as a nitric oxide (NO), 
a fundamental enzyme released from endothelial cells that capable to prevent platelet 
activity. The continual weakening of NO synthesis and release in porcine aortic endothelial 
cells, increasing endothelial oxidative stress, consequence reduced the heparan sulfate on 
endothelial (Zhang et al., 2008, Irokawa et al., 1997). Different materials travelling in the 
artery, such as cholesterol, are toxic and cellular waste products deposit inside the 
abnormal area of the intima and continued exposure and accumulation of this material 
play an important role in information of a large fatty plaque (DiCorleto and Chisolm, 1986). 
(b)  Lipoprotein deposition occurs when the endothelial layer is damaged. Lipoprotein is 
deposited in the particular area and chemical reactions occur during this deposition, 
causing cholesterol molecules to alter by oxidation by free radicals or oxidising enzymes. 
Low-density lipoprotein (LDL) builds up in the artery wall and initiates an inflammatory 
response in the injured site (Maxwell, 2000). 
(c) There is an inflammatory reaction, where inflammatory cells, including neutrophil, 
lymphocytes and monocytes from the bloodstream arrive at the injured site. The 
monocytes become macrophages and phagocytose and digest the modified LDL particles 
resulting in the macrophages being converted into foam cells, which have a key role in 
destabilising the plaque leading to rupture.  
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Foam cells accumulate with the growing arterial plaque and die by apoptosis and necrosis. 
Metalloproteinases from macrophages cause plaques to rupture and promote blood 
thrombosis (Stoll and Bendszus, 2006).     
(d)  Fibrous cap formation. At this time of lipoprotein localization and inflammatory 
response, smooth muscle cells within the second layer of the artery wall (the media) start 
to proliferate and migrate to the surface of the fatty plaque. These migrant cells contribute 
to the formation of the fibrous cup, covering the plaque area (Yano et al., 2000). Atheroma 
lesions develop when a necrotic core of dead macrophages and extracellular lipid 
accumulates. The engagement and consequent migration of travelling monocytes into the 
subintima zone (subendothelial) is assisted by hypercholesterolaemia, which promotes the 
binding molecules and the release of chemoattractant substances by the endothelial cells.  
Macrophages formation from monocytes modification, increasing uptake the droplets of 
lipoprotein, transforming into pro-inflammatory cells leading to more induction of other 
monocytes and this lead to the advance of atherosclerosis by initiated the inflammation  
(Libby, 2007). Documents have shown that monocytes are heterogeneous and consist of a 
minimum of two separate subdivision according to activation of CD14 and CD16 (Ziegler-
Heitbrock, 1996). The majority subpopulation display low level of CD16 and high level of 
CD14 and, whereas the minority subpopulation shows an opposite expression of majority 
subpopulation on the monocytes surface (Frankenberger et al., 1996).  
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A subdivision of CD16-positive monocytes can increase inflammatory trigger, leading up-
regulates many receptors, counting CCR2, CX3CR1 and CCR5.  They act in a  non-
supernumerary and self-regulating function in the atherosclerosis mechanism  (Ancuta et 
al., 2003, Tacke et al., 2007). Trigger scavenger receptor in macrophages by oxidised 
LDL,followed by activation CD36 via stimulation of the transcription factor PPAR-γ, thus 
producing a ‘vicious’ feed-forward sequence of cumulative ox-LDL in macrophages, finally 
this altering of macrophages to the pathological foam cells, according to the review of 
Gurnell (Gurnell, 2003).  
Furthermore, ox-LDL taken up by CD36 stimulates the NF-κB this in turn increases the 
transcription of pro-inflammatory elements and induces a proinflammatory type (Tak and 
Firestein, 2001, Schwarz et al., 2017). 
 
 
 
1. 3.1 Modification of LDL within Atherosclerotic lesion 
 
Modified LDL might cause endothelial dysfunction, which represents an early sign of 
atherosclerosis. Considerable modification of LDL stimulates oxidative stress and accelerates 
senescence in the endothelium (Siennicka and Zapolska-Downar, 2003). A marker of 
endothelial dysfunction is decreased endothelium-dependent vasodilatation (Szucs et al., 
2007).  
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Many chemical modifications of LDL have been documented since the 1970s, including 
oxidised LDL, acetylated LDL, glycated LDL, and methylated LDL. Changing LDL components 
through modification, specifically, apolipoprotein B-100 changes the affinity of LDL for 
binding to related receptors (Hoff et al., 1993). This event might stimulate atherogenesis via 
scavenger receptors (SRs) on macrophages and endothelial cells (Iuliano et al., 2001). LDL 
oxidation is induced via many metal ions and free radicals (Iuliano et al., 2001) and oxidising 
enzymes such as myeloperoxidase and lipoxygenase (Guo et al., 2001). 
The structural changes during LDL oxidation, involve increased density, increased 
electrophoretic mobility( due in part to the neutralisation of the positive charge of lysyl of 
residues), changes in phosphatidylcholine(due to hydrolysis by lipoprotein-associated 
phospholipase A2), fragmentation of apoB-100, (due to free radical-mediated peptide bond 
scission) modification of lysine amino groups (by reaction with aldehydes) and creation of 
fluorescent adducts because of covalent binding of lipid products to apoB-100 (Chehin et al., 
2001). Aldehydes produced during the peroxidation of LDL exhibit reactivity with proteins, 
making a diversity of intermolecular covalent adducts on the apolipoprotein B-100 in LDL 
particles.  
The main consequences as regards atherosclerosis of oxidised LDL are as follows: 
(I) Oxidised LDL affects blood cells, stimulating monocyte binding to endothelial cells, by 
activating of ICAM-1 and VCAM-1 (Quinn et al., 1988) and speeding up the conversion   of 
monocytes to macrophages (Quinn et al., 1987). 
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 (2) Ox LDL plays a  crucial role in amplified activation of growth factors, like platelet-
derived growth factor (PDGF), which is responsible for inducing smooth muscle cell (SMC) 
migration (Stiko-Rahm et al., 1992), and basic fibroblast growth factor (FGF), which 
stimulates smooth muscle cells proliferation during the atherosclerosis process (Lindner 
et al., 1991). 
(3) Ox-LDL contributes to plaque formation and development either by stimulating collagen 
production from smooth muscle cells, which is responsible for the formation of the fibrous 
cap of plaques and increasing their size by promoting the relocation of smooth muscle cells 
from tunica media throughout the elastic membrane to the intima, causing arterial 
expansion and early angiogenesis in the area (Jimi et al., 1995).  On the other hand oxidised 
LDL may contribute in stimulating fibrous cap thinning through the secretion of matrix 
metalloproteinases and promoting smooth muscle apoptosis (Loidl et al., 2004), and 
promoting necrotic core production in plaques (Schwartz et al., 1991). The aggregation and 
oxidation of LDL in the subendothelial area may show a critical event in atherogenesis. LDL 
might be oxidised by several mechanisms such as iron, copper, caeruloplasmin, 
lipoxygenase, superoxide, peroxynitrite, and myeloperoxidase (Schwartz et al., 1991). 
This oxidation of LDL happens in both humans and animal models of atherosclerosis, such as 
mice, rabbits and zebrafish (Witztum and Steinberg, 2001). Ox-LDL may cause apoptosis of 
foam cells and produce a necrotic lipid centre in the lesion, a feature of an atherosclerotic 
lesion in both human and murine species.  
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Cysteine proteases display vital influence in the growth of atherosclerotic plaque. Ox-LDL 
can release lysosomal cathepsins B and L  and may activate cysteine-aspartic proteases 
(caspases) and stimulate apoptosis (Guicciardi et al., 2000).  
Thereby, both cytotoxic ox-LDL and related oxysterols may lead to weakening or 
destabilization of lysosomes and release the cathepsins, promoting the programmed death 
of phagocytic cells and progression of the atherosclerotic lesion and necrotic core formation 
(Emanuel et al., 2014a). This pro-apoptotic process may also apply to smooth muscle cells 
and endothelial cells. Cathepsin S regulates thrombotic effects of arterial injury (Sukhova et 
al., 2003) by elastolytic activity, which can degrade collagen. Macrophages trigger elastolytic 
cysteine proteases during particular situations might stimulate elastin  and collagen 
deprivation at places of inflammation and developing plaque rupture and thrombus 
formation (Hansson, 2015 ).  
       
1. 3.2 Endocytosis of oxidised LDL by macrophages 
 
LDL is the major cause of cholesterol accumulation in macrophages. During early plaque, 
foam cells originated from transforming macrophages, whereas progressive lesions, smooth 
muscles experienced foam cell conversion. 
  This event clarified, by the discovery the hypoxia (because of the enlarged arterial wall and 
diminished oxygen circulation (Crawford and Blankenhorn, 1991)), rises LDL concentration 
and lipid gathering in SMC (Wada et al., 2002).  
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Since the ingestion of LDL through the LDL receptor (LDLR) is linked to predatory feedback, 
the build-up of extreme quantities of LDL in macrophages associated to alteration of LDL, 
leading swift unrestricted uptake (Brown and Goldstein, 1983). Numerous kinds of LDL 
alteration described permitting cholesterol internalization in vitro, counting aggregation 
acetylation and oxidation, (Khoo et al., 1988). In vitro acetylation of LDL may encourage 
cholesterol assembly in macrophages. Nevertheless, not enough indication that acetylated 
LDL happens in vivo. Oxidative of LDL, however, stimulated via all the main cell categories 
found in the plaque, endothelial cells, SMC and macrophages and lymphocytes, might 
induce foam cell development, causing atherogenesis. Furthermore, macrophages may 
encourage oxidation of LDL by exocytosis of iron, resulting from earlier phagocytosis of aged 
or broken erythrocytes (Yuan et al., 1995). 
 Iron is obtained from absorbed diet by enterocytes of the duodenal lining. Enterocytes 
allowed moving iron into the body with help marked molecules. Dietetic iron that absorbed 
as the ferrous formula (Fe2+) or as heme (Ems, 2020).  Under the effect of ferric reductase 
enzyme ferric Fe3+  convert to Fe2+.   
plasma membrane. When the iron is connected with the heme, will be relocated throughout 
the apical membrane by a particular protein called heme carrier protein (HCP1).  
Some oxidised LDL might aggregate in the arterial wall (Aviram et al., 1995) where it is linked 
with proteoglycan secretion via macrophages (Maor et al., 2000).  
 
 
Divalent metal transporter 1 (DMT1) carryings several divalent metals throughout the  
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 Moreover, can be aggregated by different factors, such as sphingomyelinase (SMase). SMase 
produces the aggregation of LDL through stimulating cleavage of the phosphocholine group 
of sphingomyelin (SM) developing in creating the hydrophobic moiety, ceramide. The 
initiation of ceramide produces LDL aggregation by displaying hydrophobic pieces on the LDL 
monolayer. This hydrolysis will increases the molar ratio of cholesterol to phospholipid in the 
monolayer part of LDL particle, developing cholesterol crystal nucleation after aggregated 
LDL.  
Enzymes including, SMase, phospholipase A2 (PLA2), phospholipase C, might lead to loss of 
LDL integrity converting to aggregated LDL. Although macrophages show numerous receptors 
related to lipoproteins modified via chemical alteration (Matsuura et al., 2005), macrophages 
also have merely limited receptors for native lipoproteins. Therefore, non-oxidised LDL might 
be internalised by macrophages mainly via fluid-phase endocytosis (Kruth, 2011). 
 Moreover, aggregated LDL is ingested by phagocytosis receptor which takes place by a 
clathrin-independent mechanism. Scavenger receptor ingested oxidised LD L and acetylated 
LDL. Nevertheless, significant indication related to  LDL uptake methods based on the shape 
and function to diverse endocytic locations. This probably linked to the participation of 
various receptors. 80% of acylated LDL uptake is facilitated by scavenger receptor, whereas 
70% of the oxidised LDL ingested is facilitated by CD36 (Schonbeck et al., 2002), and (lectin-
like oxidized low density lipoprotein receptor-1) (LOX-1) (Kume et al., 1998). Minor oxidation 
of LDL produced what has been termed minimally modified LDL (mmLDL), which is known by 
just LDL receptor rather than the scavenger receptors (Miller, 2003 ).  
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Oxidised LDL bind with CD14 and then stimulation CD36, leading accessive uptake of other 
particles from oxidised LDL (Miller et al., 2003). 
In fully oxidised LDL particles, required alteration in both parts of LDL particle, including lipid 
and protein, and uptake by a different receptor called scavenger receptor, but if there is an 
alteration in lipid area and producing lipid oxidation product then called minimum modified 
LDL (MM LDL). MMLDL has a dynamic role in cumulative inflammatory cytokine secretion 
(Chavez-Sanchez, 2010).  
In SMC, LDL receptor-related protein 1 (LRP1) is active compared to scavenger receptor  
(Llorente-Cortes and Badimon, 2005). LRP1 is usually upregulated by high levels of 
cholesterol in plasma and facilitates ingested of aggregated LDL in SMC.  
Aggregated LDL stimulates plasma membrane engulfment that transports it into a surface-
connected section in macrophages, a procedure named patocytosis (Kruth, 2002). The 
process called actin-dependent, which independently occurred of the LDL receptor.  
LDL moved to lysosomes for degradation (Brown and Goldstein, 1983). However, the 
protein part of oxidised LDL  may unaffected to lysosomal breakdown then it collects with 
a product of degradation  (Jessup and Kritharides, 2000).  
This lipid assembly process regulates foam cells development. This development in 
atherosclerosis lesion is started during the cholesterol clearance process inhibited, 
because of the massive amount of lipid accumulated in macrophages leading to disabled 
of lysosomes. 
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Consequently, either decrease the level of LDL or augmented HDL level in plasma, 
accumulation of excess amounts of LDL in subendothelial might be decreased, although 
the role of HDL in protecting against atherosclerosis is currently controversial. HDL 
concentrations are ineffectually associated to cardiovascular disease in epidemiological 
investigations (Miller, G.J.&Miller, erect 1975) but medications that elevated HDL 
concentration (cholesteryl ester transfer protein inhibitors) unsuccessfully diminish 
cardiovascular disease (Barter et al., 2007). 
 
 
 
1.3.3 LDL oxidation by transition metals and heme 
 
In the pathogenesis of atherosclerosis, LDL oxidation is an important risk factor (Steinberg, 
2009). Oxidative modification of LDL occurs after incubating LDL with copper sulphate 
overnight (Steinbrecher et al., 1984). Copper sulphate induced oxidative modification of 
the polyunsaturated fatty acids (PUFA ) in the sn2 position of phospholipids can lead to 
the breakdown of approximately  40% of the phosphatidylcholine, 50-75% of the PUFA 
(Esterbauer et al., 1987). Non-enzymatic oxidation stimulated by copper sulphate   in vitro 
is assumed to based on the existence of LOOH in LDL,  may be found in unnoticeable 
concentration in vivo or produced through LDL  extraction (Esterbauer et al., 1992).  
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Copper degrades these hydroperoxides into peroxyl radicals and alkoxyl radicals (Jerome, 
2010). The fatty acid moiety of cholesteryl esters is vulnerable to oxidation and the 
cholesterol moiety, which has an unsaturated bond in its polycyclic sterol ring, is also 
target to oxidative attack. Low levels of oxidation are adequate to oxidise it to a  level 
where it evolutions different biological characteristics (Berliner et al., 1990). This sort of 
LDL, named minimally-modified LDL (mmLDL), binds to the LDL receptor, but not to the 
scavenger receptors (Berliner et al., 1990). Many experiments have shown that mmLDL is 
a pro-atherogenic factor (Choi et al., 2009). Divalent iron cations (Fe2+) have the ability to 
stimulate LDL oxidation, but usually to a lesser degree compared with Cu2+. Nevertheless, 
the complex of iron and protoporphyrin IX is an active LDL-oxidising factor and, in 
particular, this activation of LDL occurs with a low concentration of peroxides (Miller et al., 
1995). In normal conditions, haemoglobin breaks down by catabolism and produces low 
amounts of free hemin (containing Fe3+) that associate with the red blood cell membrane. 
In abnormal or pathogenic conditions, such as inflammation and hyperlipidaemia, LDL can 
be oxidised by binding with hemin in whole blood (Miller and Shaklai, 1999). Moderate 
amounts of haemoglobin are continuously released from destroyed erythrocytes, 
especially in arterial bifurcation and aortic bends. 
In haemodialysis people with elevated levels of haemolysis, and haemoglobin stimulate 
LDL to be oxidised has been reported to raise the amount of ox-LDL in patients plasma who 
suffer from haemolysis (Sevanian and Asatryan, 2002). 
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 LDL oxidation by cells in atherosclerotic plaques possibly needs metal sources of iron or 
copper as reagents for the oxidation. Plasma iron is carried by the protein transferrin. 
Acidic pH releases iron from transferrin that catalyses LDL oxidation (Lamb & Leake, 1994). 
During LDL oxidation process by iron, ion required superoxide anion,which works as 
reducing factor in present H2O2, resulting hydroxyl radical (OH•) by the Fenton reaction 
(Georgi, 2016). Many research has been documented that LDL oxidation mediated by 
heme takes place in vivo (Lynch, 2000). The relation of iron form and cardiovascular 
disease in vivo, however is unpredictable (Sempos, 2002). 
Caeruloplasmin is a protein responsible for carrying copper in plasma and then becomes 
more active in oxidising LDL at acidic pH (Lamb & Leake 1994). Caeruloplasmin is separated 
from plasma in 1948 for the first time (Holmberg and Laurell, 1948). Although, it is 
recognised from a long period as acute form react and protein associated with copper 
transport, there is important role associated with chronic heart failure 
 (Cabassi et al., 2014).  
“moonlighting protein” is another name used to be called   Caeruloplasmin because of its 
diverse activities. Caeruloplasmin contains ferroxidase I, which is the crucial factor of 
converting Fe2 + into Fe3 + (form bound in transferrin), consequently restricted  Fe2 + from 
contributing in the production of hydroxyl radicals by this action Caeruloplasmin act as an 
antioxidant. Furthermore, the prooxidant role based on include amine oxidase (Dubick et 
al., 2015). 
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1.3.4 LDL oxidation by enzymes 
 
 
LDL is oxidised by vascular cells in culture. These cells are present in atherosclerotic lesions, 
including monocyte/macrophages, lymphocytes SMC and endothelial cells (Liao et al., 
1994). Several enzyme systems, including lipoxygenase, NADPH oxidase and 
myeloperoxidase, documented of their ability to oxidised LDL. Vascular cells express one 
or many of these enzymes. Myeloperoxidase (MPO) enzyme released from blood cells, 
such as neutrophils, monocytes/macrophages, which produces several oxidants, involving 
hypochlorous acid and reactive nitrogen specious (RNS), generating chlorinated, nitrated 
LDL and HDL. Modification of apoA1 occurred when MPO binds to HDL  (Undurti et al., 
2009).  RNS transform LDL to ligand with high ability to bind with CD36, promoting 
internalises them by macrophages (Podrez et al., 2000).  
Studies reported that Myeloperoxidase induced carbamoylation LDL particle transforms it 
to SR-A ligand (Wang et al., 2007). Both free fatty acids and lysophospholipids are released 
from glycerophospholipids at the position sn-2under the effect of enzymes called 
Phospholipase A2 (PLA2). Recently, about 30 of these enzymes are sorted based on many 
factors such as mass, size, role, and calcium necessity.  Furthermore, these enzymes have 
been split into six lines according to specific factors such as size, composition, catalytic 
component and connection. These lines contain (secretory PLA2 (sPLA2), cytosolic (cPLA2), 
Ca2+-independent (iPLA2), platelet-activating factor acetyl hydrolases (PAF-AH), which is a 
component of LDL, lysosomal PLA2 and adipose-specific PLA2).  
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It is acceptable that PLA2 can act as a biological focus for the treatment target of numerous 
illnesses, relating cardiovascular diseases and atherosclerosis.  Extraordinary 
consideration employed on a block of (sPLA2 isoforms) as a therapeutic element, 
depending on the motivation mechanism during inflammatory infrequent diseases (Quach 
et al., 2014).  
An important role might be played by pro-inflammatory secretory phospholipase A2 
(sPLA2)-IIA, which can act as the mediator of local inflammation in atherosclerosis lesion 
progression. The sPLA2 –IIA may show a pro-atherogenic outcome in the arterial wall in 
different steps (Hurt-Camejo et al., 2001). In arterial plaque, this enzyme is present within 
the lipid centre in both the extracellular matrix and in areas rich in macrophages (Romano 
et al., 1998).  sPLA2-IIA-altered LDL bound to proteoglycan (a protein family that classically 
experience general posttranslational alteration with sulphated sugar chains) (Iozzo and 
Schaefer, 2015) undergoes aggregation and fusion and consequently continues the 
accumulation of lipids in the extracellular matrix and arterial wall (Hakala et al., 2001).  
In addition to promoting the retention of LDL particles in the arterial wall, there is proof 
that sPLA2  alteration may increase macrophage uptake of LDL, resulting in foam cell 
formation (Aviram and Maor, 1992). sPLA2-IIA releases free fatty acids and 
lysophosphatidylcholine from LDL. This activity may affect the biological function of 
vascular cells, and macrophages at the location of accumulation of LDL (Leitinger et al., 
1999). NADPH oxidase is a source of superoxide anion in the vascular cells (Lassegue and 
Clempus, 2003, Seshiah et al., 2002, Zafari et al., 1998), which might be involved in LDL 
oxidation.  
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This superoxide leads to an increase in intracellular H2O2, proposing a particular role for 
these oxygen species in vascular growth.   
Studies have revealed that 12/15-lipoxygenase is extremely active in macrophages and can 
oxidise LDL (Takahashi et al., 2005). Thus, purified lipoxygenase can mediate LDL oxidation 
and conversion of LDL to a cytotoxic (Cathcart et al., 1991). 
 
1.3.5 Lipid peroxidation 
 
In later a long time it has gotten to be caught that lipid peroxidation, may be the vital stage 
in the mechanical process of numerous disease conditions in mature and newborn 
patients. This peroxidation is a reaction normally occurred in minor quantities in the body, 
generally by the influence of numerous ROS e.g. (H•, HOO•). Lipid peroxidation also 
produced under influence of some phagocytes. It has been linked with the disease such as 
atherosclerosis (Mylonas and Kouretas, 1999). Free radicals stimulate LDL oxidation, 
causing structural alterations of LDL particles. 
An initial step of this oxidation is peroxidation of polyunsaturated fatty acids (PUFA) in 
cholesteryl esters, phospholipids or triglycerides in LDL by removal of a hydrogen atom by 
a free radical. The reorganisation of the PUFA structure occurs,producing the development 
of conjugated dienes that absorb UV at wavelength 234 nm. For this reason, we can use a 
spectrophotometer at wavelength 234 nm to measure the oxidation of LDL (Esterbauer et 
al., 1989). Oxygen binds to form lipid peroxyl radicals (LOO•), which remove a hydrogen 
atom from another PUFA, which is the beginning of a chain of reactions, leading to lipid 
hydroperoxides. β-scission forms aldehydes that bind to amino acids on LDL, e.g. lysine 
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(Esterbauer et al., 1989). Cholesterol (esterified and non-esterified) is oxidised and 
produces oxysterols such as 7-ketocholesterol. (Figure 1.3A, B) 
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1.3.6 LDL uptake within acidification environment 
 
Foam cell accumulation in the intima of the arterial wall is a significant manifestation of 
atherosclerosis (Gieseg et al., 2009). Foam cells are produced when macrophages start to 
take up LDL by different processes, involving scavenger receptor activity and phagocytosis 
(Witztum, 2005). Besides, smooth muscle cells secrete substances to the extracellular 
material, which engage with aggregated LDL to increase LDL uptake by macrophages 
(Tabas et al., 1993). Acidification of extracellular fluid increases macrophage uptake of 
both native and modified types of LDL, via an increase in the levels of proteoglycans on 
cell surfaces and complexes of LDL-proteoglycans (Plihtari et al., 2011, Lahdesmaki et al., 
2012). Extracellular acidosis may increase foam cells derived from monocytes by 
promoting lipoprotein modification and consequently, stimulating uptake by macrophages 
(Leake, 1997). Furthermore, Kruth (Kruth et al., 2002) has documented a type of foam cell 
development not involving either LDL modification or macrophage receptors, when 
macrophages are incubated with a high concentration of LDL  because of fluid-phase 
pinocytosis of native LDL particles (Zhao et al., 2006). Pinocytosis has been shown to be 
augmented with an acidic environment (Vermeulen et al., 2004). Macrophages after 
capturing a large amount of LDL generate incomplete closed chambers on the surface of 
aggregated LDL (known as lysosomal synapses), causing a decline in pH, and release 
lysosomal acid lipase. The main function of this enzyme is the hydrolysis of the cholesteryl 
esters of LDL to unesterified cholesterol and fatty acids. Unesterified lipid is then able to 
enter inside the cells and the fatty acids cause acidic local environments (Haka et al., 2013). 
Interestingly, an acidic microenvironment related to macrophages activity, in which they 
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release cathepsins and H+ ions, might provide suitable conditions for increased activity of 
proteases (Haka et al., 2009).  
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1.3.7 LDL oxidation inside lysosomes 
 
LDL modified by non-oxidative processes, including modification by sphingomyelinase (Xu 
and Tabas, 1991), phospholipase A2 (Hakala et al., 1999), and lysosomal cathepsins (Leake 
et al., 1990) was taken up faster by macrophages. The non-oxidised modified LDL might be 
taken up by macrophages but oxidised within lysosomes of macrophages (Wen and Leake, 
2007).  
Ox-LDL in extracellular fluid might only be partially oxidised because interstitial fluid 
contains effective antioxidant factors (Dabbagh and Frei, 1995) or might be secreted as ox-
LDL from foam cells, which lyse due to ox-LDL stimulated apoptosis and necrosis (Zhang et 
al., 2015). Lysosomes of macrophages contain redox-active iron (Kurz et al., 2004), which 
might catalyse LDL oxidation in these organelles (Wen and Leake, 2007). Lysosomes 
contain iron as a result of autophagy of iron-containing organelles or phagocytosis of red 
blood cells inside arterial plaques with haemorrhage from neovessels (Karlsson et al., 
2013). LDL oxidation by iron is much faster at lysosomal pH about (pH 4.5) relative to 
interstitial fluid pH about (pH7.4) (Wen and Leake, 2007)(Satchell and Leake, 2012). The 
iron chelator desferrioxamine decreased lysosomal LDL oxidation (Wen and Leake, 2007).  
Oxidation of LDL in lysosomes might have many consequences, including, macrophages 
stimulating pro-inflammatory cytokine secretion from macrophages and formation of 
ceroid (Ahmad and Leake, 2018), which might act as a coating layer to protect lipid droplets 
blocking lipase activity (Lee et al., 1998) and increasing the pH of lysosomes (Ahmad and 
Leake, 2019)(Figure 1.5). 
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1.4 Lysosomes 
 
The key role of these microscopic organelles is to work as digestion bodies for cellular 
elements that have surpassed their lifetime or are then no longer beneficial. In this 
respect, the lysosomes reutilize the cell's organic features in a process known as 
autophagy. It is a common term for cytoplasmic elements hydrolysis by lysosomes. 
Lysosomes hydrolyse cellular constituents, like carbohydrates and proteins, to basic 
elements, after hydrolysis relocated, the elements return back as new materials to the 
cytoplasm. To complete the responsibilities related to digestion, the lysosomes exploit 
about 50 diverse kinds of hydrolytic enzymes, all of which are synthesised in the 
endoplasmic reticulum and packaged in the Golgi apparatus (Kurz et al., 2008a). 
Lysosomes are regularly formed from the sheath of the Golgi apparatus and fuse with, late 
endosomes, which are vesicles that hold materials transported into the cell by endocytosis. 
The pH inside the lysosome is sustained at about 4.5 by an ATP-dependent proton pump 
 
 
 
 
 
 
lysosomal membrane (Ohkuma et al., 1982). 
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1.4.1 Lysosomal iron 
 
Numerous data have confirmed that redox-active iron exists within lysosomes (Yu et al., 
2003, Zdolsek et al., 1993, Yuan et al., 1996, Petrat et al., 2001). Lysosomal iron may derive 
from the breakdown of autophagocytosed ferritin (Yu et al., 2003, Sibille et al., 1989a, 
Radisky and Kaplan, 1998, Kidane et al., 2006) and iron-rich mitochondrial proteins (Yu et 
al., 2003, Persson et al., 2001) and the phagocytosis of red blood cells (Yuan et al., 1996). 
Desferrioxamine (iron chelator) is internalised by fluid-phase endocytosis and delivered to 
lysosomes (Lloyd et al., 1991, Cable and Lloyd, 1999). Studies have shown that 
desferrioxamine can deplete the cell cytoplasm of all chelatable iron, suggesting that the 
cytoplasmic non-ferritin bound pool of iron (identified as the labile iron pool) is derived 
from lysosomes (Tenopoulou et al., 2005). There is a difference in the levels of iron in 
different lysosomes, which is possible because of differences in the amount of time passed 
since the lysosomes have been involved in the breakdown of iron-rich compounds (Kurz et 
al., 2008a). It is controversial if lysosomes contain ferrous and ferric (Collins et al., 1991), 
but both might be present (Meguro et al., 2005). The ferrous form might be favoured, 
however, because of the reducing environment of lysosomes (Terman and Kurz, 2013)  
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1.4.2 Lysosomal involvement in apoptosis 
 
Subjecting cells to moderate oxidative stress has been reported to increase lysosomal 
membrane permeability, followed by increase mitochondrial membrane permeability and 
apoptosis (Brunk et al., 2001). Hydrogen peroxide, which is constantly formed within cells 
by the damage caused by electrons from the mitochondrial electron transportation chain, 
can simply diffuse into lysosomes and it remains there as lysosomes do not have the 
hydrogen peroxide degrading enzymes catalase and glutathione peroxidase (Kurz et al., 
2008a). Lysosomal hydrogen peroxide can then react with the lysosomal iron to make the 
highly reactive hydroxyl radical by the Fenton reaction. Hydrogen peroxide can oxidise 
various kind of substrates and caused biological damage with the presence of iron  (Neyens 
and Baeyens, 2003, Winterbourn, 1995).  
 
The acidic pH of the lysosome and occurrence of reducing equivalents such as cysteine are 
favourable for the Fenton reaction (Baird et al., 2006).  
In oxidative stress, increased quantities of hydrogen peroxide diffuse into lysosomes, 
causing the formation of hydroxyl radicals, which can harm lysosome membranes, leading 
to release of lysosomal enzymes, including cathepsin B, and consequent apoptosis.  
Desferrioxamine inhibits lysosomal rupture and apoptosis after oxidative stress (Yu et al., 
2003). Phospholipase activation might also trigger mitochondrial membrane damage, 
leading to the release of pro-apoptotic molecules (Zhao et al., 2001). Lysosomal cathepsins 
Fe2+   +    H2O2   Fe3+      +  OH-    +    OH• 
   33 
B stimulates the pro-apoptotic protein Bid (Cirman et al., 2004) and result in the reduces 
the anti-apoptotic proteins like Bcl-2 , Bcl-XL (Droga-Mazovec et al., 2008).  
 
 
 
 
1.4.3 Atherosclerosis as a lysosomal storage disorder 
 
Investigations of lysosomal storage defects, which are measured by the accumulation of 
ingestible material due to defective lysosomal enzymes, have described that accretion of 
undigested material within lysosomes can weaken their role and have a devastating effect 
on the body (Hers, 1972).   
Normally, LDL is internalised by macrophages and is carried to lysosomes for the 
breakdown. Lysosomal acid lipase breaks down the cholesteryl esters in the particle and 
the products from hydrolysis moves into the cytoplasm (Brown et al., 1983). Excessive 
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cholesterol converted to fatty acid under influences of enzyme acyl-CoA: cholesterol acyl-
transferase (ACAT) and is kept in the cytoplasm as lipid droplets (Rudel et al., 2001). In 
atherosclerotic lesions, foam cells store lipids within lipid-filled lysosomes and lipid 
droplets (Haley et al., 1977). Once macrophages bind LDL altered by oxidation or 
aggregation processes, LDL is swiftly taken up, and cholesterol accumulates. There is 
diminished lysosomal apolipoprotein breakdown, less cholesteryl ester hydrolysis and 
eventually diminished cholesterol efflux from lysosomes (Mahlberg et al., 1990, Griffin et 
al., 2005, Jerome et al., 1998, Yancey and Jerome, 2001). 
Oxidised LDL might prevent both lipase and protease activity and is capable of preventing 
free cholesterol elimination from the lysosomes (Kritharides et al., 1998, Dhaliwal and 
Steinbrecher, 2000, Hoppe et al., 1994). Cells incubated with oxidised LDL, agLDL or 
cholesteryl ester with rich lipid distributions had a reduced capability of the lysosomes to 
maintain an acidic pH, which agreed with the inhibition of cholesteryl ester lipolysis (Cox 
et al., 2007). It remained proposed that as lysosomal enzymes necessitate an acidic pH to 
performance correctly, neutralisation of pH of the lysosomes decreases cholesteryl ester 
hydrolysis. Potential treatments to avoid lysosomal lipid build-up in atherosclerosis include 
treatments to avoid lysosomal membrane cholesterol accumulation, which inhibits the 
lysosomal ATP-dependent proton pump and increases the pH of the lysosome (Jerome, 
2006). 
1.4.4 The role of lysosomes in atherosclerosis 
 
Lysosome organelles are an intracellular structure have an acidic interior of pH about 4.5 
(Mindell, 2012), which comprises acidic hydrolases, certain membrane proteins, including 
mannose-6-phosphate receptor (M6PR). M6PR is marking to classify late endosomes from 
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lysosomes. The pumps that move H+ ions opposite their concentration slopes named  ATP-
dependent proton pumps, which composed from trans member proteins. They hold few 
binding positions for ATP situated on the cytosolic part of the membrane. 
They usually do not convert ATP into ADP and Pi without H+ ions are alongside transported. 
According to this constricted connection between ATP breakdown and transport, the 
energy deposited in the phosphoanhydride bond is not degenerate but served to transfer 
ions and other molecules reverse an electrochemical slope. The transmembrane pH slope 
in lysosomal organelles is made and maintained by an ATP-dependent proton pump 
residing in the organelle membrane (Schneider, 1983).  
Lysosomes have similar properties to cell type-specific organelles called lysosome-
associated organelles, such as melanosomes, lytic granules, delta granules, lamellar 
bodies, and other acidic granules (Huizing et al., 2008). Significant evidence indicates that 
lysosomes play an important role in atherosclerosis. 
 For example, in fat deposition subendothelial space of lesion expansion, cholesteryl esters 
(CEs) collect mostly in cytoplasmic droplets, demonstrating that lysosomal role is 
functioning and propose a significant part for acyl-CoA acyltransferase (ACAT)-1  in 
producing lipid droplet at this phase (Jerome and Lewis, 1985). 
 As lesions develop into fibrous plaques, a considerable build-up of CE and free cholesterol 
happens in lysosomes from an atherosclerotic lesion that collects from mammalian and 
birds (Miller and Kothari, 1969), demonstrating the defective lysosomal breakdown the 
cholesterol ester and recycle of cholesterol and signifying that lysosomal disabled is a 
contributor to the last phase of the disease. 
Another lysosomal enzymes, such as cathepsin D and acid sphingomyelinase, are changed 
during the atherosclerosis process, signifying an association between lysosomes function 
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and atherosclerosis. Lysosomal storage disorders can refer to the gathering of substances 
in lysosomes because of inherent disabled in lysosomal hydrolysis. The relation between a 
defect in a lysosomal enzyme and dysfunction is primary and is associated with the 
malfunctioning lysosomal enzymes (Platt, 2014) But, in others view, accumulation seems 
comes from secondary events, which generate inconsistencies in metabolism (Rappaport 
et al., 2016). This accumulation is the main component of macrophage foam cells clinically 
significant atherosclerotic (Jerome, 2010).  
 
1.5 Transition metals in atherosclerosis 
1.5.1 Iron Homeostasis and Regulation 
 
The only origin of iron balance is absorption from the gastrointestinal tract.  Adults slough 
off 14 μg/kg/day of iron via epithelial shedding (Green et al., 1968). Also, before the 
menopause women lose the daily equal of 0.9 mg of iron over menstruation (Hallberg et 
al., 1966). Levels of ferritin in women increase considerably in the age between 50-60 years 
old, naturally during menopause, while men have a rise in ferritin levels through the late 
adolescent years (Zacharski et al., 2000). The extra iron level may take place by increased 
nutritional or complementary consumption (Zotter et al., 2004). Genetic syndromes, such 
as haemochromatosis, cause excess gut iron absorption (Lynch et al., 1989). Iron 
insufficiency most usually happens via blooding or insufficient dietary consumption and 
nutritional blocks of iron absorption (Fleming et al., 1998), or disorders like a coeliac 
disease characterised by an unusual mucosa that lining gastrointestinal tube causing block 
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iron absorption (Bardella et al., 2005). Free iron is toxic because of its redox activity 
(Takeda and Iwai, 2016). Hence, most iron ions in the body exist in a bound structure. 
 Iron erythrocyte haemoglobin is around 2,500 mg, ferritin in liver and spleen is around 
1,000 mg,  while myoglobin is  170 mg, besides 3 mg flows in the TPT (Schenck, 1992).  
Liver synthesised  Hepcidin, which is an iron-regulating hormone (Hentze et al., 2004, 
Pigeon et al., 2001). The important function of Hepcidin is binding and downregulating 
ferroportin (Nemeth et al., 2004). Ferroprotein, situated on the external membrane of 
macrophages, permits the release of iron from these cells and ferroportin to facilitate on 
enterocytes in the small intestines facilitate absorption of dietary iron (Abboud and Haile, 
2000). Consequently, hepcidin stimulates (i) iron confiscation in hepatocytes and 
macrophages (ii) diminishes duodenal iron uptake via enterocytes. People with 
haemochromatosis, particularly due to alterations in transferrin receptor 2 (TFR2), have a 
very low hepcidin concentration causing slight to no iron sequestrations in macrophages 
(Ganz and Nemeth, 2011). Lower macrophage iron levels in haemochromatosis could 
clarify their qualified prevention atherosclerosis regardless of their iron excess status. 
Hepcidin is suppressed by several conditions such as anaemia, erythropoiesis and hypoxia,  
(Nicolas et al., 2002). Hepcidin activated by an iron response mechanism during 
inflammation and iron accretion (Milward et al., 2005). A similar case is assumed in 
anaemia of chronic inflammatory disease when patients have a comparative lack of iron 
due to it being sequestration in macrophages.  
 
Ratios of cytokines, as well as interleukin-6 (IL-6), which encourages hepcidin activation, 
are noticeably raised in continuing inflammatory conditions (Andrews, 2004, Weiss and 
Goodnough, 2005). Raised hepcidin has also been connected with the existence of several 
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metabolic disorders (Martinelli et al., 2012) and arterial inelasticity assessed by ankle-
brachial pulsation wave speed (Kuragano et al., 2011).  
 
1.5.2 Iron and atherosclerosis 
 
Electron transmission to and from iron ions is necessary for transport, usage, and storing 
of iron in tissue. Redox-active iron stimulates the creation of free radicals able to oxidise 
LDL (Nagy et al., 2010). The core mechanisms include iron-induced oxidative stress is 
producing free radicals. The redox-active ferrous type of iron (Fe2+) is mainly responsible 
for making extremely reactive hydroxyl radicals.  
 
Iron compounds, may stimulate cultured endothelial cell apoptosis, prevent proliferation 
and stimulate monocyte adhesion (Carlini et al., 2006). (Apoe−/−) mice show poor remnant 
lipoprotein removal with consequent increase of cholesteryl ester-enriched in blood, 
which stimulate the progress of atherosclerotic plaques).   
Atherosclerotic lesions in apo E knockout mice contain significant quantities of iron 
(Rosenfeld et al., 2000). (A low iron diet diminishes the iron content and the area of the 
plaques and increases plaque stability. In humans, there is a strong positive relationship 
between iron type and protein oxidation in the atherosclerotic lesion (Carlini et al., 2006). 
There are several potential mechanisms by which iron can promote atherosclerosis. Iron 
can initiate lipid peroxidation by interacting with hydrogen peroxide to create highly 
reactive OH• according to the Fenton reaction. The ferric iron produced can be converted 
back to ferrous iron by reaction with superoxide. 
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In addition to this, iron (de Whalley et al., 1990), ferryl haemoglobin (Paganga et al., 1992) 
and ferryl myoglobin (Dee et al., 1991) have been documented to catalyse LDL oxidation 
in vitro. Iron is essential to manufactures enzymes, such as 5-lipoxygenase, that might have 
a role in atherosclerosis. Iron may also initiate endothelial dysfunction (Sullivan, 2006). 
Another mechanism by which iron participates in the atherosclerosis process is by 
catalysing the intralysosomal oxidation of LDL (Wen and Leake, 2007).  
 
1.5.3 Studies of stored iron level and CVD effects 
 
Epidemiologic studies in humans have explored the link between iron status and 
cardiovascular disease (CVD) (Institute of Medicine Committee on the Prevention et al., 
1993, Tuomainen et al., 1998).  
Serum ferritin concentrations > 200 μg/l were linked with a 2.2-fold rise in the occurrence 
of acute myocardial infarction with concentrations < 200 μg/l throughout three years 
(MacDonald, 1993). Conversely, other studies did not support these findings (Sempos et 
al., 2000, Ekblom et al., 2011). One reasonable explanation is that raised serum ferritin 
concentrations do not reflect augmented iron body stores, but are the consequence of 
infections and other inflammatory developments related to coronary heart disease 
(Alexander, 1994, Lipschitz et al., 1992). However, more recently, Tuomainen et al 
(Tuomainen et al., 1998) used the ratio of serum transferrin receptors (as a marker of iron 
depletion) to serum ferritin and observed a 2.9 fold increase in the incidence of acute 
myocardial infarction among Finnish men in the lowest tertiles compared to the highest, 
even after adjusting for inflammation and alcohol intake. Another possibility is that iron 
stores may relate to established CVD risk factors, such as LDL cholesterol, in increasing the 
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risk of CVD (de Valk and Marx, 1999). On the other hand, if increased iron stores are 
causally related to increased CVD risk, a reduction in iron consumption would possibly be 
a protection factor for CVD. Iron stocks are related to CVD risk factors in women during 
reproductive age (Ramakrishnan et al., 2002).Carotid atherosclerosis was positively 
related to serum ferritin in healthy men at 45-65 years and women who were without 
subclinical inflammation, independently of traditional CVD risk factors (Zacharski et al., 
2000).More investigational trials that consider subclinical inflammation, evaluated using 
numerous markers, such as  α1-acid glycoprotein, are required to discover the pathway of 
the observed association and to better recognise the fundamental mechanisms (Ahluwalia 
et al., 2010). The novel proposal of the iron theory did not postulate a mechanism. 
Numerous mechanisms by which iron reduction might protect from atherosclerosis. Many 
researchers did not record the important variance in plasma iron levels in patients 
suffering from diverse kinds of (CHD) equated to healthy controls (Paramonov et al., 2005).  
There were significantly higher levels of serum iron in patients suffering haemorrhagic 
plaques in their carotid arteries compared to people in the control group (Tasic et al., 
2015). The data of numerous human research strongly recommend a link between serum 
iron levels and atherosclerosis progress. Based on the epidemiological data, iron levels, 
observed by measuring serum ferritin levels and transferrin saturation, positively 
connected with an augmented risk factor of myocardial infarction (Holay et al., 2012, 
Rajapurkar et al., 2012).  
 
Since atherosclerotic lesion contain redox-active iron, which might stimulate free radical 
development and then lipid peroxidation proposed important of iron in atherosclerosis 
(Smith et al., 1992). Recently statistics demonstration that iron may have a participate in 
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plaque weakness and participate in plaque haemorrhage (Mascitelli and Goldstein, 2014, 
Michel et al., 2012). 
 Peroxidation can be augmented by the existence of oxidant factors, such as iron or 
copper ions (Stadler et al., 2004). Since phagocytosed erythrocytes in macrophages have 
been recognised in plaque near microvessels, explaining the previous haemorrhage 
inside the plaque as well as oxidised LDL inside the macrophages (Kopriva et al., 2015). 
 
1.5.4 Mechanisms of iron toxicity in atherosclerosis 
 
Iron compounds, may stimulate cultured endothelial cell apoptosis, prevent proliferation 
and stimulate monocyte adhesion (Carlini et al., 2006). Atherosclerotic lesions in apo E 
knockout mice contain significant quantities of iron (Rosenfeld et al., 2000). A low iron diet 
diminishes the iron amount and the area of the plaques and increases plaque stability. In 
humans, there is a significant positive relationship between iron status and protein 
oxidation in the atherosclerotic lesion (Carlini et al., 2006).  These are several potential 
mechanisms by which iron can promote atherosclerosis. Iron can start lipids peroxidation 
by interacting with hydrogen peroxide to create highly reactive OH• according to the 
Fenton reaction. The ferric iron is produced can be converted back to ferrous iron by 
reaction with superoxide.In addition to this, iron (de Whalley et al., 1990), ferryl 
haemoglobin (Paganga et al., 1992) and ferryl myoglobin (Dee et al., 1991) have been 
documented to catalyse LDL oxidation in vitro. Iron is essential to produce enzymes, such 
as 5-lipoxygenase, that might have a role in atherosclerosis. Iron may also initiate 
endothelial dysfunction (Sullivan, 2006). Another mechanism by which iron participates in 
the atherosclerosis process is by catalysing the intralysosomal oxidation of LDL (Wen and 
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Leake, 2007).  Furthermore, free radicals can be made in vitro under the oxidative 
condition with existence of ascorbic acid and iron ions. There is another essential, although 
not commonly documented, an element known as free iron existent in blood named the 
labile iron pool (Kruszewski, 2004). It was proposed that iron treatment potently 
encourages the creation of hydroxyl radicals consequently contributing to atherosclerosis 
(Sengoelge et al., 2005, Feres and Reis, 2005).  
 
1.5.5 Copper concentration in atherosclerotic plaque 
 
Numerous studies have shown that copper is effective in catalysing LDL oxidation, however, 
the exact mechanism is not yet understood (Esterbauer et al., 1992) (Burkitt, 2001, Horsley 
et al., 2007).   
The copper-containing protein caeruloplasmin can oxidise LDL, especially at low pH (Lamb 
and Leake, 1994). Nutritional copper supplementation reduces atherosclerosis, however, in 
rabbit with highly fat-fed (Lamb et al., 1999). Copper might, however, have both pro- and anti-
atherogenic influence (Rajendran et al., 2007).  
Some investigational studies indicated a relationship between a lack of copper with high 
cholesterol concentrations and atherosclerosis in coronary arteries (Hamilton et al., 2000). 
Copper ions can transform superoxide and hydrogen peroxide into the extremely harmful 
hydroxyl radical that be able to injure the endothelium (Alissa et al., 2006). Lipid peroxidation 
may occur by copper ion, consequently, alteration of the apoB-100 protein, producing lipid 
peroxidation products, such as 4-hydroxynonenal (4-HNE), acrolein, and malondialdehyde 
(MDA). Existence of these oxidised materials on apoB-100 has been serologically 
demonstrated in atherosclerotic lesions (Uchida et al., 1995, Rosenfeld et al., 1990).   
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The low concentration of free metal ions, copper ion, insufficient amounts of reducing factor 
and proteins found in the plasma may protect LDL from oxidation (Uchida et al., 1995). 
Nevertheless, the mechanism of copper ion-induced LDL oxidation happens in physiological 
environments remain uncertain (Itabe, 2003).  
The initial stage in the copper-stimulated oxidation of LDL thought to be the binding of Cu (II) 
to several Cu (II)-binding positions on the surface of the ApoB-100. The particular number of 
these positions is not agreed, but values extending from 3 -40 per apoB-100 molecule have 
been measured (Roland et al., 2001). 
 Once bound, Cu (II) can be reduced to Cu (I) by several possible reductants, including amino 
acid residues (Giessauf et al., 1995) protein and lipid peroxides (Patel et al., 1997) and α-
tocopherol (Lynch and Frei, 1993, Schnitzer et al., 1997). Monitoring metal ion level 
atherosclerotic plaque occurred in many methods. ( Ex vivo electron paramagnetic resonance 
(EPR) spectroscopy, together with inductively coupled plasma mass spectroscopy (ICPMS)), in 
healthy and atherosclerotic carotid artery tissue (Stadler et al., 2004). Iron and copper levels 
were increased in diseased arteries. 
 
1.6 Antioxidants 
 
Based on the biological perspective, antioxidants described as materials that the level less 
than that of the oxidisable substrate are proficient at suspending or stopping oxidative 
reaction (Halliwell, 2012). The main methods to keep biological molecules from oxidation 
because they become oxidised themselves. The constancy of oxidised antioxidant 
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molecules is important, so to avoid oxidised antioxidants reacting with other biomolecules 
(Bors et al., 1990).  
 
1.6.1 Mechanisms of antioxidant protection in the body 
 
All cells in the body are vulnerable to attack by ROS and oxidative if the pro-oxidant-
antioxidant equilibrium is troubled because of extreme oxidative factor or insufficient 
antioxidant protection. The equilibrium between oxidative factor and antioxidant 
protection is a dynamic circumstance for healthy tissues. Antioxidant mechanisms act as 
scavenging oxidizing factors, using enzymes or biochemical reactions, diminishing the 
creation of a single atom of oxygen, chelating necessary transition metal ions required to 
change weakly reactive species like H2O2 or O2.- into highly reactive ones, and replacing 
damaged target molecules (Zhang et al., 2014). 
Antioxidants can either be small molecules, like proteins and enzymes. The functional 
antioxidant programs have numerous positions of defence. This antioxidant system 
starting with, antioxidants inhibit the creation of ROS/RNS, by isolating active redox metal 
ions and reducing ROOH and H2O2 to OH− and H2O, correspondingly. In the next line of 
protection, antioxidants scavenge ROS/RNS before they damage biological particles. In the 
other protection position, an antioxidant may treat the damage and rebuild injured 
tissues. Moreover, an insufficient amount of oxidative stress may persuade an effect, 
which intensifications the creation of antioxidant, consequently transfers them to the 
correct location at the correct phase and in the accurate amounts (Higdon et al., 2012).  
Therefore, antioxidants role supportively and synergistically inside the body to manage 
oxidative stress and antioxidant balance. Oxidative risk is produced by free and non-free 
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radical pathway. Both types of oxidants affect and change biological substances, 
interference of thiol redox roles caused by ROS/RNS (Jones, 2008). 
 Numerous types of free radicals are implicated in vivo, for example, (superoxide (O2•−), 
hydroxyl (HO•), alkoxyl (RO•), peroxyl (RO2•), aryloxy (ArO•), nitric oxide (•NO), nitrogen 
dioxide (NO2•), thiyl (RS•), thiyl peroxyl (RSOO•), sulfonyl (RSO2OO•), and carbon-centred 
radicals (R•)). Few radicals are moderately unstable, but some are not. Antioxidants (IH) 
react with free radicals X•. Theoretically, the reactions are explained by different equations 
based on radicals, antioxidants, and microenvironment. 
 
 For example (Vitamin E, vitamin C,). Vitamin E may have another role in a signalling 
mediator, which is independent of the antioxidant role, which is a subject of discussion 
(Traber and Atkinson, 2007, Azzi, 2007). α-tocopherol has been labelled as a radical-chain 
breaker which, because of its hydrophobic nature, functions in a lipid environment in 
membranes and lipoproteins (Azzi, 2007). 
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1.6.2 EDTA  
 
EDTA (ethylenediaminetetraacetic acid) is a member of an amino polycarboxylic family of 
ligands. It acts as a hex dentate (“6 toothed”) ligand (Figure 1.7) and binds metal ions such 
as Ca2+ and Fe3+. 
 EDTA has a high affinity for transition metals (Xing et al., 1998). During the treatment of 
(CHD), EDTA provided together with the vitamins intravenously (Ernst, 2000). 
Nevertheless, global studies have documented that this therapy is unsuccessful as 
medicine for coronary heart disease, and in many conditions, it has shown unfavourable 
effects (Ibad et al., 2016).  
The main role of EDTA in this situation is to try to decrease the blockages in blood vessels 
by binding with the metals from the blood or decalcify artery plaques (Bolick and 
Blankenhorn, 1961). EDTA cannot easily enter mammalian cells (Krishnamurti et al., 1980). 
EDTA may decrease extracellular metals activity. 
EDTA will diminish metal uptake by cells and therefore will inhibit the level of metal 
intracellularly Metals such as cadmium and lead, which are chelated by EDTA are linked 
with an augmented risk of (CVD) (Ouyang et al., 2015). The combination  EDTA  with 
existing propofol demonstrations no remarkable outcomes on calcium and magnesium 
contours, haemodynamic indicator in interoperative anaesthesia  (Wahr et al., 2000). 
Researchers demonstrated in the tissue culture media, LDL oxidation by copper or cells is 
augmented if a low concentration of EDTA is carried over during LDL isolation (Lamb and 
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Leake, 1992). Low concentration  1-3 µM EDTA  can raise LDL oxidation rate by Cu2+, in 
Ham,s F-10 medium, while high concentration 10 µM show inhibition of  LDL oxidation by 
macrophages. 
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1.6.3   Vitamin E (α -tocopherol) 
  
Micronutrients can serve as antioxidants, such as vitamin C and, α- tocopherol (Jialal and 
Fuller, 1993). α-Tocopherol characterises the most biologically powerful member of the 
vitamin E family in mammals (Machlin and Bendich, 1987). α-Tocopherols are composed 
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of two rings with a hydrocarbon chain (Figure 8). Natural vitamin E has different types such 
as α, β, γ, and δ depending on the methyl groups, which are bound to the benzene ring 
(Brigelius-Flohe and Traber, 1999). Synthetic α -tocopherol consists of eight isomers. RRR-
α-tocopherol is believed to be the most important form of vitamin E since it is digested 
and then absorbed better than other types from the diet by the intestine. The (α-
tocopherol transfer protein) is capable for the intracellular transportation of vitamin E. 
Furthermore, detection of α-tocopherol specific membrane receptors and cytosolic 
transfer proteins bolster the concept that vitamin E has a role beyond a basic antioxidant 
function (Engin, 2009) (Sies and Murphy, 1991). Vitamin E is found mainly in vegetable oil 
and has a role to protect tissues from damage caused by oxidation. It is absorbed by the 
small intestine and α-tocopherol is retained and dispersed between lipids in cell 
membranes and plasma lipoproteins. α-Tocopherol captures free radicals during chain 
reactions. The hydrogen atom from the phenolic hydroxyl group of α-tocopherol is given 
to the free radical, leading to a more stable free radical in the form of the from vitamin E 
radical (Sies and Murphy, 1991). Vitamin E is a strong radical-scavenging antioxidant, but 
there is a limitation in his effectiveness with non-radical oxidants group, including 
cyclooxygenase, lipoxygenase, and hypochlorite (Niki, 2014). Researchers have shown that 
α-tocopherol diminished the activity of CD36, decreasing macrophages uptake of oxidised 
LDL and consequently reduces foam cell formation (Mathur et al., 2015). Vitamin E has 
been assessed as an antiatherogenic factor by reducing LDL oxidation, preventing the 
formation of macrophage foam cells and atheroma and inhibiting the immune and 
inflammatory response (Wallert et al., 2014).  
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α - Tocopherol appears antioxidant properties under high oxidative circumstances but can 
show pro-oxidant influences under minor oxidative circumstances (Bowry et al., 1992). The 
major mechanism by which it acts as an antioxidant is by the scavenger of one radical (R•) 
by a molecule of α-tocopherol (TocOH) (reaction 1), and then inhibition of a next radical 
by α- tocopheroxyl radical, (reaction 2), causing inhibition of 2 radicals by 1 molecule of α 
-tocopherol. 
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α-Tocopherol can demonstrate as a pro-oxidant agent under low oxidative stress 
conditions since the α-tocopherol radicals capable remove a hydrogen atom from a PUFA 
moiety (Bowry, 1992). 
 
vitamin E is present in the intestine as a component of micelles composed of dietary lipids.  
Micelles are hypothetically important for absorption by the brush border of the 
enterocyte. Certainly, varied micelles are solubilizing hydrophobic particles and spreading 
into the (glycocalix) to reach enterocyte (Reboul, 2017).  α-Tocopherol is then absorbed 
into chylomicrons (Sokol et al., 1983). Once it spreads into the bloodstream, absorbed 
vitamin E is transforming to new lipoproteins under the effect of phospholipid transfer 
protein (PLTP) and to cells by the action of PLTP and lipoprotein lipase (LPL) (Kostner et al., 
1995). The liver also uptake and re-spread vitamin E when chylomicron remnants are taken 
up and released back to the circulation as a  form of low density lipoproteins (VLDL) (Havel, 
1994). In liver α-tocopherol bind with a specific protein, the α-tocopherol-transfer protein 
(α-TTP) (Hosomi et al., 1997), and convert α-tocopherol to several lipoproteins (Brigelius-
Flohe and Traber, 1999).  
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The cytochrome P450 enzymes regulate vitamin E level. γ-Tocopherol absorbed and secret 
into the bile, while α-Tocopherol release in the bile via the multidrug resistance (MDR) 
family of carriers. The MDR family contains several members, the most vital being those 
of the ATP-binding cassette, (Mustacich et al., 2007, Tang et al., 2013).  
 
 
1.6.3.1 Biological Functions of Vitamin E  
 
statistics provided the fundamental role of vitamin E in health and contributed a good 
knowledge about vitamin E from different aspects such as biological roles and metabolic 
outcomes. The finding of α-TTP, which selectively recognise and join to  RRR-α-tocopherol, 
this indicates the importance of this vitamin also emphasises its dominance biologically 
compared to another isomer. Because of α-tocopherol renewal system as the antioxidant 
system is mostly responsible for the deficiency in humans and the infrequent diminishing 
its level in the adult human. Majority of extra tocopherols digestive is expelled in the faeces 
unaffected, while it's expelled to urine with the side chain condensed with the chromane 
ring unbroken.  
Vitamin E can protection against mitochondrial superoxide generation and may act as a 
biological modifier independently of its antioxidant properties. By reducing the production 
of ROS/NOS, vitamin E protects against oxidative damage and also regulates important 
cellular events (Chow, 2004). Supplementation Vitamin E may increase the threat of 
haemorrhage in humans (Pastori et al., 2013). 
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1.6.3.2 Regulation of Cell Survival, Proliferation and Apoptosis by Vitamin E 
 
The first predictable non-antioxidant activities of vitamin E  was an inhibitory influence on 
protein kinase C (PKC) (Mahoney and Azzi, 1988). Vitamin E effects to trigger 
phosphoserine/threonine phosphatase 2A (PP2A), regulating the dephosphorylation of 
PKC, on the plasma membrane (Boudreau et al., 2002). The greatest noticeable outcome 
of vitamin E caused by block PKC pathway, decreasing of cell multiplication. This has been 
presented to take place in several cells (Zingg, 2007). The disruption in the proliferation of 
vascular smooth muscle cells (VSMC), leading disruption atherosclerosis mechanism  
(Boscoboinik et al., 1991, Tasinato et al., 1995). The mitogen-activated protein kinase 
(MAPK) pathway also blocked by the effect of vitamin E.  
 In VSMC activated when exposed to certain concentration from oxidized LDL, MAPK 
function and increased cell survival can be reduced under the effect of vitamin E (de Nigris 
et al., 2000). Protein kinase B pathway also inhibited by vitamin E and stimulated protein 
tyrosine phosphatase and,  increased cell propagation and survival (Zingg, 2007) 
 
1.6.3.3 Improvement of Endothelial Function by VitaminE 
 
Vitamin E has a role to improve numerous characteristics of the endothelium, like 
antithrombotic role vasodilatation. In macrophages, vitamin E has a blocking impact on 
arachidonic acid (AA), while causing an intensification in arachidonic acid by endothelial 
cells. This influence accompanied by inhibition cyclooxygenase (COX) 1 and 2 pathway, 
another influence is an intensification in the formation of vasodilating prostanoids (PGE2 
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and PGI2 ) (Wu et al., 2004). Vasodilatation by phosphorylation endothelial nitric oxide 
synthase (eNOS) on serine 1177 (Heller et al., 2004a, Heller et al., 2004b), 
 These outcomes translate to augmented amounts of NO metabolites after vitamin E 
treatment (Desideri et al., 2002b). Controversially, the influence of vitamin E on 
vasodilation remains uncertain, as many researchers have documented an improvement 
in vasodilation after exposure to vitamin E, by a mechanism increasing the phosphorylation 
of eNOS and inhibition production of O2− (Green et al., 1998, Heitzer et al., 1999) but other 
studies have not shown this (McSorley et al., 2005, McDowell et al., 1994). 
 
 
 
1.6.3.4 Regulation of Inflammtory Process by Vitamin E 
 
Vitamin E role documented to prevent numerous inflammatory events that occur during 
the process of atherosclerosis.  The main role Vitamin E inhibition inflammatory 
chemokines formation by endothelial cells and leukocytes in vitro (Wu et al., 1999) 
(Yoshikawa et al., 1998) and in vivo (Koga et al., 2004). Supplementation of vitamin E  with 
a high dosage, reporting a reduction in adhesion molecules (Desideri et al., 2002b, Desideri 
et al., 2002a, van Dam et al., 2003).  
Moreover, vitamin E  prevented the secretion of tumour necrosis factor-α (TNF-α) (Devaraj 
and Jialal, 2005) and interleukin-1β (IL-1β) (Devaraj and Jialal, 1999, Devaraj et al., 1996).  
CD36, which recognised oxidized LDL and internalization by macrophages, is inhibited by 
vitamin E (Munteanu et al., 2004, Munteanu et al., 2006). Lastly, vitamin E suppresses the 
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function of inducible NOS and NADPH oxidase, thus preventing the macrophage rupture 
(Khanduja et al., 2005, Cachia et al., 1998).  
 
1.6.3.5 Antioxidant actions by Vitamin E 
 
α -Tocopherol is categorised to be an antioxidant because of its capability to trapped lipid 
radicals and break the oxidation chain. It can end radical chain reactions mediated by the 
LOO•, inhibiting creating another radical, which continuing the sequences reaction by 
oxidizing other lipid particles. This process depends on the degree of the reaction between 
L and LOO•, around 1,000-fold less than the degree of the reaction between α-tocopherol 
and LOO• (102 M-1S-1) compared to (105-106 M-1S-1). It is questionable that vitamin E may 
affect the radical sequences response in aqueous phases. 
The oxidation chain reaction is generally started with water-soluble particles, someplace 
vitamin E unavailable because of its lipophilic behaviour. Its reaction with L• is improbable 
since the degree of the response between L• and O2 is 100-1,000-fold more equated to 
that of L•and vitamin E. After oxidation of vitamin E, the regeneration process may occur 
in the presence of vitamin C, resulting in inhibition of vitamin E radicals and prevention 
lipid peroxidation (Brigelius-Flohe, 2009). 
 
1.6.4 Tempol 
 
Tempol is a low-molecular-weight molecule (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-
oxyl) (Figure 1.9), also identified as 4-hydroxy-TEMPO. Tempol is a radical scavenger which 
has SOD and catalase actions. Furthermore, tempol inhibition endothelial dysfunction in 
 56 
diabetic rats and diminishing expansion regional myocardial ischaemia/reperfusion 
(McDonald et al., 1999).  
Tempol is a synthetic component with SOD-like activities (Mehta et al., 2004). It increases 
the conversion of the superoxide radical into oxygen and hydrogen peroxide.  
The tempol free radical is utilized as an activator and a chemical oxidant because it is a 
stable radical (Rak et al., 2000). It detoxifies ROS and stimulates the disproportionation of 
superoxide and helps hydrogen peroxide metabolism. Further, it is useful as a free radical 
scavenger. Oxygen molecules with single electrons are reactive and can cause damage by 
chemically reacting with cell constituent and leading to destabilization. Clinical data shows 
that oxidative factors might influence the progress of hypertension. Hypertension is 
further involved in the progress of cardiovascular diseases, obesity and stroke. Tempol 
inhibits the production of free radicals by oxidation of iron, thus ending oxidative stress 
(Januschowski et al., 2014).  Being highly cell-permeable (Mitchell et al., 1990b), it saves 
cells from injury prompted by hypoxanthine/xanthine oxidase and H2O2, while it shows no 
catalase activity.  
Tempol also disruption Fenton reaction and formation OH•. Whether by SOD-like activity 
or capture of an electron from metal ions, protecting from oxidative stress (Mitchell et al., 
1990b). Experimental evidence shows in vivo neuroprotective properties of tempol 
(Lipman et al., 2006). Tempol decreases the pro-oxidant impact due to fructose overload, 
reduces lipid peroxidation and decreases NADPH oxidase system by blocking the of 
p47phox activity in the vasculature (Cannizzo et al., 2014). 
 Tempol suppressed the appearance of VCAM-1 of in the aorta and diminished the 
progress of atherosclerosis (Joo et al., 2015). Studies show that tempol decreases oxidative 
effect by inhibiting the precise assemblage of the Nox2 oxidase in the artery and is capable  
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of diminishing atherosclerosis. Therefore, tempol is a possible therapeutic drug for 
treating risk factors related to metabolic disorder (Cannizzo et al., 2014). 
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1.6.5 Probucol 
 
Probucol is a clinically used cholesterol-lowering and antioxidant drug (Heel et al., 1978). It 
has been used as a pharmaceutical agent to treat a diversity of infections, traumas, and 
pathologic disorders, including lowering plasma cholesterol levels in hypercholesterolaemia 
patients (Zimetbaum 1990). Probucol is lipophilic antioxidant, bis-tertiary butyl-phenol 
capable of basically providing one of the hydrogens from its phenolic groups and (Figure 1.10). 
 Throughout lipid oxidation process, (L•), (LO•) or (LOO•) simply taken an H atom from 
probucol, preventing continuous sequences of lipid peroxidation (Jackson et al., 1991). Then, 
LDL  oxidation by these radicals probucol competent to fully inhibit this oxidation (Maiolino 
et al., 2013). Both in vitro and in vivo, probucol showed an inhibitory impact on LDL 
oxidation. Probucol showed diminishing restenosis in patients, nevertheless, probucol impact 
on atherosclerosis have been inconstant. It did not decrease femoral atherosclerosis in 
patients (Wallduis et al., 1994). 
 Probucol oxidation produces toxic material, including spiroquinone  and a  bis-quinone , 
which involved in initiating QTC prolongation and fatal arrhythmia (Steinberg, 2007). 
Probucol was permitted in the united state in the 1980s, but in 1995 probucol withdrawn 
from the US market (Bourne et al., 2007). Several hypotheses have been offered to explain 
the variability of antioxidant results.  
It was proposed that the antioxidant effect was associated with long-term accumulation of 
this compound that could be essential for its relationship to other antioxidants and leads the 
maximum benefit. We suggest that the peroxidation process is transmitted within lipoprotein 
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particles by the reaction of the alpha-tocopheroxyl radical with PUFA moieties in the lipid 
after α-tocopherol enrichment. This lipid peroxidation pathway can be explained by the 
recognised chemistry of the α -tocopheroxyl radical and might explain how reagents, such as, 
probucol which inhibit the α -tocopheroxyl radical, ending lipid peroxidation in LDL enriched 
with α -tocopherol. 
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1.7 Thesis aims and hypothesis 
Atherosclerosis, a prolonged inflammatory disease of the arterial wall, is the main reason for 
morbidity and mortality from cardiovascular disease (CVD).  There is onsiderable evidence 
that oxidation of LDL  is involved  in the pathogenesis of atherogenesis.  The large clinical trials 
of antioxidants  (mainly α-tocopherol)  have, however, shown no protection against 
cardiovascular diseaeses. Almost all the studies of LDL oxidation have assumed that LDL 
oxidation occurs in the extracellular space of atherosclerotic lesions. It has been shown, 
however, that LDL can be oxidised in the lysosomes of macrophages and that this depends on 
iron and the acidic pH of lysosomes (Wen and Leake , 2007 ). The main hypothesis tested in 
this thesis is that antioxidants do not function as effectively in protecting LDL from oxidation 
at lysosomal  pH as they do at pH 7.4. This hypothesis was investigated by enrichment of LDL 
with α-tocopherol and oxidising it by different concentrations of copper and ferrous and ferric 
ion at pH 4.5 and 7.4. Conjugated dienes were measured by an automatic spectrophotometer 
and oxysterol by using HPLC. 
Another aim was to compare the effects of other antioxidants (probucol and tempol) to these 
α-tocopherol at lysosomal pH.   
Another hypothesis was that α-tocopherol enrichment of macrophages would protect them 
from apoptosis due to oxidative stress. This was investigated by detecting the percentage of 
apoptotic cells, necrotic cells and secondary necrotic cells by flow cytometry. The final 
hypothesis was that macrophages,  containing LDL that they have oxidised in their lysosomes, 
die and lyse in atheroscleriotic lesions exposing other cells to toxic oxidised LDL. We 
approached this hypothesis by testing if LDL oxidised under lysosomal conditions (by iron at 
pH 4.5) decreased endothelium-dependent vasodilatation in rat aortic rings. 
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Chapter 2 
 
 
Materials and methods 
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2.1 General laboratory reagents , solutions and equipments 
 
2.1.1 Laboratory reagents  
 
General laboratory reagents and companies from which they were purchased are listed below 
 
Chemicals Supplier 
Alpha-tocopherol Sigma-Aldrich Ltd 
Acetylcholine Sigma-Aldrich Ltd 
Amphotericin Sigma-Aldrich Ltd 
Bio Red®DC TM PROTEIN ASSAY KIT Bio Red 
Blocking kit Vector 
Avidin/Biotin 
Bovine serum albumin (BSA) Invitrogen Ltd 
CD 31 rat antibody AbD Serotec 
Chelex-100® Sigma-Aldrich Ltd 
eNOS antibody  Cell signalling 
ECL Fisher Scientific 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich Ltd 
EGM-2 Clonetics/Lonza 
  
Ethanol Sigma-Aldrich Ltd 
Folin and Ciocalteu phenol reagent Fisher Scientific 
Fetal calf serum (FCS) Invitrogen Ltd 
Ferrous sulphate Sigma-Aldrich Ltd 
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Halt Tm protease & phosphatase inhibitor Fisher Scientific 
Harris haematoxylin  Sigma-Aldrich Ltd 
HRP-Goat Anti Rabbit-IgG Invitrogen Ltd 
HRP-Goat Anti-Mouse IgG Invitrogen Ltd 
HEPES sodium salt Sigma-Aldrich Ltd 
 Sodium nitroprusside (SNP) Fisher Scientific 
Sphingomyelinase Sigma-Aldrich Ltd 
Sodium Dodecyl Sulphate Sigma-Aldrich Ltd 
Sodium acetate Sigma-Aldrich Ltd 
Penicillin/streptomycin Invitrogen Ltd 
Phosphate buffered saline Invitrogen Ltd 
Phenylephrine Fisher Scientific 
Phorbol 12-myristate 13-acetate (PMA) Invitrogen Ltd 
p-eNos (S1177) Rabbit antibody Cell Signalling 
PVDF Transfer membrane Fisher Scientific 
Magnesium chloride Sigma-Aldrich Ltd 
Dihydroethidium (Hydroethidine) 
 
Fisher Scientific 
Dako Fluorescence Mounting Medium Dako 
Dimethyl sulphoxide(DMSO) Fisher Scientific 
Oil Red O  Sigma-Aldrich Ltd  
MCDB131 Atlantic &Georgia  
RIPA buffer Sigma-Aldrich Ltd 
RPMI 1640 medium Invitrogen Ltd 
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1.2.2 Laboratory equipments 
 
 
Name 
 
Company   
 
Optima TM XPN ultracentrifuge 
 
Beckman  
 
 Lambda-2-6-cell spectrophotometer 
 
PerkinElmer  
Lambda Bio 40 8-cell spectrophotometer 
 
PerkinElmer  
 
Agilent 1100 HPLC System Agilent 
BD Accuri TM C6 flow cytometer 
Biosciences  
BD 
Biosciences 
 
Axioskop epifluorescent microscope 
Zeiss 
Carl Zeiss 
 
  Countess II FL automated cell counter Invitrogen                   
DMT Myography system  DANSH Myo Technology 
HPLC series 200 PerkinElmer  
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1.2.3 General solutions 
 
High-density KBr solution (HDS) 1.316g/ml for LDL oxidation. 
1 L of HDS (2.97 M KBr, 2.62 M NaCl and 297 µM EDTA) was prepared by the addition of 354 
g KBr, 153g  NaCl, 110.5 mg EDTA.Na2H2O and made up to 1 litre of purified water and pH 
adjusted to 7.4 with NaOH solution.  
 Low density KBr solution (LDS; density 1.006 g/ml) for LDL oxidation. 
(150 mM NaCl and 297 µM EDTA), pH adjusted to 7.4 with NaOH solution. 
 
Lowry solution A for protein measurement. 
0.2 M Na2CO3, 0.1 M NaOH, 5.7 mM sodium tartrate and 35 mM sodium dodecyl sulphate 
(SDS). 
Lowry solution B for protein measurement 
0.16 M CuSO4 .   
Sphingomyelinase LDL stabilising buffer  
MgCl2 100 mM,150 mM NaCl, 10 mM MgCl2 and 5mM HEPES, pH7.4, used for diluting LDL 
before adding sphingomyelinase.  
 
Phosphate buffer saline (PBS) 
NaCl (137 mM), KCl (2.68 mM), KH2 PO4 (1.47 mM) and Na2HPO4  (8.1 mM) made up in 800 
ml of ultrapure water, pH adjusted to 7.4 with 1M HCl and final volume made up to 1 litre 
with ultrapure water. PBS keeps an osmotic balance between the internal and external 
environment of cells. It maintains physiological pH.  
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LDL Dialysis buffer 
140 mM NaCl, 8.1 mM Na2HPO4,1.9 mM NaH2PO4 and 100 µM EDTA. The pH was adjusted to 
pH 7.4, by using pH Meter. LDL is dialysed against this buffer at the end of its isolation. 
 
 Sodium chloride/sodium acetate buffer for the oxidation of LDL at pH 4.5   
NaCl (150 mM, 8.8g/l), sodium acetate (10 mM, 0.82g/l) adjusted at pH 4.5 with HCl 
solution. Chelex-100 (washed in ultra-pure water) was added at 1g/l and mixed overnight 
with stirring. The Chelex was removed by paper filtration and the pH was checked. This 
buffer was used to dilute LDL to measure conjugated diene formation by a 
spectrophotometer 
 
 
Lipid hydroperoxide assay colour reagen 
KH2PO4 (163 mM), KI (120 mM), K2HPO4 (37 mM), Triton X-100 (2 g/l), NaN3 (150 µM), pH 
adjusted to 6.0. 
 
MOPS buffer (Chelex -100 treated) 
 
3-[N-morpholino] propane sulfonic acid (MOPS, 10 mM), NaCl (150 mM), pH 7.4.Chelex-
100 (washed in ultrapure water) added at 0.1% (w/v), mixed overnight and removed by 
filtration prior to pH adjustment. 
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HPLC oxidation mobile phase 
Acetonitrile, isopropanol and water (all HPLC grade):40/54/2% by volume. The mobile phase 
in reverse-phase chromatography has to  have the correct polarity and it has to give a 
reasonable competition for the absorption sites for the analytic molecules. 
 
Oil Red O Stain 
Stock solution: Oil Red O (0.35 g) dissolved in isopropanol (100 ml), filtered and stored at 
room temperature. The working stain was freshly prepared by mixing Oil Red O Stock with 
ultrapure water 60/40, followed by filtering.  It was used to detect intracellular lipid and 
ceroid 
FACS buffer 
 Hanks balanced salt solution HBSS with 0.6% BSA, 5 mM EDTA for apoptosis detection by 
using a flow cytometer.  
 
 
Cell fixing solution (4% (w/v) paraformaldehyde solutions) 
4g paraformaldehyde was placed in a 200 ml flask that already contained 60 ml PBS. The 
combination was warmed to 60 oC in a fume hood and dissolved with a magnetic stirrer. NaOH 
(0.5 M) was added dropwise until a clear solution was made. The solution was set to cool and 
the pH was adjusted using NaOH to pH 7.4. The volume was made up to 100 ml with PBS. 
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2.2. LDL 
2.2.1 Isolation of LDL 
 
LDL (d=1.019 to 1.063g/ml) was isolated by sequential ultracentrifugation of plasma. Venous 
blood was collected from healthy adult volunteers after checking their haemoglobin level was 
normal who had fasted for 12 hours before blood donation (Havel et al., 1955, Wilkins and 
Leake, 1994b).  Ethical permission had been given by the University of Reading Ethics 
Committee. The blood was collected into 50 ml syringes that contained 1 ml of Na2EDTA (0.15 
M) as an anticoagulant and to inhibit LDL oxidation and then transferred to 50 ml centrifuge 
tubes. The blood was centrifuged at 1500xg for 30 min at 4 oC and the plasma collected and 
pooled. High-density KBr solution (HDS, 1.316 g/ml) was added to the collected plasma to 
adjust its density to approximately 1.019 g/ml, using equation 1 to calculate the volume of 
HDS to add. 
Equation 1:           VHDS = VPlasma (Dreq- DCurr /DAdd- DReq) 
Where VHDS is the volume of HDS that was added to the plasma, DAdd is the density of the high-
density KBr solution, VPlasma   is the volume of added plasma, DCurr is the current density of 
plasma (1.006 g/ml) and DReq is the final required density. The plasma was added to the 
solution, it was dialysed against 2 litres of 1.019 g/ml density solution for 2 hours in the cold 
room (4 oC) to adjust the density to exactly 1.019 g/ml.  The plasma was pooled to 35ml Ultra 
crimp ultracentrifuge tubes (ThermoFisher Scientific Inc., USA) and was centrifuged at 40,000 
rpm for 18 hours at (4 oC). The ultra-crimp tubes were then sliced through the clear band 
solution in their centre, using a tube slicer. The top part containing VLDL and IDL was disposed 
of and the lower part containing LDL, HDL and the other plasma proteins was collected and 
pooled. The density of the pooled LDL-containing fraction was then adjusted to approximately 
   69 
1.063 g/ml by adding HDS, using equation 1 to determine the volume of HDS required. The 
density was adjusted to exactly 1.063 g/ml by dialysing the pooled fraction against 2 litres of 
1.063g/ml solution at 4oC for 2 hours. The plasma was then transferred to 35 ml Ultracrimp 
tubes and centrifuged at 40,000 rpm  (145,250 gav)for 18 hours at 4oC. The tubes were then 
sliced below the upper LDL layer, using a tube slicer. There was another centrifugation at 
1.063 g/ml (wash spin). The LDL was then dialysed against NaCl/phosphate/EDTA buffer at (4 
oC) with multiple changes overnight with stirring to remove the KBr. Finally, the LDL was filter 
sterilised with a Minisart filter 0.45 µm and stored at 4oC in the dark (Wilkins and Leake, 
1994a) 
 
 
2.2.2 Measuring LDL protein concentration 
 
LDL protein concentration was assessed using a modified Lowry assay (Schacterle and Pollack, 
1973). Standard concentrations of bovine serum albumin (BSA) were prepared from a 400 
µg/ml stock with purified water. LDL samples (125 µl plus 375 µl water) were made in 
triplicate. Lowry A reagent (1.5 ml) was added to each assay tube and incubated for 10 min 
at room temperature. Freshly made Lowry B reagent (150µl) was added to each assay tube 
and incubated in a water bath at 55 oC for 5 min. The tubes were allowed to cool at room 
temperature and the absorbance was measured at 650 nm. The principle of the assay is that 
peptide bonds in the LDL apolipoprotein B-100 or in the BSA standard from a complex with 
copper ions in the Lowry (A reagent). The complex then reduces the phosphomolybdic-
phosphotungstic Folin reagent (Lowry B), producing a blue chromophore which absorbs light 
at 650 nm. 
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 2.2.3 Aggregation of LDL with sphingomyelinase  
 
 
The subendothelial aggregation and retention of LDL are important events in atherogenesis. 
Incubation of LDL with bacterial sphingomyelinase (SMase) in vitro results in the formation of 
LDL aggregates similar to those that develop in the extracellular matrix and cause macrophage 
foam cell formation (Schissel et al., 1998). Native LDL was diluted to 2 mg protein/ml with a 
buffer called stabilizing buffer, which contains NaCl (150mM), MgCl2 (10mM) and HEPES (5 
mM), pH7.4. Sphingomyelinase from Bacillus cereus (Sigma-S9396-25N) was added at a final 
concentration of 10mU/ml and the sample was then incubated in a water bath maintained at 
37 oC to aggregated LDL, as described by Walters and Wrenn (Walters and Wrenn, 2008). 
Aggregation was measured by light scattering at 680 nm in a spectrophotometer (Khoo et al., 
1988). Sphingomyelinase aggregated-LDL (SMase-LDL) was dialysed against phosphate buffer, 
pH 7.4 (which had been pre-treated with washed Chelex-100 to remove contaminating 
transition metals (Van Reyk et al., 1995) and sterilised with a 0.45 µm. Minisart filter before 
use. 
 
2.2.4 Enrichment of LDL with α-tocopherol 
 
 
LDL α-tocopherol content was enriched, using the method previously described by Esterbauer 
et al. (Esterbauer et al., 1991b). Blood was obtained from a healthy volunteer and drawn into 
50 ml sterile syringes (containing 3 mM Na2EDTA) as an anticoagulant. Immediately the blood 
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was transferred to 50ml centrifuge tubes. The blood was centrifuged at 1500xg for 30 minutes 
at (4 oC) and the plasma was collected and pooled. The plasma was incubated at 37 oC  with 
1% (v/v of DMSO containing 100 mM ( +)α-tocopherol for 3 hours (final concentration 1mM)  
or with DMSO (1% of plasma volume) alone as control. After the incubation period finished, 
the LDL was isolated, as described above. α-Tocopherol  in the isolated LDL was measuered 
by the method described by Ramirez-Tortosa (Ramirez-Tortosa et al., 1999). Lipids were 
extracted from LDL samples (250 µl) using methanol and hexane. Methanol (1 ml) was added 
to each LDL sample and they were vortexed for 10 seconds. Hexane (3 ml) was then added 
and vortexed for 30 seconds in order to transfer α- tocopherol of LDL to the hexane. Samples 
were centrifuged 1500xg for 15 min at room temperature. The upper hexane layer (2 ml) was 
collected and transferred to 15 ml polypropylene tubes and dried by using an ISSIIO speed 
vac system. The samples were re-dissolved in 200 µl of ethanol and stored at -20 oC described 
in section 2.2.1 and the level of α-tocopherol in the LDL was measured by HPLC. Each sample 
(20 µl) inserted into a Capital C18 column (250 x 4.6 mm, 5 µm particle size, 5 µm guard 
column, Capital HPLC Ltd, West Lothian, Scotland). α-Tocopherol was recognised at 298 nm, 
using the mobile phase ( 99% methanol 1% water by volume, flow rate of 1.00 ml/min of run 
time 20 min) in a PerkinElmer HPLC. 
 
2.2.5 Measurement of α- tocopherol in oxidised LDL  
 
Control LDL or enriched with α -tocopherol (1.6ml at a concentration of 50µg protein/ml)  was 
oxidised with freshly dissolved FeSO4, FeCl3, CuSO4 (5 µM) at 37oC in Chelex-100 treated 
NaCl/sodium acetate buffer (4.5) and CuSO4  5 µM in MOPS buffer (pH 7.4) in 15 ml 
polypropylene tubes (Triple Red Ltd,  Bucks,  UK) in the existence or absences of antioxidants. 
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At several time points until 24h, the oxidation in each tube was stopped by addition of BHT 
(final oxidation 80 µM, from a stock of 2mM in ethanol) and EDTA (final concentration 4 mM). 
Samples were then stored in the dark at 4oC,  they were assayed by HPLC for α -tocopherol. 
 
 
 
2.2.6 Cuvette preparation 
 
 
Fused quartz cuvettes were used in the UV spectrophotometer because they do not absorb 
much UV. It is important that the quartz cuvettes are completely clean to remove any 
contaminating residues such as iron. After use, the cuvettes were rinsed multiple times with 
water and soaked in warm soapy water and cotton buds were used to scrub all walls of the 
cuvettes. The cuvettes were then rinsed with purified water and ultra-purified water. 
Absolute ethanol than added for 15 minutes, and rinsed with ultra-purified water many times. 
Diethylenetriaminepentaacetic acid (DTPA) at 100 µM was used to fill each cuvette for 1 hour 
at room temperature. It is a chelating factor with a very high affinity for metal cations such as 
iron and has the ability to chelate all 6 ordination sites of iron, making it a successful agent to 
remove iron (Tang et al., 1997). The cuvettes were then rinsed with purified water and ultra-
purified water and finally rinsed with ethanol and left to dry in an oven. 
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2.2.7 Removing EDTA from LDL by dialysis 
 
LDL was stored in 100 µM EDTA to decrease autoxidation. EDTA was removed from LDL by 
dialysis,  with the dialysis tubing previously soaked with warm water for 30 minutes, and 
dialysed overnight at 4 oC with stirring against phosphate buffer solution (140 mM NaCl, 8.1 
mM Na2HPO4, 1.9 mM NaH2PO4 adjusted to pH7.4). The buffer was changed three times. 
 
 
2.2.8 Monitoring LDL oxidation by the formation of conjucated dienes  
 
The sodium acetate pH4.5 buffer was prepared with NaCl (150 mM), sodium acetate (10 mM) 
and Chelex-100 (0.1%w/v) dissolved in ultra-purified water and stored overnight at 4oC with 
stirring  Chelex-100 were removed by using Whatman filter paper and adjusted to pH 4.5 if 
required. The LDL was diluted to 50 µg of protein /ml in the sodium acetate buffer. LDL/buffer 
solution (2ml) was placed in test quartz cuvettes and 2 ml buffer added to the reference 
cuvettes, which contained all the component except LDL. The cuvettes were maintained at 37 
oC by a water bath. In a PerkinElmer Lambda 35 or Lambda Bio 40 automate 8-position double 
–beam spectrophotometer. The program was set to measure the changes in attenuance as a 
result of conjugated diene formation and LDL aggregation at 234 nm for 1500 minutes at 1-
minute intervals.  The attenuance is defined as the log decrease in UV spacepassing through 
the cuvette due to absorbance by the oxidised LDL plus that lost due to scattering of the UV 
beam by aggregates of LDL. 
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 The attenuance at time zero was subtracted from all the other time points to allow for the 
initial absorbance of UV to the silica cuvettes and components of the LDL.  Free radical 
attached on polyunsaturated lipids inside the LDL particle cause the formation of lipid species, 
known as conjugated dienes, which contain two or more conjugated double bonds. 
Conjugated dienes can be measured directly using a spectrophotometer as they absorb UV 
strongly at 234 nm (Esterbauer et al., 1989). LDL was oxidised with freshly dissolved FeSO4, 
FeCl3  or CuSO4 (all at 5 µM final concentration) at 37oC in a Chelex-100 treated sodium 
chloride /sodium acetate buffer pH 4.5 or with CuSO4 in Chelex-100 treated MOPS buffer 
(pH7.4) in capped quartz cuvettes.  
 
2.2.9 Preparation of Lipoprotein -Deficient fetal calf serum 
 
 
 Lipoprotein-deficient serum (LPDS) was made according to a protocol adapted from Renaud 
et al. (Renaud et al., 1982). A sample of fetal calf serum (virus and mycoplasma screened; 
GIBCO), was taken for protein assay. 47.71 g KBr (BDH) was added to 120 ml of fetal calf serum 
to adjust the density to 1.21 g/ml with stirring by hand. It was added to 35 ml Beckman 
ultracentrifuge tubes, centrifuged in a Sorvall T1250  rotor at 40,000x g at 10 oC for 48 hours. 
The tubes were sliced, and the lower layer was taken, which contained the lipoprotein –free 
serum dialysed against   PBS pH 7.4 at 4oC with 5 changes over the course of 24 h.  The dialysed 
LPDS was adjusted to the original volume of serum using the dialysis buffer. It was filtered 
using a 0.22 µm Millex-GV, assayed for protein and stored at -80 oC.  
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2.3 Monitoring of ferrous iron levels 
 
The ferrous iron chelator bathophenanthrolinedisulfonic acid (BP) was used to measure 
ferrous iron (Fe 2+) levels. BP is chosen to distinguish iron levels in the blood and other 
biological fluids as it makes a red coloured complex with Fe2+ at pH 2-9, with a molar 
absorption coefficient of 22,140 M-1 cm-1 at 535 nm (Pieroni et al., 2001). LDL (50 µg 
protein/ml) was oxidised with freshly dissolved  FeCl3  (5 µM in a sodium chloride /sodium 
acetate buffer pH 4.5) in 15 ml polypropylene tubes in a water bath at 37oC. Samples of 1ml 
were taken at several time points to new tubes, BP (3 µl of 100 mM) was an add to them and 
absorbance was measured immediately at 535 nm with a spectrophotometer.  
 
 
 
2.4 Monitoring of cuprous copper levels 
 
 
Cuprous ion quantification was achieved by the chelator bathocuproinedisulfonic acid (BC). 
BC is selected to identify copper levels in the blood and other biological fluids as it forms a 
red coloured complex with Cu+ at pH 2-9, with a molar absorption coefficient of 12,000 M-1 
cm-1, at 480 nm (Perugini et al., 1997). LDL (50 µg protein/ml) was oxidised with freshly made 
CuSO4 (5 µM in a sodium chloride /sodium acetate buffer pH 4.5) in 15 ml polypropylene tubes 
in a water bath at 37 oC.  Samples of 1 ml were taken at several time points into new tubes, 
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(3 µl of 100 mM) was added to them and absorbance was measured at 480 nm with a 
spectrophotometer.  
 
 
2.5 Measurement of lipid hydroperoxide 
 
 
Lipid hydroperoxides (LOOH)  in LDL were measured using a technique modified from that 
described by El-Saadani et al (el-Saadani et al., 1989). Standard concentrations of H2O2 were 
prepared using ultrapure water. Both samples (oxidised LDL) and standards (250 µl) were 
added to assay tubes in triplicate and 1ml of colour reagent (0.2M potassium phosphate, 0.12M 
potassium iodide 0.15 mM sodium azide,2g/Lpolyethyleneglycolmono[p-(1,1’,3,3’-
tetramethyl-butyl)-phenyl]ether,0.1g/L alkybenzydimethylammoniumchloride, 20 µM of 
ammonium molybdate (pH 6.0-6.2) was added to each tube. After incubating the tubes in the 
dark for 1 h, the absorbance at 365 nm was measured. The basis for the assay is that molecular 
iodine will be created after the reaction between peroxides in the samples or standards and the 
iodide ions in the colour reagent. Molecular iodine consequently reacts with excess iodide ions 
in the colour reagent to make the tri-iodide chromophore (I3-) which absorbs ultraviolet 
radiation at 365 nm. The hydroperoxide content of the samples is then measured by comparison 
with the H2O2 standard 
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2.5.1 Preparing oxidised LDL samples for HPLC analysis of oxidised LDL 
 
Methanol (2 ml) was added to each oxidised LDL sample (1.6 ml) and the samples were 
vortexed for 10 seconds. Hexane (3 ml) was then added into each sample and then vortexed for 
30 seconds to move the hydrophobic lipid fraction (cholesterol, cholesteryl esters and 
triglycerides) of LDL into the hexane phase. The samples were centrifuged for 15 min at room 
temperature and 1500xg, and 2 ml of the upper hexane layer was transferred to a 5 ml 
polypropylene tube and dried in a Speed Vac. The dried samples were re-dissolved in 200 µl 
of an appropriate mobile phase and stored at -20oC until analysis. 
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2.5.2 HPLC analysis 
 
High-Performance Liquid Chromatography (HPLC) is a system of column chromatography 
that pumps a sample mixture in a solvent (identified as the mobile phase) at high pressure 
through a column with chromatographic packing material (stationary phase). Because of this 
flexibility, HPLC is useful in a diversity of industrial and research applications, such as 
pharmacological, ecological, forensics, and chemicals. 
The sample retaining time will differ dependent on the interaction between the stationary phase, 
the molecules analysed, and mobile phase used. After injection into the column,  the analytes 
interact between the two phases at a different rate, mainly due to diverse polarities in the 
analytes and are separated (Sharp et al., 2015). 
 
All samples (20 µl) were injected by using an autosampler. The reverse-phase C18 columns 
have a hydrophobic stationary phase so the more hydrophilic molecules are eluted first 
(Krokhin and Spicer, 2009). The oxidation products were identified at 234 nm using a suitable 
mobile phase and conditions as described in Table 2.1. Example chromatograms are 
presented in Figure 11. The oxidation products were measured by comparison of peak area 
measurement with those of commercially available standards. 
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Table2.1 Target lipid species and analysis conditions for HPLC 
 
 
 
 
 
 
 
 
Mobile phase Wavelength Flow rate Time Lipid detection
44% Acetonitrile
54% Isopropanol
2% water by volume
234 nm 1.2 ml/min 15 min 7-Ketocholesterol,
Cholesteryl-linoleate
hydroperoxide(CLOOH)
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Figure 2.1 Example chromatogram of standards showing (A) Cholesteryl linoleate hydroperoxide and 
(B) 7-ketocholesterol. A C18 column was used with a mobile phase of Acetonitrile (44%), isopropanol 
(54%) and water (2%) by volume. Detection was at 234 nm. Minor more polar contaminants were 
present 
 
 
 
 
 
A 
B 
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2.6 Cell culture 
 
Cell culture is the method in which cells are isolated from an organism and maintained in a 
fluid medium. In suitable conditions, the cells will live and even proliferate. The growth can 
be distinguished by cell division and differentiation, throughout which the cells can 
transform into particular forms that are capable of functions equivalent to  those of tissues 
in the whole organism (Baust et al., 2017). 
 
 
2.6.1 Human THP-1 cells 
 
THP-1 cells were used to study the interaction of macrophage with oxidised LDL. 
Human THP-1 cells, a monocytic cell line derived from an acute monocyte’s leukaemia 
patient, were purchased from the European Collection of Cell Culture (Salisbury, UK). Cells 
were counted with a Countess II FL automated cell counter (Invitrogen) and seeded at 3x 105 
cell/ml in PRMI-1640 medium (containing 2 mM L-glutamine, 10 mM HEPES, 1Mm sodium 
pyruvate, glucose(4.5 g/l) and sodium bicarbonate(1.5 g/l)],supplemented with 10% v/v fetal 
calf serum(FCS),penicillin (20 IU/ml), streptomycin (20 µg/ml) and amphotericin B (0.95 
µg/ml), in Corning® T75 or T150 flat-bottomed flasks with filter caps. Cells were cultured at 
37oC in humidified 95% air and 5% CO2 atmosphere until confluent. Culture medium was 
changed every 3-4 days. Cells were subculture by transferring the cell suspension under sterile 
conditions into 50 ml centrifuge tubes and centrifuging at 500 xg for 5 min at room 
temperature. The culture medium was then removed, and the pellet was re-suspended in 
fresh pre-warmed culture medium and seeded into new flasks as above. 
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2.6.2 Cryopreservation of THP-1 cells 
 
Cryopreservation is a technique used  at cryogenic temperatures  (-191 oC )to preserve a fine 
structure of living cells and tissues in a condition of suspended activation at such temperature 
for any considerable time (Pegg, 2007).   THP-1  cells were frozen in cryopreservation media 
(DMSO). Cells were centrifuged at 500 x g for 5 min at room temperature. The culture media 
was discarded, and the pellet was enriched with cryopreserve medium (2ml per confluent 
T150). The cells were relocated to sterile cryopreservation vials and were kept in polystyrene 
containers (to allow them to freeze gradually) at -80 oC overnight.  Vials were moved to liquid 
nitrogen for long-term storage. When needed, vials were thawed rapidly in a 37oC water bath 
and their contents were transferred into 50 ml centrifuge tubes containing RPMI-1640 
medium,  to dilute the DMSO in the cryopreservation media. They were centrifuged at 500 x 
g for 5 min at room temperature, new culture medium added and seeded, as described above. 
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2.6.3 Differentiation of THP-1 cell into macrophages 
 
 
The THP-1 cells were subcultured in a T75 flask and left to reach a density of 8 x 105  cells /ml. 
To get larger cell numbers, T150  flashed with a maximum of 80 ml of culture medium were 
used to maintain the activity of the cells, the cell density was not allowed to surpass 1x 106  
cells/ml. Converting THP-1 monocytes into macrophages was achieved by incubating the cells 
with phorbol 12-myristate 13-acetate (PMA) dissolved in DMSO (McSwine-Kennick et al., 
1991, Park et al., 2007). The transformation was done in 6, 12 or 96 well plates according to 
the type of experiment by adding PMA (25ng/ml) in the culture medium and incubating with 
THP-1 monocytes for 72h. After 72h, the non-adherent cells were cleared by washing with 
sterile PBS and the adherent macrophages were allowed to rest in culture medium without 
PMA for another 24 h before being used in experiments.  
 
2.6.4 Culturing THP-1 cells to detect ceroid 
 
Glass coverslips 18x18mm were washed with alcohol for a few minutes and added to 6 well 
tissue culture plates and  THP-1 cells at 300,000 cells/ml were add in RPM1640 medium, 
which contained (penicillin and streptomycin, amphotericin and 10 %( v/v) heat-inactivated 
foetal calf serum. To each well, tissue culture plate was added 200 µl of RPMI 1640 containing 
PMA (25 ng/ml) and the cells incubated for 48-72 hours to allow for the conversion of the 
THP-1 monocytes to macrophages.   
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Fresh medium (2 ml) for each well was then added for one day. THP-1 cells cultured on glass 
coverslips were incubated in medium containing either SMase-LDL, native LDL, LDL enriched 
with alpha-tocopherol or SMase-LDL enriched with alpha-tocopherol at 200 µg protein /ml or 
without LDL for 24 hours. They were washed 3times with warm PBS (200 µl) and incubated 
with RPMI medium containing 10 % ( v/v) lipoprotein-deficient serum (LPDS) for 7 days with 
a change of medium every 2-3 days. 
PBS was removed and 4% paraformaldehyde in PBS (2ml) was added and incubated for 15min. 
The cells were washed with PBS, the coverslips treated within 60 %( v/v) ethanol, 90% (v/v) 
ethanol and ethanol for (3 min) each in sequence. Coverslips were transferred to a glass Petri 
dish (100x15mm with a cover), which contained 2ml xylene and treated with ethanol, 90% 
(v/v) ethanol.60 % (v/v) ethanol for (3min) respectively. The coverslips were then soaked 
momentarily in 60 % (v/v) isopropanol and then incubated with Oil Red O (0.5 %w/v) in 60% 
(v/v) isopropanol by adding (1.5 ml) to each well for 5-10 min at room temperature. The cells 
were washed 4 times with distilled water and they were mounted on to slides using 
Vectashield® mounting medium (Vector Laboratories, UK) and stored at 4 oC. Ceroid was 
imaged using light microscopy (Axioskop2, Carl Zeiss Ltd) and images were taken with 
Axiovision software. 
 
2.6.5 Enriching THP-1 cells with α-tocopherol 
 
α-Tocopherol (2 mM) in ethanol ( final ethanol concentration) 0.1% (V/V) was added to heat-
inactivated FCS (10 %)( v/v), and incubated with shaking at 37 oC for 15 min in the dark. RPMI 
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1640 medium was added and mixed. The solution was then incubated with shaking at 37oC 
for 15 min. The subsequent medium was sterilized by using a 0.45 µm filter. 
 One millilitre of the α-tocopherol enriched medium was added to adherent THP-1 cells. After 
the medium was removed, the cells were washed twice with PBS containing 0.25% (w/v) BSA, 
followed by two washes with PBS, alone in order to remove α-tocopherol that non-specifically 
bound to the cell surface (Chan and Tran, 1990), The level of α -tocopherol in the cells was 
measured by HPLC. 
 
2.7 Apoptosis detection 
Apoptosis is a distinct form of cell death. It happens normally during growth,  during ageing 
as a homeostatic procedure to preserve cell populations in tissues and  as a defence 
mechanism such as in immune reactions.  It can be rapidly examined by flow cytometry. 
(Norbury and Hickson, 2001). We have investigated apoptosis of macrophage-like cells 
induced by oxidative stress. 
 
 
2.7.1 Measuring apoptosis and necrosis of THP-1 cells  
 
THP-1 macrophage apoptosis and necrosis were detected by flow cytometry, using a 
commercially available kit (Apo Alert V-FITC apoptosis kit, Clontech Laboratories Inc., Palo 
Alto, CA, USA). This compound binds to phosphatidylserine, which is transferred to the cell 
surface during apoptosis and so is suitable to use as a marker of apoptotic cell death. 
Propidium iodide (PI) can be used to differentiate apoptotic cells from necrotic cells, as it is 
capable of entering the cell and staining the nuclear DNA during necrosis. Cells with 
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augmented annexin V binding to phosphatidylserine are undertaking apoptosis and cells with 
increasing PI staining are undertaking necrosis. Cells with augmented levels of both annexin 
V and PI labelling are experiencing secondary necrosis, i.e. they were initially apoptotic and 
then had developed necrosis.  
THP-1 cells (5 x105 cells/ml) were plated in 6 well tissue culture plates (2 ml/well). RPMI was 
removed from the cells and was replaced with RPMI containing α-tocopherol (100 µg LDL 
protein/ml) that had been oxidised by H2O2 (100 μM) for 24h. After48 hr, the cells were 
removed by into plastic sterile 15 ml polypropylene tubes. The mixture was then centrifuged 
at 250 x g for 10 min at room temperature. The resulting pellets were washed with PBS and 
the cells were then centrifuged again using the same conditions. Cell pellets were suspended 
in the kit binding buffer provided (0.5 ml) and centrifuged at 250 x g for 10 min at room 
temperature. Each pellet was dissolved in 100 µl of a binding buffer containing FITC-annexin 
V (0.5 µg/ml) and PI (2.5 µg/ml) that previously were incubated for 15 min in the dark. The 
volume of each sample was made up to 500 µl with binding buffer provided with the kit and 
the samples were evaluated immediately. Samples were analysed with a Becton Dickinson 
FACS can flow cytometer (Becton Dickinson, NJ, USA), using Cell Quest software, permitting 
the percentage of healthy, apoptotic, necrotic cells in the population to be identified. 
 
2.8 Human microvascular endothelial cells  
 
SV40 large T Ag-transformed human dermal microvascular endothelial cells (HMEC-1) were 
obtained from Center For Disease Control and Prevention (Atlanta, Georgia) and were 
grownin MCDB131 supplemented with 10% heat-inactivated FBS, L-glutamine, 
hydrocortisone acetate (1mM) and human epidermal growth factor (10 ng/ml). 
   87 
 
2.9 Human aortic endothelial cells  
 
Endothelial cells are found  at the  edge between the blood and the underlying tissue. 
Variations in the role of endothelial cells seem to play a key in the pathogenesis of 
atherosclerosis. Endothelial cells produce and secrete stimulators as well as blockers of both 
the coagulation system and the fibrinolysis system, in addition to mediators that influence 
the adhesion and aggregation of blood platelets. Endothelial cells likewise discharge 
molecules that regulate cell proliferation and modify vessel wall tone. Human aortic 
endothelial cells (HAEC) secrete antithrombotic and thrombotic elements, such as t-PA and 
PAI-1 and react to TNF-α by modifying growth characteristics, producing cytokines such as 
GM-CSF. Human aortic endothelial cells (HAEC) provided by Lonza were isolated from the 
human aorta. HAEC were cryopreserved at passage by 10 % (v/v) DMSO, 10 % (v/v) FCS and 
frozen in liquid nitrogen. 
They were cultured in Basal Medium-2 (EBM™-2 Medium) and the following growth 
supplements: human epidermal growth factor (hEGF), 0.5 ml; vascular. endothelial growth 
factor (VEGF), 0.5 ml; R3 insulin-like growth factor-1 (R3-IGF-1), 0.5 ml. ascorbic acid, 0.5 ml; 
hydrocortisone, 0.2 ml; human fibroblast growth factor-Beta (hFGF-β), 2.0 ml heparin (0.5 
ml);  fetal bovine serum(FBS), 10 ml; gentamicin/amphotericin-B (GA), 0.5 ml. 
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2.10 Effect of LDL oxidised at lysosomal pH on endothelial cells 
 
We investigated the effect of LDL oxidised at pH 4.5 on endothelial function in a variety 
of ways, as described below.  
2.10.1 Rat aorta Vasoreactivity assessment  
 
Endothelial dysfunction is an initial, key distinguishing feature of development of 
atherosclerotic plaque and consequent complication events. This is described by an 
impaired bioavailability of endothelium-derived vasodilators, such as a nitric oxide (NO), 
along with a comparative increase in available vasoconstrictors. Oxidised LDL  might damage 
the endothelium and decrease vasodilatation. We investigated the effect of  LDL  oxidised 
by iron ion at lysosomal pH on vasodilatin,  as described in chapter 6,  as this might be  
released from lysed macrophages in atherosclerotic lesions. 
Wire myography (Mulvany and Halpern 1977) is an in vitro research technique for 
investigating both active and passive characteristics of arteries with the diameters of 
between 100 and 1000 μm. Blood vessels used in this procedure are arteries such as 
femoral, mesenteric, carotid, and aorta (Puzserova et al., 2007, Khazaei et al., 2008, Bal et 
al., 2009, Zaloudikova et al., 2009), from rats and other animals in both physiological and 
pathological conditions (Spiers and Padmanabhan, 2005). The myography technique 
involves the following stages: dissecting and mounting of the arteries, normalisation, 
assessment of tissue viability and construction of a cumulative concentration-response 
curve (Spiers and Padmanabhan, 2005).  The thoracic arteries were obtained from 12-14 
week-old male healthy Wistar rats (body weight 261±6 g, n=10) and investigated using wire 
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myography (Mulvany and Halpern, 1977). The rats were anaesthetized by isoflurane. After 
cervical displacement, the arteries were carefully dissected, and moved to Kerbs solution 
and then cleaned to remove the adipose and connective tissues. Arterial segments 
(approximately 2 mm long) were mounted in a small vessel wire myography (Dual Wire 
Myography System, DMT)  and were stabilized for 30 min. The vessels were contracted with 
the α1 –adrenergic agonist phenylephrine (100 nM) and finally relaxed with the M3 agonist 
acetylcholine at different concentrations (Figures 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Typical tension traces the curve of intraluminal pressure in response to vasoconstriction 
and vasorelaxation therapy, showing responses of rat arteries rings with 100 nM phenylephrine (to 
produce contraction), followed by relaxation with different concentration of acetylcholine (1-3,000 
nM).  
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2.10.1 Histological analysis and immunohistochemistry 
 
After the wire myography experiments, the rat aorta was directly frozen in liquid nitrogen-
cooled isopentane and mounted in Optimal Cutting Temperature compound (OCT) (TAAB 
O023) cooled by dry ice/ethanol. Immunohistochemistry was performed on 10 μm 
cryosections that were air-dried at room temperature for 30 min before the use of block wash 
buffer (PBS with 5% foetal calf serum (v/v), 0.05% Triton X-100). Antibodies CD-31 primary 
antibody 1:1000 were diluted in wash buffer 30 min before use (Table 2.1.1) Fluorescence-
based secondary antibodies were used to detect all primary antibodies except for CD-31 
where the Vectastain ABC-HRP kit was deployed (Vector PK-6100) with an avidin/biotin-based 
peroxidase system and DAB peroxidase (HRP) substrate (Vector SK-4100). Morphometric 
analysis of aortic sections was performed by Image-J analysis software. 
 
 
 
2.10.3 Measurement of reactive oxygen species in endothelial cells exposed to 
oxidised LDL 
 
Superoxide production in cultured of human microvascular endothelial cells (HMEC-1) was 
detected by a dihydroethidium (DHE) assay, according to the manufacturer’s instructions. In 
brief, cells or tissue (arteries) were incubated with oxidised LDL for the specified time. Before 
treating cells with LDL enriched with α-tocopherol oxidised at pH 4.5 (described in section 
2.2.6), free iron, copper, EDTA and BHT were removed from the LDL samples and the pH was 
adjusted to7.4 (pH 7.4). LDL was dialysed in 500ml of phosphate dialysis buffer containing 
BHT (80 µM) and EDTA (4mM), with one change of the solution. They were then dialysed 
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against 500 ml of phosphate dialysis buffer overnight, with repeated changes of the solution, 
to remove the EDTA and BHT. DHE 10 μM in PBS for 30 min. Fluorescence was measured with 
a fluorescence microscope with wavelength 488nm and quantified using Image-J analysis 
software. 
 
2.10.4 Western blot analysis  
 
Proteins from human microvascular cells (HMEC) and  human aortic endothelial cells (HAEC 
)were extracted using RIPA buffer (Sigma-Aldrich) and Halt™ (protease & phosphatase 
inhibitor). Western blotting was performed (Xie et al., 2012) for total and phosphorylated 
eNOS. 
Proteins in HMEC and HAEC lysates were separated on SDS-PAGE 10-12 % gels and transferred 
to polyvinylidene difluoride membranes (Millipore). The membranes were blocked by 
incubation in Tris-buffered saline ( Tris10 mmol/l, pH 7.5, and NaCl 100 mmol/l containing 
0.1% (v/v) Tween 20 and 5% (v/v) non-fat dry milk) for 1 h.  To decrease non-specific binding, 
followed by a 24 h incubation at 4°C  with rabbit polyclonal eNOS antibody and 
phosphorylated-eNOS antibody 1:1000 (S1177) (Cell Signalling Technology) and the 
Developmental Studies Hybridoma Bank (DSHB) mouse monoclonal beta-actin (antigen 
molecular weight 43 kDa). The membranes were washed in Tris-buffered saline containing 
0.1% (v/v) Tween 20 before incubation for 1 h at room temperature with a horseradish 
peroxidase-conjugated secondary antibody (Invitrogen). The membranes were then washed 
and developed using ECL substrate (Thermo Scientific) to identify proteins, which are bound 
to the secondary antibody - HRP. The Reagent 1 together with the Reagent 2 provide a 
reaction catalysed by the enzyme HRP causing the emission of light.  
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2.11 Statistical analysis  
 
Unless specified otherwise, all results are expressed as means ± standard error of the mean 
(S.E.M) of joint data from 3 – 5 independent experiments as identified in the figure legends. 
Testing differences of two means was done using a 2-tailed unpaired Student’s t-test. For 
comparing more than two means, one-way ANOVA (statistical test, which compares the 
difference in the group means within a sample though considering merely one independent 
variable) followed by Tukey’s post hoc analysis to measure the level of statistical significance 
between paired differences. Two-way ANOVA  was used to (compare the mean variances 
between groups that have been divided into two independent variables). The main aim of a 
two-way ANOVA is  to recognise if there is an interaction between the two independent 
variables on the dependent variable. Two-way ANOVA followed by Bonferroni post-tests were 
employed to compare the results of different HPLC time points of an LDL sample. The level of 
significance of the difference is shown in the graph as follows: * p < 0.05, ** p < 0.01, and *** 
p < 0.001. ANOVA and post hoc analyses were analysed with Graph Pad Prism 4 software (La 
Jolla, CA). A p-value of <0.05 was taken to be a statistically significant difference. 
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Chapter 3 
 
 
 
 
Effect of α-tocopherol enrichment on LDL oxidation by 
transition metals at lysosomal pH 
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3.1 Introduction 
 
In the last decades, numerous studies have documented the potential role of oxidative stress 
in atherogenesis (Bonomini et al., 2008). Because of their ability to lose electrons, delocalised 
transition metals are a thought to be toxic mainly because they can form ROS causing, 
oxidative damage (Bonomini et al., 2008, Heinecke, 2003). 
It is now extensively believed that oxidative alteration of  LDL transformed these natural 
particles into pathogenic (Zuliani et al., 2013, Matsuda et al., 2013),  immunogenic (Lopes-
Virella et al., 2012, Perrin-Cocon et al., 2013, Matsuda et al., 2013, Gomez et al., 2014)  and 
atherogenic particles (Yang et al., 2012). 
Apolipoprotein B-100, has 4536 amino acid residues, with numerous exposed tyrosines and 
lysines, which can be directly oxidized or altered by lipid oxidation products. In vivo, the 
process of LDL oxidation remains ambiguous and there are divergent mechanisms that may 
be accountable for the process. They are categorised as enzymatic and non-enzymatic 
mechanisms. The enzymatic mechanisms contain a number of different enzyme systems, such 
as lipoxygenases, myeloperoxidase (which induces hypochlorous acid), NADPH oxidases and 
nitric oxide synthases (Tsimikas and Miller, 2011). The non-enzymatic processes include free 
transition metal ions such as copper and iron, which catalyse lipid peroxidation. Several 
studies reported that transition metals may have importance during later stages in the 
development of atheroma (Yoshida and Kisugi, 2010, Mowri et al., 2000, Ojo and Leake, 
2018), but they might possibly be involved in early atherosclerosis as well.  Oxidised LDL, 
which taken directly from atherosclerotic lesions is analogous to lipoproteins oxidized in vitro 
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with copper sulphate (Heinecke et al., 1986). Copper can breakdown performed lipid 
hydroperoxides (Thomas and Jackson, 1991, Esterbauer et al., 1992).  Oxidized LDL (ox-LDL) 
and metal-catalysed oxidation systems, such as Fe3+ with ascorbic acid, increase free radical 
production (Sener et al., 2009) 
The molecular mechanism by which Cu2+ induces oxidation in LDL is not clear and it is also 
unclear if this in vitro activity reflects LDL oxidation in vivo (Esterbauer and Ramos, 1996).  LDL 
oxidation by copper depends on experimental conditions, such as copper concentrations used 
or the temperature (Kleinveld et al., 1992). This is also supported by some reports of the 
presence of low, sub-micromolar concentrations of pro-oxidative copper or iron ions in the 
arterial wall or in lesions (Dubick et al., 1987, Smith et al., 1992), either free or in complexed 
forms.  
Chelation therapy, a programme of continual intravenous injection of EDTA, regularly in 
combination with vitamins and minerals, has been reported as a harmless alternative 
treatment for atherosclerotic vascular disease (Ernst, 2000, Ernst, 1997, Lewin, 1997).  One 
early analysis of uncontrolled trials and unpublished data claimed that EDTA chelation 
therapy effectively improved the symptoms of cardiovascular disease in over 80% of cases 
(Seely, 2005). Chelation therapy is thought to not only remove contaminating metals but also 
to decrease free radical production (Roussel et al., 2009). Clinical trials have shown that 
chelation therapy is not effective (Villarruz et al., 2002, Seely et al., 2005). Chelation therapy 
has side effects, including burning at the intravenous site, fever, headache, nausea or 
vomiting. Rarely, there is hypocalcaemia, sudden drop in blood pressure, drop in bone 
marrow counts (Babu and Gonzalez-Pena, 1994), heart failure, kidney damage (Weaver et 
al., 2012) and death (Baxter and Krenzelok, 2008)( Anderson et al., 2003) 
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Several studies offer evidence for the efficacy of vitamin E as an antioxidant in atherosclerosis 
(Diaz  et al., 1997). However, experimental trials of vitamin E for inhibiting cardiac disorders 
in patients with recognised coronary artery disease have been generally disappointing (Collins 
et al., 200) (Vardi et al., 2013, Ginter, 2000,), and this has persuaded many to doubt the 
validity of the oxidation theory of atherogenesis ( Yusuf et al., 2000, de Gaetano, 2001, 
Heinecke, 2001, Investigators, 2000). In vitro studies reported that vitamin E  was 
unsuccessful to inhibit LDL oxidation induced by tyrosyl radical made by myeloperoxidase and 
the absence of protection of α-tocopherol on LDL apoB-100 and lipid oxidation by 
lipoxygenase (Savenkova et al., 1994, Ganini and Mason, 2014, Ziouzenkova et al., 1996, 
Micheletta et al., 2004). Moreover, vitamin E stimulates LDL lipid peroxidation when the flux 
of radicals is low (Savenkova et al., 1994). These studies highlight the suggestion that in order 
to understand how to design antioxidant interventions it is necessary to know which oxidative 
pathways are operative in vivo.  
 
Hypothesis and aims 
α-Tocopherol is well known to inhibit LDL oxidation at pH 7.4 (Jessup, 1990; Dieber-
Rotheneder et al. , 1991),but the large clinical trails of α-tocopherol did not show any 
protection against cardiovascular disease ( Collins et al ., 2002 ; Yusuf et al ., 2000). To try to 
explain this discrepancy, this project investigated the effect of α-tocopherol supplementation 
of LDL on its oxidation at lysosomal pH. The hypothesis was that α-tocopherol would not 
inhibit LDL oxidation as well at pH 4.5 as it does at pH 7.4. If so,this might helps to explain why 
the clinical trails of α-tocopherol failed. 
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3.2 Methods 
Conjucated dienes in  oxidising LDL were measured spectrophotometerly as described in 
chapter 2.2.8. Cholesterol linoleate hydroperoxide and 7- ketocholesterol were measured 
by HPLC as described in chapter 2.5.2 and total lipid hydroperoxides were measured by a tri-
iodide assay  as described in chapter 2.5. Ferrous ion concentrations were measured as 
described in chapter 2.3,using bathophenanthrolinedisulfonic acid. 
Section 3.3.1 
The phases of LDL oxidation at pH 4.5 are described. 
Section 3.3.2  
The effect of EDTA on LDL oxidation  at pH 4.5 are described. The rationale for this is that 
LDL is stored in the presences of EDTA will be carried over into the incubation buffer when 
LDL is oxidised. 
Section 3.3.3 
The aim of this section is to determine the effect of α-tocopherol supplementation of LDL on 
LDL  oxidation by  Cu2+ Fe 2+ and Fe3+ at pH 4.5 (lysosomal pH). Different concentrations of 
these metals were used because it is known that α-tocopherol can have a pro- oxidant 
effect on LDL at low oxidative stress (Thomas and Stocker, 2000). 
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3.3 Results 
3.3.1 Monitoring oxidised LDL with iron at pH 4.5 and 7.4 
 
This study investigated the oxidation in vitro of LDL with iron at  plasma and interstitial fluid 
pH (7.4) and lysosomal pH (4.5). The oxidation of the LDL was observed by measuring 
conjugated diene formation by spectrophotometry at 234 nm (Esterbauer et al., 1989). At pH 
4.5 there were different phases, including a short lag phase, followed by a rapid oxidation 
phase and then a slower oxidation phase, an aggregation phase and a sedimentation phase 
(Figure 3.1). Attenuance (defined as absorbance plus UV scattering) above about 0.7 is due 
mainly to UV scattering by aggregated LDL, as when all the polyunsaturated fatty acyl group 
in LDL are oxidised to conjugated dienes (at 50 μg LDL protein/ml) the absorbance is about 
0.7. (Esterbauer et al., 1989). The attenuance eventually falls because the LDL aggregates 
sediment before the beam of UV.  
There was very little oxidation noticeable with Fe2+ at a pH of 7.4 (Figure 3.1). Using one-way 
ANOVA to analyse the data, there is a significant difference (p<0.001) between the control 
LDL and LDL oxidised by 5μM Fe2+, while there was no significant difference between the 
control LDL at pH 4.5 with LDL oxidised by Fe2+ at pH 7.4. These phases agree with those 
shown by Satchell & Leake (Satchell and Leake, 2012). The experiments were run overnight, 
so that aggregation would be monitored, as LDL aggregates at pH 4.5, but much less at pH7.4 
(Satchell and Leake, 2012). 
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Figure 3. 1 A Graph showing the different phases of LDL oxidation with or without the addition of 5µM 
FeSO4  at pH 4.5 and 7.4. LDL (50 µg protein/ml) was incubated at 37 oC and pH 4.5 with sodium acetate 
/NaCl buffer and MOPS buffer of pH 7.4 in quartz cuvettes for roughly 800 minutes. Oxidation was 
observed by measuring the change in attenuance (absorbance plus UV scattering) due to the 
formation of conjugated dienes and LDL aggregation in LDL samples at 234 nm. There was a marked 
difference between control LDL and LDL oxidised by 5 μM Fe2+ at pH 4.5, with very little oxidation with 
5 μM Fe2+ at pH 7.4. A time of 50 minutes was chosen to analyse the results statistically because this 
corresponds to the mid- to the upper range of the rapid oxidation phase.  B The bar chart shows the 
mean ± SEM of four experements. A one-way ANOVA was significant (*** p < 0.001) Tukey’s posthoc 
tests were then carried out. 
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3.3.2 Effect of EDTA on LDL oxidation by iron at lysosomal pH. 
 
It is standard practice to store LDL in the presence of EDTA to inhibit its oxidation during 
storage. EDTA can inhibit or increase the oxidation of LDL depending on the conditions(Lamb 
and Leake, 1992). Therefore, this study investigated  the effect of EDTA on LDL oxidation by 
iron at pH4.5, as EDTA would be carried over from the stored LDL to the incubation solution. 
The LDL was stored in 100 mM EDTA. If the stored LDL concentration were to be 2 mg 
protein/ml and LDL is oxidised at 50 µg protein/ml, the carried over EDTA concentration 
would be 2.5 µM. 
LDL was oxidised by 5 µM FeSO4 with addition of 1, 2, 5, 10 µM EDTA. EDTA at 1 or 2 µM 
partially inhibited LDL oxidation and 5, 10 µM EDTA inhibited it almost totally (Figure 3. 2). 
Thus equimolar EDTA to Fe2+ (5 µM) inhibited the oxidation of LDL almost totally.  To confirm 
that one atom of Fe2+ bind to one molecular of EDTA,in this study LDL was oxidised in the 
presence of 5 or 10 µM Fe2+ and  5 or 10 µM EDTA (Figure 3.3). The oxidation given by  5 µM 
FeSO4  was similar to that given by 10 µM FeSO4   plus 5 µM EDTA, implying that there was 5 
µM FeSO4 available in the latter. This means that one molecule of EDTA (which has 6 
coordination sites) binds to and inactivates one atom of iron. We can, therefore, calculate the 
concentration of EDTA carried over from the LDL preparation to the cuvettes and add the 
same additional molar concentration of FeSO4 to give the same available concentration of 
iron (usually 5 µM) in all experiments involving different preparations (of different 
concentrations) of LDL. This should improve the reproducibility of the experiments. This will 
be important for the experiments involving α-tocopherol supplementation of LDL in which 
the control and α-tocopherol supplementated LDL will have slightly different concentration 
of LDL. 
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Figure 3.2. Effect of EDTA on LDL oxidation by ferrous ion at pH 4.5. A LDL was dialiysed to remove 
EDTA  and incubated with 5 µM FeSo4  at pH 4.5 in the absence or presence of EDTA (1-10 µM ) and 
the attenuance at 234 nm  was monitored.The values in the bar chart were used to perform an ANOVA 
test, to evaluate the significance of the bindings. The P-value compared to the attenuance with just 5 
µM Fe 2+ as shown. One-way ANOVA followed by Tukey's Multiple Comparison Test showed a 
significant difference P<0.001 between the control and EDTA groups. Attenuance at 200 minutes was 
used because it measured oxidation but not aggregation. The bar chart shows the mean ± SEM of the 
experiments. A one-way ANOVA was significant (*** indicate P < 0.001 compared to the control., n=4) 
Tukey's posthoc tests were then carried out. 
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Figure 3.3. Effect of EDTA on LDL oxidation by iron at pH 4.5.  
LDL was dialysed against a phosphate buffer overnight before the experiment in order to remove EDTA 
from the LDL. LDL (50 µg protein/ml) was incubated with pH 4.5 sodium acetate /NaCl buffer in quartz 
cuvettes at 37o C for roughly 1000 minutes. FeSO4 (final concentration 5 µM or 10 µM with or without 
EDTA) was added to duplicate cuvettes. The attenuance at 234 nm was monitored. Oxidation was 
quantified by determining the increase in attenuance at 100 minutes as this corresponds to the time 
at which about half-maximal oxidation occurred in the absence of EDTA.  The bar chart shows the 
mean ± SEM of four independent experiments. A one-way ANOVA was significant (*** indicates P < 
0.001, n=4) Tukey's posthoc tests were then carried out.  
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3.3.3 Effect of α-tocopherol on LDL oxidation at lysosomal pH. 
 
3.3.3.1 Effect of α-tocopherol on LDL oxidation by ferrous ion at lysosomal pH.  
 
It is well known that α-tocopherol can inhibit LDL oxidation at pH 7.4, but the large clinical 
trials of α-tocopherol did not inhibit cardiovascular disease (Kontush et al., 1996, Huang et 
al., 2002, Upston et al., 2001, Weinberg et al., 2001). This study, therefore investigated the 
effect of α-tocopherol on LDL oxidation at lysosomal pH. LDL was enriched with α-tocopherol 
(final concentration 1%) by adding α-tocopherol in dimethyl sulphoxide (DMSO) to plasma 
and isolating LDL by ultracentrifugation. α-Tocopherol is soluble in DMSO,  DMSO  is  miscible 
with and would later be dialysed away. Plasma was incubated with DMSO (1/% v/v) alone as 
a control. (Adding α-tocopherol to LDL in a simple buffer does not lead to its incorporation 
into LDL).  
LDL was oxidised in NaCl/sodium acetate buffer (pH 4.5) at 37 oC, in the presence of ferrous 
iron (FeSO4 2, 5 or 20 µM). Different concentrations of iron were used because α-tocopherol 
has a greater pro-oxidant effect at low metal concentrations (Bowry et al., 1995). The 
oxidation was tracked by measuring the attenuance at 234 nm  (Figure 3. 4, 3. 5 and 3. 6). As 
expected (Satchell and Leake, 2012), LDL oxidation level was faster as the concentration of 
ferrous ion increased. α-Tocopherol enrichment of LDL did not inhibit (or increase) the 
oxidisability of LDL by 2 µM ferrous ion (FeSO4) (Figure3.4). It did, however,inhibit the 
oxidation of LDL by 5 µM (Figure 3.5) or 20 µM (Figure 3.6) ferrous ion. 
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Figure 3. 4. (A) Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol  was 
incubatedin a sodium chloride /sodium acetate buffer (pH 4.5) containing with 2 µM Fe2+ at 37 0C in 
capped quartz cuvettes. The oxidation was quantified by measuring the change in the attenuance at 
234 nm at 200 minutes. (B )bar chart shows the mean ± SEM of four experiments  at a time of 200 
minutes  a time at which substantial oxidation was obtained with the different concentrations of iron 
used in these experiments. No significant difference  was observed in LDL oxidationof the oxidation at 
200 min, paired t-test, (n=4 independent experiments). 
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Figure 3. 5 (A )control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in sodium 
chloride /sodium acetate buffer (pH4.5) incubated with 5 µM Fe 2+ at 37 0C in capped quartz cuvettes 
in quadruplicate. The oxidation was monitored by measuring the change in the attenuance at 234 nm 
against the appropriate reference cuvettes quadruplicate are shown. (B )Bar chart shows attenuance 
at 200 min of oxidation (* indicate p<0.05, paired t-test, n=4 independents experiments). 
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Figure 3. 6. (A) Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a sodium 
chloride /sodium acetate buffer (pH4.5) incubated with 20 µM Fe 2+ at 37 0C in capped quartz cuvettes. 
Oxidation was monitored by measuring the change in attenuance at 234 nm against the appropriate 
reference cuvettes. (B )Bar chart shows decreased LDL enriched with α -tocopherol oxidation at 200 
min of oxidation (* indicate p<0.05, paired t-test, n=4 independents experiments).  
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3.3.3.2 Effect of α -tocopherol on LDL oxidation  by ferric ion at lysosomal pH. 
 
Lysosomes might contain both ferric (Fe3+) and ferrous (Fe2+) ion (Meguro et al., 2005).  As 
described in previous section. It  showed that α -tocopherol  did not affect LDL oxidation by a 
low concentration of ferrous ion (2 µM ), but inhibited it by higher concentrations (5 or 20 
µM ) of ferrous ion. We then investigated the effect of α-tocopherol on LDL oxidation by ferric 
(Fe 3+) ion by measuring the attenuance for control LDL and compare it with LDL enriched with 
α-tocopherol oxidation by different concentrations of ferric chloride (2 ,  5  or 20 µM FeCl3 ). 
α-Tocopherol had no effect on LDL oxidation by ferric ion  (2 or 5 µM) but increased it at 20 
µM (Figures 3. 7, 3. 9). Therefore, α-tocopherol-enrichment of LDL inhibited considerably the 
oxidation of LDL by 20 µM ferrous ion,but modestly (although statistically ) increased by 20 
µM ferric ion. 
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Figure 3. 7 (A )Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in sodium 
chloride /sodium acetate buffer (pH 4.5) incubated with 2 µM Fe 3+ at 37 0C in capped quartz cuvettes. 
Oxidation was monitored by measuring the change in attenuance at 234 nm. (B )Bar chart shows 
control LDL  and enriched with alpha-tocopherol at 200 min of oxidation (no significant differences,  
paired t-test, n=4 independents experiments). 
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Figure 3. 8 (A) Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a sodium 
chloride /sodium acetate buffer (pH4.5) incubated with 5µM Fe 3+  at 37 0C in capped quartz 
cuvettes. Oxidation was monitored by measuring the change in attenuance at 234 nm. (B )Bar chart 
shows control LDL  and enriched with α-tocopherol at 200 min of oxidation (no significant 
differences, paired t-test, n=4 independents experiments). 
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Figure 3. 9 (A )Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a sodium 
chloride /sodium acetate buffer (pH4.5) incubated with 20 µM Fe 3+ at37 0C in capped quartz cuvettes. 
Oxidation was monitored by measuring the change in attenuance at 234 nm. (B) Bar chart shows 
increase LDL enriched with alpha-tocopherol oxidation at 200 min of oxidation (* indicates p<0.05,  
pairedt-test, n=4 independents experiments). 
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3.3.3.3 Effect of α-tocopherol does not inhibit LDL oxidation  by  copper at  
lysosomal pH. 
 
Copper is often used to oxidise LDL in vitro studies and it is possible it might have a role in 
oxidising LDL in lysosomes in vivo if copper-containing  protein are endocytosed or taken by 
autophagy.  Therefore, in this study we investigated  the effect of α-tocopherol  on LDL 
oxidation at pH 4.5 by copper ion . When we used  2, 5 or 20 µM copper, the α -tocopherol 
had no effect as an antioxidant in diminishing the LDL oxidation (Figure 3. 10, 3. 11 and 3. 
12). Similarly to Fe2+ or Fe3+  at pH4.5, LDL oxidation by Cu2+ at pH4.5 showed a  short lag 
phase, a rapid oxidation phase, a slow oxidation phase, an aggregation phase and a  
sedimentation phase. There was a hint of a pro-oxidant effect ,but it was not statistically 
significant. 
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Figure 3. 10. (A ) Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a sodium 
chloride /sodium acetate buffer pH 4.5 incubated with 2 µM Cu 2+ at 37 0C in capped quartz cuvettes. 
Oxidation was monitored by measuring the change in attenuance at 234 nm. (B) Bar chart shows 
control LDL and enriched with α-tocopherol at 200 min of oxidation (no significant difference,  paired 
t-test, n=4 independents experiments). 
 
 
 
 
A 
B 
   113 
 
 
 
 
 
 
 
 
 
 
Figure 3. 11. (A )Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a sodium 
chloride /sodium acetate buffer (pH 4.5) incubated with 5 µM CuSO4 at 37 0C in capped quartz 
cuvettes. Oxidation was monitored by measuring the change in attenuance at 234 nm. (B ) Bar chart 
shows control LDL and enriched with α- tocopherol oxidation at 200 min of oxidation (no significant 
difference, paired t-test, n=4 independent experiments). 
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Figure 3. 12. (A) Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a sodium 
chloride /sodium acetate buffer (pH 4.5) incubated with 20 µM CuSO4 at 37 0C in capped quartz 
cuvettes. Oxidation was monitored by measuring the change in attenuance at 234 nm. (B) Bar chart 
shows control LDL enriched with α-tocopherol at 200 min of oxidation (no significant difference,  
paired t-test, n=4 independent experiments).  
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3.3.3.4 α- Tocopherol inhibit LDL oxidation by copper at pH 7.4 
  
The purpose of the current study is to determine if treatment with α-tocopherol protects LDL 
from the oxidative effects induced by the transition metal copper at pH 7.4, to compare the 
action of α- tocopherol at plasma or interstitial pH and lysosomal pH.  The results from this 
compersion might helpe to explain why the large antioxidant trails of α-tocopherol  failed to 
show protection from cardiovascular disease.LDL oxidation at pH 7.4 does not  causes 
aggregate in. The characteristic time sequence of copper-mediated LDL oxidation displays a 
lag phase, in which conjugated diene absorption shows merely a slight increase, followed by 
a propagation phase in which 234-nm absorption swiftly increases. In sequence, the 234-nm 
absorption decreases and is the decomposition phase of lipid hydroperoxides. This is followed 
by an increase in absorbance due to the formation of lipid decomposion products, which 
absorbe at 234 nm (Esterbauer et al., 1991). Therefore, the oxidation profile is different from 
that at pH 4.5. The term absorbances rather than attenuance was used in the figures because 
there was no aggregation of the LDL and UV scattering at pH 7.4, In marked contrast to Fe2+ 
or Fe3+.  LDL oxidation by Cu2+ is much faster at pH 7.4 than at pH 4.5. At all copper 
concentrations (2, 5 and 20 µM), α- tocopherol had a significant influence on reducing the 
level of LDL oxidation (Figures 3. 13, 3. 14 and 3. 15). α- Tocopherol therefore, as 
expected,inhibits LDL oxidation at pH 7.4, but does not inhibits LDL oxidation at at pH 4.5. 
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Figure 3.13. (A )Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a buffer (pH 
7.4) incubated with 2 µM CuSO4 at 37 0C in capped quartz cuvettes. Oxidation was monitored by 
measuring the change in absorbance at 234 nm. The absorbance at 20 minutes was measured because 
it corresponds to LDL oxidation before the decomposition phase. (B ) Bar chart shows decreased LDL 
enriched with alpha-tocopherol oxidation at 20 min of oxidation (** indicate p<0.005, paired t-test, 
n=4 independent experiments). 
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Figure 3. 14. (A ) Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a buffer 
(pH 7.4) incubated with 5µM CuSO4 at 37 0C in capped quartz cuvettes. Oxidation was monitored by 
measuring the change in absorbance at 234 nm. (B ) Bar chart shows decreased LDL enriched with 
alpha-tocopherol oxidation at 20 min of oxidation (** indicate p<0.005,  paired t-test, n=4 
independent experiments).   
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Figure 3. 15.  
 
(A )Control LDL (50 µg LDL protein/ml) and LDL enriched with α-tocopherol in a buffer (pH 7.4) 
incubated with 20 µM CuSO4 at 37 0C in capped quartz cuvettes. Oxidation was monitored by 
measuring the change in absorbance at 234 nm. (B )Bar chart shows decreased LDL enriched with 
alpha-tocopherol oxidation at 20 min of oxidation (** indicate p<0.005, paired t-test, n=4 independent 
experiments). 
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3.4 Measurement of ferrous ion levels during LDL oxidation by ferric chloride.  
 
To investigate why α-tocopherol did not inhibit LDL oxidation by ferric ion, in this study we 
measured the effect of α-tocopherol enrichment of LDL on the rate of conversion of ferric 
ion to ferrous ion. 
The levels of ferrous iron were detected during LDL oxidation by ferric ion using the ferrous 
iron chelator bathophenanthrolinedisulfonic acid (BP). Control LDL and LDL enriched with α-
tocopherol (50 μg LDL protein/ml) was oxidised in NaCl/sodium buffer (pH 4.5) at 37 °C in 
the presence of ferric ion (FeCl3, 5 μM) in plastic tubes and during the oxidation, samples 
were collected and measured for the ferrous iron levels using BP (300 μM). During the 
process of LDL oxidation, all the ferric ions (Fe3+) were converted in the first 30 min (Figure 
3.16). The conversion  of ferric to ferrous increased faster with LDL enriched with α-
tocopherol than control LDL (the concentrations were 5.02± 0.2 μM compared to 2.10± 0.4 
μM at 60 min (P<0.001). This sharp increase relates to the rapid oxidation phase of LDL. 
These results show that ferric ion is reduced to ferrous iron during the rapid phase of LDL 
oxidation and that α-tocopherol is able to reduce ferric ion to ferrous iron and this might 
help to explain why α-tocopherol did not inhibit LDL oxidation by ferric ions, as discussed in 
the discussion section. 
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Figure 3.16 Kinetics of ferrous ion formation during LDL oxidation by FeCl3 at pH 4.5  
 
 
Control LDL and LDL enriched with α-tocopherol (50 μg protein/ml) in NaCl/sodium acetate buffer (pH 
4.5) were incubated with 5 μM FeCl3 in plastic tubes at 37 °C. At certain time points, samples were 
collected, and ferrous ion concentration measured by measuring absorbance at 535 nm after treating 
with the iron chelator bathophenanthrolinedisulfonic acid (300 μM). (*** indicate p<0.001, two-way 
ANOVA followed by Bonferroni post-test , n=4 independent experiments). 
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3.5 Measurement of Cu+ levels during LDL oxidation by copper at lysosomal pH. 
 
In this study examined if α-tocopherol in LDL could reduce the higher valency state of copper 
(Cu2+) to the lower valency state of copper (Cu+). The ability to control LDL and LDL 
supplemented with α- tocopherol to reduce cupric ions (Cu2+) to cuprous ion (Cu+) was 
measured using chelator bathocuproinedisulfonic acid.  Cuprous concentrations increased 
more rapidly with α- tocopherol-enriched LDL than control LDL (5.0± 0.3Μm compared to 
2.30± 0.1 at 120 min (***p<0.001) (Figure 3.17). Investigation of the time course of Cu2+ 
reduction in tocopherol enriched and control LDL shows  of Cu2+ reduction to Cu+ at early time 
points. This suggests a pro-oxidant role for tocopherol under lysosomal conditions of LDL 
oxidation. As described later, this might help to explain why α- tocopherol did not inhibit LDL 
oxidation at acidic pH. 
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Figure 3.17 Kinetics of cuprous ion levels during LDL oxidation by CuSO4 at pH 4.5  
 
Control and LDL enriched with α- tocopherol (50 μg protein/ml) in NaCl/sodium acetate buffer (pH 
4.5) was incubated with 5 μM CuSO4 at plastic tubes maintained at  37 °C. At several time points, 
samples were taken and Cu+ ion concentration detected by measuring absorbance at 480 nm after 
treating with the cuprous copper chelator bathocuproinedisulfonic acid (300 μM). ( * indicates p<0.05 
and *** indicate p<0.001, two-way ANOVA followed by Bonferroni post-test. , n=4 independent 
experiments). 
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3.6 Monitoring α-tocopherol Content of LDL particles during the oxidation 
process 
 
α-Tocopherol is known to be consumed when it acts as an antioxidant during LDL oxidation 
(Proudfoot et al., 1997). Hence, the purpose of the present study was to determine if α-
tocopherol is consumed faster when its levels in LDL are increased. Control and LDL 
supplemented with α-tocopherol were incubated in NaCl/sodium acetate buffer (pH 4.5) with 
5 μM FeSO4 and samples were taken at different time points during the oxidation process and 
were analysed for α-tocopherol by HPLC. There was a significant difference in α-tocopherol 
levels between control LDL and LDL enriched with α-tocopherol, with an approximately two-
fold enrichment (24.3± 0.3 nmol/mg LDL protein (Figure 3.18) compared to 14.4±0.2 nmol/mg 
LDL protein ( ***p<0.001). This corresponds to about 12 and 7 molecules of α-tocopherol per 
particle of LDL. The level of α-tocopherol  in α-tocopherol- enriched LDL decreased  faster 
during LDL oxidation by 5 μΜ FeSO4. This might explain why α-tocopherol-enriched LDL 
converted Fe3+ to Fe2+ and Cu2+ to Cu+ faster. 
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Figure 3.18. The depletion of α-tocopherol in LDL during oxidation. 
 
 
 Control and LDL enriched with α- tocopherol (50 μg protein/ml) was incubated in NaCl/sodium 
acetate buffer (pH 4.5) with 5 μM FeSO4 in plastic tubes maintained at 37 °C. α- Tocopherol content 
in LDL was measured periodically. (** indicate p<0.005 and *** indicate p<0.001, two-way ANOVA 
followed by Bonferroni post-test , n=5 independentexperiments). 
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3.7  Total lipid hydroperoxides in oxidised LDL 
 
A spectrophotometric technique was used for the measurement of lipid hydroperoxides, 
which depends on the capability of lipid hydroperoxides to oxidize iodide (I-) to iodine (I2), 
which reacts with unreacted iodide (I-) to form the triiodide anion (I3-). The aim of this study 
to investigate the role of α-tocopherol as an antioxidant to reduce the formation of total lipid 
hydroperoxide.  
Total lipid hydroperoxide levels were measured by a tri-iodide assay in control LDL and LDL 
enriched with α-tocopherol oxidised by 5 μM FeSO4 at pH 4.5.  There was a modest, 
but  statistically  significant,decrease in hydroperoxide formation  by α-tocopherol (Figure 
3.19). This result agreed with the conjugated diene results (Figure 3.5). 
 The levels of hydroperoxides at 24 h were consistent with those of fully oxidised LDL (Satchell 
and Leake, 2012). 
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Figure 3.19 Effect of enrichment of LDL with α- tocopherol on total lipid hydroperoxides during LDL 
oxidatio by 5 μM FeSO4. Control LDL and LDL enriched with α- tocopherol was oxidised by 5 μM FeSO4 
at 37 oC at pH 4.5 and then evaluated for the presence of lipid hydroperoxides by a tri-iodide assay at 
different time points. (*indicate p<0.05, two-way ANOVA followed by Bonferroni post-test,n=5 
independent experiments). 
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3.8 HPLC analysis of oxidised lipids in LDL  
 
To investigate the effect of α-tocopherol on LDL oxidation at lysosomal pH in more detail, in 
this study I examined the level of individual  of oxidised lipids ,such as 7-ketocholesterol and 
cholesteryl linoleate hydroperoxide (CLOOH), which absorb UV radiation at 234 nm by using 
reverse-phase HPLC 
Control LDL and LDL enriched with α-tocopherol (50 μg LDL protein/ml) were oxidised in 
sodium chloride/sodium buffer (pH 4.5) at 37 °C by   5 μM FeSO4. Samples were taken at 
several times and were treated for HPLC analysis as declared in detail in the Methods section 
in chapter 2.  
Throughout LDL oxidation by iron, there was continuous production of 7-ketocholesterol 
which  had an increased  rate of production in α-tocopherol-enriched LDL (Figure 3.20). The 
levels of CLOOH decreased after 12 h either because the hydroperoxide groups were 
degraded (for instance into an alkoxyl or peroxy radical) or another part of the CLOOH 
molecules become oxidised and the molecules elute from the HPLC column at a different 
time. The 7-ketocholesterol increased at a lower rate than the  oxidisation of the cholesteryl 
linoleate fatty acyl group, having just one double bound instead of two. The levels of CLOOH 
and 7-ketocholesterol observed were compatible with previous result (Satchell and Leake, 
2012)  
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Figure 3.20. Effect of α- tocopherol enrichment on LDL oxidation products during oxidation by FeSO4 
(5 μM) at pH 4.5.  
 
Control LDL and LDL enriched with α- tocopherol (50 μg LDL protein/ml) were oxidised with freshly 
dissolved FeSO4 (5 μM) at 37 °C in a sodium chloride/sodium acetate buffer of pH 4.5. At several times 
until 24 hours, oxidation was blocked by adding EDTA (final concentration 4mM) and BHT (80 μM, 
form stock 2mM in ethanol). The samples were then assayed for cholesteryl linoleate hydroperoxides 
(A) and 7-ketocholesterol (B) by reverse-phase HPLC.  (* indicate p<0.05, ** indicate p<0.005 *** 
indicates p<0.001, n=4 two-way ANOVA followed by Bonferroni post-test) compared with the control 
LDL. 
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3.9 Discussion  
This chaper shows for the first time that α-tocopherol is less effective at inhibitory LDL 
oxidation at lysosomal pH then at pH 7.4. 
Iron is a candidate for oxidising LDL in vivo. Animal investigations have presented a positive 
correlation between iron localised in plaques and atherosclerosis (Lee et al., 1999). Human 
atherosclerotic lesions contain iron and are capable of stimulating LDL oxidation by 
macrophages (Lamb et al., 1995). In addition to this, iron has been noticed in vivo at higher 
levels in atherosclerotic lesions compared with the normal artery (Rajendran et al., 2007). 
Redox-active iron  has been documented to exist in lysosomes (Yu et al., 2003, Petrat et al., 
2001) ,possibly because of processes, such as the breakdown of ferritin (Sibille et al., 1989b, 
Radisky and Kaplan, 1998),the degradation of iron-containing organelles (Persson et al., 2001) 
and the phagocytosis of erythrocytes (Yuan et al., 1996). 
Consistent with experiments carried out earlier in the Leake laboratory (Wen and Leake, 
2007), LDL is oxidised successfully by iron at lysosomal pH 4.5 (Figure 3.1) but ineffectively 
oxidised at the pH of blood plasma or interstitial fluid (pH 7.4). It is likely that acidity may 
increase the solubility of iron permitting it to oxidise LDL more effectively at low pH (Morgan 
and Leake, 1995) or convert superoxide radicals into the much more reactive hydroperoxyl 
radicals (Ahmed & Leake,2018). Extracellular fluids have the high antioxidant ability, with just 
a low percentage of serum or interstitial fluid greatly inhibiting the ability of metals to oxidise 
LDL (Leake and Rankin, 1990). LDL oxidation by iron inside lysosomes may reconcile the 
suggestion for iron as oxidising an agent in vivo, with the data for an overwhelming 
antioxidant defence is the interstitial fluid of the inner layer of arteries.  
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LDL oxidation with ferrous iron at pH 4.5 progresses with a particular pattern including a lag, 
swift oxidation, slow oxidation, and aggregation and sedimentation phases. This pattern of 
oxidation with ferrous iron was quite similar to that with ferric iron but was faster (Figure 3.6). 
Iron may be capable to start the oxidation of LDL by reacting with existing lipid 
hydroperoxides in the LDL particle, as follows 
Fe2+ + LOOH                          Fe3+ + OH- +LO• (Fast)  
Fe3+ + LOOH                         Fe2+ + LOO• + H+ (Slow)  
Fe2+ + O2                                   Fe3+ + O-2• 
O-2• + H                           HO2•  
HO2• + LH                       H2O2 + L•  
L• + O2                            LOO•  
HO2• is much more reactive than O-2• (Bedwell et al., 1989) and can dissolve in the lipids of 
LDL.  
The reaction of ferrous iron with lipid hydroperoxides is quicker than the reaction of ferric 
ions and this may help to explain why the oxidation of LDL is slower with ferric iron. Ferrous 
ion also gives an electron to oxygen, forming the superoxide anion. The rapid phase might be 
due to the cholesteryl ester core oxidising and the slow phase might be due to the 
phospholipid monolayer oxidising (Ahmed & Leake, 2018). 
Redox-active iron is present in lysosomes of macrophages and foam cells in atherosclerotic 
lesions (Stadler et al., 2004, Yuan et al., 1996). In this study, it has been shown that the 
addition of different concentrations of EDTA (1, 2, 5, and 10 μM) inhibited LDL oxidation by 5 
μM iron at pH 4.5 in a concentration-dependent manner (Figure 3.2), LDL oxidation 
proceeded at a similar rate with 10 μM iron plus 5 μM EDTA as at 5 μM iron ion, indicating 
that EDTA molecules bind to the iron atom at 1:1 ratio (Figure 3.3).  Extra iron can, therefore, 
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be added equimolar with the EDTA carried over from the LDL preparation to allow for the 
different EDTA concentrations carried over from individual LDL preparation. This should 
improve the reproducibility of experiments. It was important to establish this as EDTA can 
sometimes  have pro-oxidant as well as antioxidant properties (Lamb and Leake, 1992). 
α-Tocopherol is the most important lipid-soluble antioxidant in LDL, with typically six 
molecules per LDL particle (Esterbauer et al., 1991a). Previous experiments have shown that 
enrichment of LDL with α -tocopherol inhibits LDL oxidation by macrophages (Jessup et al., 
1990) or copper ion at pH 7.4 (Esterbauer et al., 1991a). It was hypothesised that 
supplementation with α-tocopherol would diminish the incidence of cardiovascular disease, 
but, large clinical trials have found no protective effect of α-tocopherol supplementation 
(Yusuf et al., 2000, de Gaetano, 2001, 2002). 
 We approximately doubled the α-tocopherol content of LDL (Figure 3.18) by adding α- 
tocopherol to plasma, incubating and isolating the LDL by ultracentrifugation (Esterbauer et 
al., 1991b).  In the presence of oxidative stress by copper (2,5 or 20 μM) at pH7.4, the  rate of 
the oxidation of α-tocopherol-enriched LDL was lengthier than with non-enriched LDL (Figure 
3.15), as expected, while when α-tocopherol -enriched LDL was oxidised by ferrous and ferric 
ion at pH 4.5, there was no inhibition of LDL oxidation (Figure 3.7- 3.9). α-Tocopherol acts as 
an antioxidant, particularly by scavenging lipid peroxyl radicals. The α-tocopherol radical is 
then able to react with a further radical to create a non-radical product. In a mildly oxidising 
environment, it is less expected that the α-tocopherol radical will encounter another radical 
within the relatively small LDL particle  (about 22 nm in diameter) and so it may react with a 
polyunsaturated fatty acid to form a lipid alkyl radical instead, a process named tocopherol-
mediated peroxidation (Upston et al., 1999).  
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α-tocopherol-OH + LOO•                     α-tocopherol –O• +LOOH  
α-tocopherol –O• + R•                          Non-radical product  
 α-tocopherol –O• + LH                          α-tocopherol –OH + L•  
L• + O2                           LOO• 
α-Tocopherol had an antioxidant effect with 5 and 20 μM Fe2+ (Figure 3.5and 3.6) but not with 
2μM Fe2+ at pH 4.5 (Figure 3.4).  
 This finding is in contrast to previous reports (Lynch and Frei, 1995, Schnitzer et al., 1997) 
suggesting that the α-tocopherol content of LDL may not be rate-limiting in Cu (II) reduction. 
α-Tocopherol enrichment increased the rate of Cu (II)  reduction to Cu (I) by LDL at pH4.5 of 
(Figure 3.17). Bathocuproine was not present throughout the incubations but was added just 
before samples were taken for Cu (I) measurement.  Bathocuproine was therefore not giving 
artefactual results by pulling the equilibrium over in fevour of Cu+  in the reaction below. 
Cu 2+.   + α -toc-OH                                          Cu+. +     α -toc-O• + H+ 
 LDL oxidation by high copper concentrations was calculated by kinetic simulation by Abuja et 
al. (Abuja et al., 1997). According to this simulation, the  following reactions determine the 
kinetics of initiation:  
 
Cu 2+( or Fe 3+ + α-toc-OH                                             Cu+( or Fe 2+) +α -tocO• + H+  
α -toc-O• + LH                                                   α -toc-OH + L•  
L• +O2                                                                LOO•  
Cu 2+ (or Fe 3+) + LOOH                                                       Cu + (or Fe2+)   LOO• + H+  
Cu + (or Fe 2+) + LOOH                                                 Cu 2+ ( or Fe 3+) + LO + OH-  
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I was able to show that increasing the α-tocopherol content of LDL increased the rate of Cu 2+ 
reduction to Cu + (Figure 3.17) and Fe 3+ reduction to Fe 2+ (Figure 3.16). LDL oxidation by 
copper at pH 4.5 was much slower than at pH 7.4 (in marked contrast to what was observed 
with iron). The reason for this is unclear, but there might be a mechanism by which LDL 
becomes oxidised  at pH 7.4   that does not operate at pH 4.5, e.g. Involving the oxidation of 
tryptophan,upsteire on methionine residues by copper. Giessauf et al,  found that 8 or 9 of 
the 37 trytophan residues in apo B-100 seem to be vulnerable  to chelation with Cu2+  leading 
to a rapid decrease in tryptophan fluorescence (Giessauf et al., 1995). The rate of LDL 
oxidation by Cu2+ at pH 4.5 was not increased  as the concentration of Cu2+ increased (Figure 
3.10-3.12). In a previous study it was observed that the rate of LDL oxidation at pH 4.5 by 
ferric ions (Fe3+) was not increased by increasing the concentration of Fe3+ (whereas it was by 
increasing  the concentration of Fe2+) (Satchell and Leake, 2012).  
In marked contrast to the antioxidant effect of α-tocopherol on LDL oxidation by Cu2+  at pH 
7.4, α-tocopherol did not inhibit LDL oxidation by Cu2+  (2, 5 or 20 μM) (Figure 3.10-3.12) at 
pH 4.5. The reason for this is unknown, but it might be speculated that the rapid mechanism 
for LDL oxidation by Cu2+   at pH 7.4 is inhibited by α-tocopherol, but the slower oxidation at 
pH 4.5 is not inhibited by α-tocopherol. α-Tocopherol has both antioxidant and pro-oxidant 
effects and the net balance of these effect on LDL oxidation depends on the nature of the 
metal ions, its concentration and the pH. One possibility is that the hydroperoxyl radical at pH 
4.5 might convert α-tocopherol into a pro-oxidant  
α -toc-OH + HO•2                                                 α -toc-O•      +  H2O2 
α -toc-O•      +   LH                                                α -to-OH + L• 
α-Tocopherol lost its antioxidant effect on LDL with Cu2+ at pH 4.5 and did not inhibit LDL 
oxidation by Fe3+ at pH 4.5 or 2μM Fe2+ at pH 4.5, although it did inhibit with 5 or 20μM Fe2+ 
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at pH 4.5. This might help to explain why the large clinical trials of α-tocopherol 
supplementation did not decrease cardiovascular disease if the oxidation of LDL occurs mainly 
in the lysosomes, which have an acidic pH. Since LDL preparations frequently have  small 
amount of pre-formed lipid hydroperoxides, the breakdown of these to alkoxyl and peroxyl 
radicals would appear a feaisble place to start when addressing mechansim of copper-
induced LDL oxidation. It is largely accepted that α-tocopherol can quicken this oxidation 
process in vitro by converting Cu (II) to Cu (I), which can then convert the hydroperoxides to 
alkoxyl radicals. The concentration  of Cu (I) started to increase significantly from 30 minuts 
and plateaued at about 480 minutes for both control and α-tocopherol enriched LDL. α-
Tocopherol accelerated the conversion Cu (II) to Cu (I) (Figure 3.17),. These findings suggest  
that the pro-oxidant effect of α-tocopherol enriched LDL  might be due to the conversion of 
Cu2+  to more reactive Cu+ . This study provides new information on the weaker antioxidant 
effects of α-tocopherol at lysosomal pH then at pH7.4. If LDL oxidation in atherosclerotic 
lesions occurs mainly in lysosomes, rather than in the interstitial fluid,it might helps to explain 
why the large antioxidant trails of α-tocopherol failed to provide protection against 
cardiovascular disease. 
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Chapter 4 
 
 
Effect of tempol and probucol on low density lipoprotein 
oxidation at lysosomal pH 
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4.1Introduction 
 
4-Hydroxy-2, 2, 6, 6-tetramethylpiperidine-1-oxyl (Tempol) is a membrane-permeable 
aminoxyl-type free radical scavenger, with antioxidant properties. Tempol is a steady 
piperidine nitroxide, free radical with low molecular weight, which infiltrates biological 
membranes and scavenges superoxide anions in vitro (Araki et al., 2006). This complex shows 
a superoxide dismutase mimetic action to diminish superoxide radicals. The beneficial effect 
of aminoxyl action is partly due to prevent the results of Fenton’s reaction  
(Fe2+  + O2          Fe3+ +O2•_    ) induced by Fe2+ ions (Soule et al., 2007a). Preclinical studies, with 
a variety of rat models, have shown the possibility for numerous clinical uses, including 
regulation of hypertension  (possibly by increasing the availability of nitric oxide), weight gain, 
defence from ionising radiation and DNA damage, and inhibition of doxorubicin treatment-
related cardiomyopathy (Bartha et al., 2011). To date, most of the considerations have been 
paid to the capacities of nitroxides to lower superoxide and peroxide, (Krishna et al., 1996a) 
prevent the effects of Fenton reactions (Mitchell et al., 1990b) and undergo radical–radical 
reorganisations (Soule et al., 2007a) particularly for carbon-centered radicals. Tempol which 
has been demonstrated to modify sensitivity to radioactivity, tumourigenesis and diet-
stimulated body mass gain (Mitchell et al., 2003). Tempol (at 10 mg/g of food) has inhibitory 
properties on body weight increases in C3H mice and inhibits obesity-induced alterations in 
leptin levels. Leptin is a hormone manufactured from white adipocytes, which binds to its on 
receptors in the hypothalamus to control food consumption and energy expenditure. 
Alterations in leptin and its receptor lead to genetic obesity in rodents and humans (Mitchell 
et al., 2003, Phillips et al., 1996). Leptin can encourage the production of the effective 
vasoconstrictor, endothelin, and intensification of the expression of its receptors in both 
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endothelial and vascular smooth muscle cells (Chao et al., 2007, Juan et al., 2008).  Tempol 
enhanced NO signalling by  increasing cGMP  levels in models of oxidative stress (Wilcox and 
Pearlman, 2008). Similar influence on mass increase has recently been described for mice on 
a high-fat diet (Li et al., 2013). Tempol has also been documented to decrease production of 
reactive oxygen species in diabetes (Frances et al., 2011) and hypertension (Wilcox and 
Pearlman, 2008, Schnackenberg et al., 1998), with the latter due to increased nitric oxide 
(NO.) production by endothelial cells (Wilcox and Pearlman, 2008) and resulting 
vasodilatation (Patel et al., 2006). Tempol also protects the endothelium in spontaneously 
hypertensive rats and small arteries from the effect of visceral lipid in obese subjects (Patel 
et al., 2006). Nitroxides have also been suggested to modify atherosclerotic lesions and 
vascular inflammation by decreasing vascular adhesion molecule-1 (VCAM-1) and by 
diminishing the amounts of particular NADPH oxidase-2 (NOX2) subunits (Cannizzo et al., 
2014). Tempol has been shown to inhibit obesity-stimulated alterations in adipokines and to 
increase plaque collagen and macrophage numbers, and to decrease lipid levels (Kim et al., 
2015). Tempol was used as a redox probe (Tada et al., 2013). Nitroxyl radicals (nitroxides) 
such as 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (hydroxy-TEMPO, Tempol) have been 
widely reported to have protective properties against oxidative stress and degenerative 
illnesses in cells and in animals (Soule et al., 2007b, Yamada et al., 2006). These properties 
depend on their reaction with reactive oxygen species (ROS) (Krishna et al., 1996a, Krishna et 
al., 1996b, Takeshita et al., 2002). The antioxidant reactions of tempol have been investigated 
in detail as superoxide dismutase (SOD) mimics (Krishna et al., 1996a) and for their catalase-
like ability (Krishna et al., 1996b). However, the swift transformation of nitroxyl to 
hydroxylamine in vivo requires the use of a high amount of nitroxyl to understand its 
therapeutic properties. The main cause of transformation of nitroxyl to hydroxylamine is the 
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one-electron reaction by several types of reductants, for instance, ascorbic acid (AsA). Both 
enzymatic and non-enzymatic antioxidants work in a network way to employ their protective 
effects, no single antioxidant could provide the whole antioxidant properties in plasma. 
Hence, plasma antioxidant status is the result of communication and cooperation of various 
antioxidants. The idea of total antioxidant capacity (TAC) was established considering the 
synergistic role of those antioxidants rather than the simple amounts of individual 
antioxidants (Wang et al., 2013, Gaziano, 2004). 
This study have investigated the effect of both α-tocopherol and tempol alone and in 
combination on LDL oxidation. Combination treatment was used because antioxidants can 
complement each others action. 
Probucol is a clinically used cholesterol-lowering drug, Probucol has also been used as a 
pharmaceutical agent to treat a variety of infections, traumas, and pathologic conditions, 
including, lowering plasma cholesterol levels in hypercholesterolaemia patients (Zimetbaum 
1990). Probucol is a lipid-soluble, bis-tertiary butyl-phenol capable of giving one of the 
hydrogens from its phenolic-OH groups and consequently performing as an antioxidant. 
During lipid oxidation, the lipid radical (L●), lipid alkoxyl radical (LO●) or lipid peroxyl radical 
(LOO●) easily abstract a hydrogen atom from probucol, hence inhibiting the lipid peroxidation 
chain reaction (Mao et al., 1991, Jackson et al., 1991). Then, if the oxidation of LDL is mediated 
by any of these radicals (as is believed) probucol should be able to completely inhibit the 
oxidation of LDL by oxidative stress (Maiolino et al., 2013). LDL oxidation is inhibited by 
probucol (Parthasarathy et al., 1986, Jackson et al., 1991, Leake and Rankin, 1990). Probucol 
inhibits atherosclerosis in most animal models (Carew et al., 1987, Sasahara et al., 
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1994).Probucol did not, however, protect against human femoral artery atherosclerosis in the 
PQRST trail (Walldius et al., 1994).  
 
 
4.2 Material and Methods 
LDL was enriched with α-tocopherol, as described in the methods chapter. Its oxidation by 
iron or copper at lysosomal pH was then measured by monitoring the formation of conjugated 
dienes at 234 nm or by measuring the formation of cholesterol linoleate hydroperoxide and 
7-ketocholesterol by HPLC in presence or abscence of the antioxidants tempol or probucol. 
The aim was to ascertain if tempol or probucol are good antioxidants for LDL  at lysosomal pH 
and if a combination of tempol or probucol and α-tocopherol enrichment would be an 
effective antioxidant combination therapy. It was wondered if these antioxidants might 
convert the α-tocopheroxyl. 
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4.3 Results 
4.3.1 Effect of α-tocopherol and tempol on LDL oxidation by 5μM ferrous iron 
at pH 4.5 
 
Two antioxidants, α-tocopherol and tempol, on LDL oxidation by ferrous ion at lysosomal pH 
(Figure 4.1). The oxidation showed the usual pattern of lag, slow oxidation, rapid oxidation, 
aggregation and sedimentation phases (Satchell and Leake, 2012). The rate of oxidation of 
LDL was decreased when it was supplemented with α-tocopherol, but it did not alter the 
pattern of oxidation and aggregation (Figure 4.1). Tempol (10 μM) decreased the rate of 
oxidation of both control and α-tocopherol-enriched LDL (Figure 4.1). Unlike α-tocopherol, it 
altered the pattern of oxidation, in that it inhibited the slow phase of oxidation much more 
than it inhibited the rapid phase of oxidation. This is similar to the effect of tempol observed 
with LDL oxidation by the iron-storage protein ferritin (Ojo and Leake, 2018) and the effect 
of probucol on LDL oxidation by ferrous ion (Ahmad and Leake, 2018) at lysosomal pH. 
Tempol inhibited CLOOH and 7-ketocholesterol formation in LDL and LDL enriched with α-
tocopherol, with the inhibition being more after 3h than before 3h (Figure 4.2). These data 
suggest, that tempol changs the pattern of LDL oxidation by iron in both control LDL and  
LDL enriched with α -tocopherol. However, there was no significant difference between 
control LDL plus tempol, α -tocopherol -enriched LDL plus tempol and enriched LDL with α -
tocopherol, but if we compared these groups with control LDL, there were significant 
differences. This indicates that tempol shows its antioxidant properties at the late slow 
phase of oxidation, rather than the earlier rapid phase. 
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Figure 4.1. Effect of α-tocopherol and tempol on LDL oxidation by ferrous ion.  (A) Control LDL and LDL 
enriched with α-tocopherol (50µg protein/ml) were oxidised by 5µM FeSO4 at pH 4.5 and 37 
o
C with 
or without 10 µM tempol. Oxidation was monitored by measuring the change in attenuance at 234 
nm. (B) The increase in attenuance at 100 min, around the transition between the rapid and slow 
phases of oxidation. The bar chart shows the mean ± SEM of the four experiments during the oxidation 
period of 100 min. A one-way ANOVA followed by Tukey's posthoc tests were significant (**P<0.01, 
***P<0.001, n=4) compared to control. 
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Figure 4. 2. Effect of α-tocopherol and tempol on LDL oxidation by ferrous ion in the presence or 
absence of 10 µM tempol.  Control LDL and  LDL enriched with α-tocopherol (50 µg LDL protein/ml) 
were oxidised by 5 µM FeSO4 at pH 4.5 and 37 
o
C. (A) CLOOH and (B) 7-ketocholesterol were 
measured by HPLC.  The mean± SEM of 3 independent experiments is shown. Two-way ANOVA 
followed by Bonferroni post hoc tests were significant (* P< 0.05 ***P<0.001, n=3) compared control 
LDL with LDL enriched with α- tocopherol and tempol. 
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4.3.2 Effect of tempol on LDL oxidation by 5μM Ferric ion at pH 4.5 
 
 
Regarding chapter 3, α-tocopherol had no effect to inhibit LDL oxidation by different 
concentrations of ferric ion at lysosomal pH. The aim of this study was to investigate the 
effect of the antioxidant tempol on LDL oxidation by 5μM ferric as well as its effect in 
combination with α-tocopherol.  
As expected, (Ahmad and Leake, 2018, Satchell and Leake, 2012) LDL oxidation by ferric ion 
was slower than by ferrous ion at lysosomal pH (Figure 4.3).  Tempol (10μM) did not inhibit 
the oxidation of either LDL or α- tocopherol-enriched LDL by ferric ions, in marked contrast 
to the inhibition observed with ferrous ions. HPLC showed that tempol did not inhibit LDL 
oxidation of either control LDL or α- tocopherol-enriched LDL (Figure 4.4). Instead, tempol 
increased the oxidation of α- tocopherol-enriched LDL. The rate of LDL oxidation was 
increased, rather than decreased, by α-tocopherol enrichment. α-Tocopherol enrichment of 
LDL did not inhibit the formation of CLOOH, and 7-ketocholesterol (Figure 4.4). This finding 
suggests that, tempol did not inhibit α-tocopheroxyl radical. 
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Figure 4. 3. Effect of α-tocopherol and tempol on LDL oxidation by ferric iron.  
( A ) Control LDL or LDL supplemented with α-tocopherol (50 µg protein/ml) were oxidised by 5 µM 
FeCl3 at pH 4.5 and 37 
o
C in the presence or absence of 10 µM tempol. Oxidation was monitored by 
measuring the change in attenuance at 234 nm. (B) The increase in attenuance at 200 minutes (the 
transition between the rapid and slow phases of oxidation) for the experiments was measured. The 
bar chart shows the mean ± SEM of the three experiments during the oxidation period of 200 min. A 
one-way ANOVA  followed by Tukey's posthoc tests were significant (**P<0.01, n=3) compared to 
control. 
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B 
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Figure 4.4. Effect of α-tocopherol and tempol on LDL oxidation by ferric iron.   
 
Control LDL or LDL supplement with α-tocopherol (50 µg protein/ml) were oxidised by 5 µM FeCl3 at 
pH 4.5 and 37 
o
C in the presence or absence of 10 µM tempol. (A) CLOOH and (B) 7-ketocholesterol 
were measured by HPLC. Two -way ANOVA, followed by Bonferroni post hoc tests were significant 
(*P< 0.05, ** P< 0.01 ***P<0.001, n= 3) compared to control LDL for LDL enriched with α- 
tocopherol and tempol.  
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4.3.3 Effect of α-tocopherol and tempol on LDL oxidation by 5μM copper at pH 
4.5 
 
LDL oxidation by copper at lysosomal pH showed the oxidation profile as that shown by iron 
at this pH, i.e., there was a short lag phase, a rapid oxidation phase, a slow oxidation phase, 
an aggregation phase and sedimentation phase (Figure 4.5). The rate of LDL oxidation during 
the slow oxidation phase was increased, rather than decreased, by α-tocopherol. When 
adding 10 μM tempol, there was a decrease in the oxidation of LDL supplemented with α-
tocopherol at the later times but not the early times. α-Tocopherol enrichment increased 
the formation of CLOOH and 7-ketocholesterol. (Figure 4.6). Tempol decreased the rate 
formation of CLOOH and 7-ketocholesterol in α-tocopherol-enriched LDL. These results show 
that tempol does not inhibit the early oxidation of LDL by copper at lysosomal pH, but 
inhibits the later oxidation. 
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Figure 4.5. Effect of α-tocopherol and tempol on LDL oxidation by copper ion at lysosomal pH.   
 
(A) Control LDL and LDL enriched with α-tocopherol (50 µg protein/ml) were oxidised by 5µM CuSO4 
at pH 4.5 and 37 
o
C. Oxidation was monitored by measuring the change in attenuance at 234 nm. (B) 
The bar chart shows the mean ± SEM of the three experiments during the oxidation period of 200 
min before the aggregation phase was reached. A one-way ANOVA followed by Tukey's posthoc 
tests were significant (***P<0.001, n=3) compared to LDL supplemented with α-tocopherol. 
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Figure 4.6. Effect of α-tocopherol and tempol on LDL oxidation by copper ion at lysosomal pH. 
 
 
Control LDL and  LDL enriched with α-tocopherol (50 µg protein/ml) were oxidised by 5 µM CuSO4 at 
pH 4.5 and 37 
o
C.  (A) CLOOH and (B) 7-ketocholesterol were measured by HPLC. Two -way ANOVA, 
followed by Bonferroni post hoc tests were significant ***P<0.001, (n=3) compared to control LDL 
with LDL enriched with α- tocopherol and tempol.  
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4.3.4 Effect of α-tocopherol and tempol on LDL oxidation by 5 µM copper ion 
at pH 7.4 
 
LDL oxidation by copper ions at pH 7.4 was much faster than at pH 4.5 (Figure 4.7), in 
marked contrast to what was observed with ferrous or ferric iron. The pattern of oxidation 
was as expected (Esterbauer at al., 1989), with no aggregation observed at pH 7.4. As 
expected, (Jessup et al., 1990; Dieber-Rotheneder et al., 1991), enrichment of LDL with α-
tocopherol decreased its rate of oxidation but did not totally inhibit LDL oxidation. Tempol 
(10 μM) decreased the rate of oxidation of LDL and α-tocopherol-enriched LDL but only at 
later time points, there is no inhibition initially. α-Tocopherol enrichment of LDL decreased 
the rate of formation of CLOOH and 7-ketocholesterol (Figure 4.8). Tempol also decreased 
significantly the rate of formation of these two oxidised lipids (Figure 4.8).  Thus,α-
tocopherol  inhibits LDL oxidation  by copper considerably at pH7.4 , with tempol having a 
more modest inhibition.  
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Figure 4.7. Effect of α-tocopherol and tempol on LDL oxidation by copper ion at pH7.4.  
 
(A) Control LDL and LDL enriched with α-tocopherol (50 µg protein/ml) were oxidised by 5µM CuSO4 
at pH 7.4 and 37 
o
C with or without tempol (10 μM). Oxidation was monitored by measuring the 
change in attenuance at 234 nm.  This is a representative example of three experiments. (B) The bar 
chart shows the mean ± SEM of the three experiments during the oxidation period of 50 min. A one-
way ANOVA  followed by Tukey's posthoc tests were significant (***P<0.001, n=3) compared to 
control LDL. 
A
 
B 
 
   151 
 
 
 
 
 
Figure 4.8. Effect of α-tocopherol and tempol on LDL oxidation by copper ion at pH 7.4.  
Control LDL and LDL enriched with α-tocopherol (50 µg protein/ml) were oxidised by 5 µM CuSO4 at 
pH 7.4 and 37 
o
C with or without tempol 10 μM. (A)CLOOH and (B) 7-ketocholesterol were measured 
by HPLC. (Two -way ANOVA, followed by post hoc Bonferroni tests were significant*P< 0.05,** P< 
0.01 ***P< 0.001, n=3) compared to control LDL with LDL enriched with α- tocopherol plus tempol. 
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4.3.5 Effect of Probucol on LDL oxidation by 5μM Fe 2+ at pH 4.5 
 
A diversity of agents have been employed in the treatment of hyperlipidaemia, including 
probucol (Jialal and Grundy, 1992).  Probucol is also a good antioxidant for LDL at pH 7.4. 
Our hypothesis was that a combination of probucol and α- tocopherol would give a greater 
antioxidant effect because probucol might possibly scavenger alpha-tocopheroxyl radicals 
by donation  of  a hydrogen atom fromits hydroxyl groups. In agreement with the result in 
chapter 3 (Figure 3.5), α- tocopherol enriched with LDL delayed but not change the pattern 
of  LDL oxidation by 5 μM FeSO4 at pH 4.5. Adding probucol (5 μM) (Figure 4.9), greatly 
reduced the pattern of oxidation for both control LDL and LDL enriched with α-tocopherol, 
but was less affective at early times. α-Tocopherol enrichment decreased the formationl of 
CLOOH and 7-ketocholesterol during LDL oxidation by 5 μM Fe SO4 at pH 4.5 (Figure 4.10). 
The addition of probucol (5 μM) greatly decreased the formation of these oxidation 
products in both control LDL and LDL enriched in α-tocopherol,  especially CLOOH.  Probucol 
greatly inhibited LDL oxidation by copper at pH7.4. 
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Figure 4.9 Graphs showing the effect of probucol (5 µM) on LDLoxidation by ferrous iron. 
 
 (A)  Control LDL and LDL enriched with α-tocopherol (50 µg LDL protein/ml) were oxidised by 5 µM 
FeSO4 at pH 4.5 and 37
o
C. Oxidation was monitored by measuring the change in attenuance at 234 
nm. (B) The bar chart shows the mean ± SEM of the four experiments during the oxidation period of 
200 min. A one-way ANOVA followed by Tukey's posthoc tests were significant (***P<0.001, n= 4) 
compared to control LDL. 
 
 
A 
 
B 
 
 154 
 
 
 
 
Figure 4.10 Effect of α-tocopherol and probucol on LDL oxidation by ferrous ion.  
 
 Control LDL and LDL enriched with alpha-tocopherol  (50µg protein/ml) were oxidised by 5µM FeSO4 
at pH 4.5 and 37
o
C in the presence or absence of probucol (5 µM). At different time points, the 
oxidation was stopped by adding EDTA (final concentration 4μM) and BHT (80μM). The samples 
were assayed for (A) CLOOH and. (B) 7-ketocholesterol, by  C18 reversed-phase HPLC. (Two -way 
ANOVA, followed by post hoc test Bonferroni tests was significant (***P< 0.001, n=4) compared to 
control LDL with LDL enriched with α- tocopherol plus probucol. 
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4.3.6 Effect of probucol on LDL oxidation by 5μM Fe 3+ at pH 4.5 
 
This study aimed to examine the therapeutic effects of the combined use of probucol and α -
tocopherol on LDL oxidation by ferric ion at lysosomal pH. In agreement with the results in 
chapter 3, α-tocopherol enrichment did not inhibit LDL oxidation by Fe3+ at pH 4.5 (Figure 
4.11.). in the presence of probucol (5 µM), there was a considerable decrease in the oxidation 
rate of both control and α-tocopherol enriched LDL (Figure 4.11). Probucol (5 µM) greatly 
decreased CLOOH and 7-ketocholesterol formation during the course of oxidation of control 
LDL and α -tocopherol -enriched LDL (Figure 4.12). These results show that probucol with or 
without α-tocopherol can greatly inhibit the oxidation induced by Fe3+ at pH 4.5 of the 
cholesteryl ester-rich hydrophobic core of LDL as well as the oxidation of non-esterified 
cholesterol, which is mainly in the surface monolayer of LDL.  
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Figure 4.11 Graphs showing the effect of probucol (5 µM) on LDL oxidation by ferric iron. 
 
( A) control  LDL and LDL enriched with α-tocopherol (50µg LDL protein/ml)  were oxidised by 5µM 
Fe3+ at pH 4.5 and 37oC. Oxidation was monitored by measuring the change in attenuance at 234 nm. 
(B) The bar chart shows the mean ± SEM of the four experiments during the oxidation period of 300 
min. A one-way ANOVA followed by Tukey's posthoc tests were significant (*P<0.05, n= 4) compared 
to LDL supplemented with α-tocopherol. 
 
 
 
 
A 
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Figure 4.12 Effect of α-tocopherol and probucol on LDL oxidation by ferric iron.   
 
Control LDL and enriched LDLwith α -tocopherol (50 µg LDL protein/ml) were oxidised by 5µM FeCl3 
at pH 4.5 and 37
o
C in the presence or absence of probucol (5 µM). At different time points, the 
oxidation was stopped by adding EDTA (final concentration 4mM) and BHT (80μM). The samples 
were assayed for (A) CLOOH and (B) 7-ketocholesterol by C18 -reverse-phase HPLC. (Two -way 
ANOVA, followed by post hoc test Bonferroni tests  were significant ***P< 0.001, n=4) compared to 
control LDL with LDL enriched with α- tocopherol plus probucol.  
B 
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4.3.7 Effect of probucol on α-tocopherol-enriched LDL oxidation by 5μM Cu2+ 
at pH 4.5 
 
LDL the oxidation by 5μM Cu2+ at pH 4.5 was not inhibited by α-tocopherol supplementation, 
but in theses experiments was increased by it (Figure 4.13). Addition of probucol (5 µM) 
greatly inhibited the LDL oxidation induced by copper at lysosomal pH in both control and LDL 
enriched with α-tocopherol. There was also much less formation of CLOOH and 7-
ketocholesterol in the presence of probucol (5μM) (Figure 4.14).  
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Figure 4.13 Graphs showing the effect of probucol (5 µM) on  LDL oxidation by copper ion  at lysosomal 
pH. 
 
( A) control  LDL and LDL enriched with α-tocopherol (50µg LDL protein/ml)  were oxidised by 5µM 
Cu2+ at pH 4.5 and 37oC. Oxidation was monitored by measuring the change in attenuance at 234 nm. 
(B) The bar chart shows the mean ± SEM of the four experiments during the oxidation period of 300 
min. A one-way ANOVA followed by  Tukey's posthoc tests were significant (***P<0.001, n= 4) 
compared to  control LDL.  
B 
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Figure 4.14 Effect of α-tocopherol and probucol on LDL oxidation by copper ion at pH 4.5.  
 
 
Control LDL and LDL enriched with α-tocopherol  (50µg LDL protein/ml) were oxidised by 5µM CuSO4 
at pH 4.5 and 37
o
C in the presence or absence of probucol (5 µM). At different time points, the 
oxidation was stopped by adding EDTA (final concentration 4mM) and BHT (80μM). The samples 
were assayed for (A) CLOOH and (B) 7-ketocholesterol by C18- reverse-phase HPLC. (Two -way 
ANOVA, followed by post hoc test Bonferroni tests were significant (*P< 0.05 ***P< 0.001, n=4) 
compared to control LDL with LDL enriched with α- tocopherol plus probucol.  
 
 
 
 
B 
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4.3.8 Effect of probucol on α-tocopherol-enriched LDL oxidation by 5μM Cu2+ 
at pH 7.4 
 
In agreement with the result shown in chapter 3, α-tocopherol enrichment delayed LDL 
oxidation by Cu2+ at pH 7.4 (Figure 4.15). In the presence of 5µM probucol, there was an 
almost total decrease in oxidation in both control and α-tocopherol-enriched LDL. α-
Tocopherol enrichment inhibited the formation of CLOOH and 7-ketocholesterol (Figure 
4.16). Probucol greatly inhibited the formation of both CLOOH and 7-ketocholesterol of both 
control and α-tocopherol enriched LDL (Figure 4.16). It may be concluded that oxidation of 
LDL can be delayed by α-tocopherol supplementation, but did not totally inhibit, but addition 
of  probucol can almost totally inhibit LDL oxidation at pH 7.4.  
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Figure 4.15 Effect of α-tocopherol and probucol (5µM) on LDL oxidation by copper ion at pH 7.4. 
 
 ( A) control and LDL (50µg LDL protein/ml) was oxidised by 5 µM CuSO4 at pH 7.4 and 37
o
C. Oxidation 
was monitored by measuring the change in absorbance at 234 nm. ( B) The bar chart shows the 
decrease in absorbance during the propagation phase of oxidation at 50 min. A one-way ANOVA 
followed by  Tukey's posthoc tests were significant (***P<0.001, n= 4) compared to  control LDL.   
 
B 
 
A 
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Figure 4.16 Effect of α-tocopherol and probucol on LDL oxidation by copper ion at pH 7.4.  
 
 
Control LDL and LDL enriched with α -tocopherol (50µg LDL protein/ml) were oxidised by 5 µM 
CuSO4 at pH 7.4 and 37
o
C in the presence or absence of probucol (5 µM). At different time points, 
the oxidation was stopped by adding EDTA (final concentration 4mM) and BHT (80μM). The samples 
were assayed for (A) CLOOH and (B) 7-ketocholesterol by C18- reverse-phase HPLC. (Two -way 
ANOVA, followed by post hoc test Bonferroni tests were significant ( ***P< 0.001, n=4) compared to 
control LDL with LDL enriched with α- tocopherol plus probucol.  
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4.4 Discussion 
 
Our group have raised the possibility that LDL might be oxidised in the lysosomes of 
macrophages in atherosclerotic lesions and be catalysed by redox-active iron (Wen and 
Leake, 2007). α-Tocopherol usually inhibits LDL oxidation at pH 7.4 as shown in numerous 
studies (Jessup et al., 1990, Dieber-Rotheneder et al., 1991),but Stocker’s group (Bowry et 
al., 1992, Upston et al., 1999, Ingold et al., 1993) have shown that α-tocopherol can increase 
the rate of LDL oxidation if the oxidative stress is low.  Under low oxidative stress conditions, 
the α-tocopheroxyl radicals can abstract a hydrogen atom from a polyunsaturated fatty acyl 
group in LDL particles, unless it becomes reduced by a co-antioxidant, such as a vitamin C or 
ubiquinol-10. In chapter 3, the results showed that the antioxidant/ pro-oxidant activity of 
α-tocopherol depends on the pH and kind of oxidant. α-Tocopherol is transformed to α-
tocopheroxyl radical during oxidative reactions. To regenerate α -tocopherol, it is required 
to get a  hydrogen atom either from another polyunsaturated fatty acid or co-antioxidant. 
Therefore, α-tocopherol requires a co-antioxidant to quench the  α -tocopheroxyle radical. 
In this study, tempol and probucol were chosen to perform as possible  co-antioxidants.  
  The stable aminoxyl faces radical tempol inhibited the oxidation of LDL by Fe2+ at pH 4.5, 
especially the later stage of oxidation but was less effect at inhibitoring the initial oxidation. 
Tempol has a hydroxyl group and four methyl group and is soluble in both water and 
ethanol. It would, therefore, be expected to reside in the phospholipid monolayer of LDL, 
rather than the hydrophobic cholesteryl ester core. This might explain why it inhibited the 
later oxidation of LDL more than the initial oxidation, as we believe the core of LDL oxidises 
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before the surface monolayer at pH 4.5 (Ahmad and Leake, 2018). Tempol might scavenge 
hydroperoxyl radicals or phospholipid or non-esterified radicals in the surface monolayer. 
 
tempol• +   HO2•                  tempol OOH 
tempol•   + PLOO•                                tempol OOPL    
tempol•    + cholesterol OO•                            tempol OO cholesterol 
 
Tempol might also scavenge the pro-oxidant α-tocopheroxyl radical. 
 
α-toc O• + tempol•                    α-toc O tempol   
 
α-Tocopherol-enrichment of LDL in these experiments reduced the oxidation of LDL by 5 µM 
ferrous ion, but in contrast the lack of antioxidant effect observed with ferric ion (Figure 4.3 
& 4.4).  The reason for this difference is unknown, but might be due to a difference in the 
balance between antioxidant and pro-oxidant effects observed with ferrous and ferric ion. 
Tempol inhibited the oxidation of LDL (especially LDL enriched with α-tocopherol) by Cu2+    
at pH 4.5 (Figure 4.5),  which might have been due to a direct antioxidant effect of tempol or 
possibly due to the conversion of the α-tocopheroxyl radical to α-tocopherol .  It did not, 
however, inhibit with Fe 3+ at pH 4.5 (Figure 4.3). The reason for this is unknown and is 
unexpected as both metal ions were in their in their higher valency states (Cu2+ Fe3+ rather 
than   Cu+  and Fe2+). 
 
Probucol is a diphenol structure with antioxidant and anti-inflammatory properties (He et 
al., 2017). It inhibited LDL oxidation by Cu 2+   at pH 7.4 very effectively (Figure 4.15& 4.16), 
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in agreement with previous studies (Parthasarathy et al., 1986, Leake and Rankin, 1990), but 
it does not decrease atherosclerosis in humans (Walldius et al., 1994) or decrease the 
primary endpoints in cardiovascular clinical trials (Yamashita et al., 2008, Tardif et al., 2008).  
Probucol did not inhibit so effectively the oxidation of LDL at lysosomal pH (Figure 4.9, 4.11 
or 4.13). Probucol would be expected to reside in the surface phospholipid monolayer of 
LDL, as it contains two hydrophilic hydroxyl groups, and there is evidence for this based on 
the distribution of  14C probucol in lipoproteins according to their phospholipid content 
(Bard et al., 1994). If LDL oxidation at lysosomal pH starts mainly in the hydrophobic core, 
probucol in the surface monolayer might not effectively inhibit it. If LDL is oxidised in 
lysosomes in vivo, this might help to explain why it does not decease atherosclerosis in 
patients very effectively.  In conclusion, tempol inhibited the later oxidation of LDL more 
effectively than the early oxidation of LDL by  Fe2+  or Cu2+   at pH 4.5. It did not inhibit 
LDLoxidation by Fe3+at pH 4.5 and modestly inhibited the later oxidation of LDL by Cu2+ at 
pH 7.4. Probucol inhibited the oxidation of LDL by Cu2+  at pH 7.4 very effectively,but not 
quite as effectively at pH 4.5. Probucol inhibited the later oxidation of LDL by Fe2+  more 
effectively than the early oxidation of LDL at pH 4.5, but inhibited the early oxidation of LDL 
by Fe3+ at pH 4.5. The detailed chemistry to explain these complex effect remains to be 
explained. 
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Chapter 5 
 
The effect of LDL oxidised at lysosomal pH on cultured 
macrophages. 
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5.1 Introduction  
Scavenger receptors are known by their ability to endocytose modified (e.g. acetylated or 
oxidised) types of LDL and were first described by Goldstein and Brown in 1979 (Goldstein 
and Brown, 1979). LDL contains a cholesteryl ester-rich core wrapped by phospholipids and 
apoB-100, which targets uptake by the LDL receptor. Both the lipid and protein of LDL are 
subjected to oxidative damage through the action of free radicals. There is a debate about 
the exact nature of the chemical alterations to LDL in vivo.  Oxidised LDL is widely belived to 
involved in the pathogenesis of atherosclerosis  (Chisolm and Steinberg, 2000). The classical 
LDL receptor is downregulated by increasing cellular cholesterol levels but scavenger 
receptors  are not down-regulated. Modified LDL therefore converts macrophages to foam 
cells, where cytoplasm  and lysosomes are swollen with lipid droplets. SR-A knock out mice 
show a reduced size of atherosclerotic lesions, suggesting a proatherogenic role for SR-A 
(Babaev et al., 2000). Numerous lines of evidence indicate that lysosomal dysfunction is a 
serious step in foam cell establishment and plaque progression (Emanuel et al., 2014b). 
Ceroid pigments, which are analogous to lipofuscins, are formed under pathological 
circumstances associated with ageing and are known to accumulate in lysosomes producing 
fluorescence between 360 and 430 nm. Oxidized LDL accumulation results in intense 
lysosomal dysfunction in cultured macrophages, resulting in disruptions in lysosomal pH, 
proteolytic ability, membrane integrity, and morphology of their lysosomes (Emanuel et al., 
2014b). Earlier studies have described the variable impact of different sorts of modified LDL 
on build-up of cholesterol, in the cytosol or in lysosomes, with oxidised LDL and aggLDL 
leading  to accumulation of cholesterol in lysosomes, whereas acetylated LDL and LDL 
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modified by enzymes lead mostly to cytosol cholesterol accumulation (Yancey and Jerome, 
2001, Griffin et al., 2005, Orso et al., 2011).  
In our laboratory, mouse macrophages swiftly phagocytosed aggregated LDL into their 
lysosomes and oxidised it with iron (Wen and Leake, 2007). Macrophages endocytose native 
LDL and aggregated LDL by the LDL receptor, and modified lipoproteins through SR such as 
SR-A1 and CD36 (Steinberg et al., 1989, Greaves and Gordon, 2009). Cholesteryl esters 
resulting from the lipoproteins are hydrolysed in late endosomes/lysosomes to release free 
cholesterol, which is then trafficked to the plasma membrane and peripheral organelles. 
Additional free cholesterol is re-esterified then in the macrophages on the endoplasmic 
reticulum via acyl-CoA: cholesterol acyltransferase1 (ACAT1) and stored in cytoplasmic lipid 
droplets (Chang et al., 2006). This lipid-scavenging role of macrophages is originally useful, 
but under specific conditions of unregulated or increased lipid engulfment, it leads to extreme 
accumulation of cholesteryl ester in macrophages that lead to foam cell formation (Accad et 
al., 2000). Macrophages might phagocytose LDL in the atherosclerotic lesion and oxidised it 
with iron in their lysosomes.  Macrophages death (by apoptosis or necrosis) is common in 
atherosclerotic lesions and contributes to the “necrotic” lipid core in atheroma. Other 
macrophages might be expected to endocytose lysosomally oxidised LDL from dead and lysed 
macrophages. The uptake of dead cells or fragments of cells containing oxidised lipids might 
be toxic to macrophages. In this study the aim was to investigate the effect of giving 
antioxidants to macrophages as possible protection against these toxic effects. 
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5.2 Material and Methods 
 
Lipid accumulation and lysosomal LDL oxidation  was induced macrophages using 
sphingomylinase -aggregated LDL as described in chapter 2.  The effect of tempol and 
probucol on lipid accumulation and ceroid formation was measured. The effect of α-
tocopherol, tempol and probucol on reactive oxygen species generation by macrophages as 
a result of oxidised LDL exposure was assessed,  as described in chapter 2. Finally, the effect 
of α-tocopherol treatment of the macrophages on apoptosis due to oxidative stress (H2O2) 
was investigated,  as described in chapter 2. 
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5.3 Results 
 
5.3.1 Measurement of intracellular lipid accumulation in macrophages  
 
A typical feature of initial atherosclerotic lesions in the presence of lipid-laden macrophage 
foam cells (Groh et al., 2018). It has been recognised that both physically altered (vortexed) 
LDL, as well as SMase LDL, is oxidised in the lysosomes of macrophages and eventually 
produces ceroid. Ceroid (lipofuscin) is an ultimate product of lipid oxidation that contains 
insoluble polymerized lipids and is observed within foam cells in atherosclerotic lesions.  
Ceroid accumulation is detected via  its fluorescence and cytochemical staining characteristics 
(Haka et al., 2011). The aim of this  study was to investigate the effect of antioxidants on 
intracellular lipid and ceroid accumulation in macrophages. 
Incubation of THP-1 human macrophages with LDL aggregated by sphingomyelinase 
produced extensive total lipid accumulation, (Figure 5.1) . The enrichment of LDL with α-
tocopherol, followed by its aggregation by sphingomyelinase SMase-α-LDL, did not affect the 
lipid content of macrophages compared to (SMase- LDL). Adding the antioxidant tempol (10 
μM) did not affect lipid accumulation in macrophages. Tempol slightly increased lipid 
accumulation in macrophages incubated with aggregated α-tocopherol-enriched LDL. 
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      Figure 5.1.  Measuring intracellular lipid accumulation in macrophages with or without tempol. 
 
 (A)THP-1 macrophages were grown on coverslips in 6 well sterile tissue culture plates. cells were 
treated with LDL aggregated by sphingomyelinase (Smase-LDL) or α-tocopherol-enriched LDL 
aggregated by sphingomyelinase (200 μg protein/mL) for 24 h and after washing were further 
incubated for 7 days with and without tempol 10 μM in fresh RPMI containing 10% (v/v)lipoprotein – 
deficient serum as a control. After 7 days, cells were washed, fixed and treated with, Oil Red O staining, 
and examined by light microscopy to demonstrate intracellular lipids. ( B) The bar chart shows 
intracellular lipid accumulation in macrophages  as a percentage of that in the cells incubated with 
Smase-LDL. A one-way ANOVA  followed by Tukey's posthoc tests were significant (***P<0.001, n= 4) 
compared to control LDL. 
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5.3.2 Intracellular lipid accumulation in presences of probucol in macrophages 
 
Probucol has been experimentally used as an antiatherogenic drug, not only for of its lipid-
lowering outcome but because of its antioxidative properties  that inhibit oxidative 
modification of LDL shown in vitro (Gotoh et al., 1992) and in vivo models (Carew et al., 
1987). The aim of this study is  to investigate the effects of antioxidants on intracellular lipid 
accumulation caused by aggregated LDL. The probucol (5 μM) was added to the THP-1 
macrophages together with SMase-LDL or SMase-α-tocopherol supplemented LDL. Probucol 
did  not prevent lipid accumulation with SMase-LDL but markedly decreased lipid 
accumulation with SMase-α-tocopherol supplemented LDL (Figure 5.2). The concentration 
of probucol added to the medium was nearly equivalent to the plasma concentration of the 
drug regularly obtained from patients after treatment with probucol. 
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Figure 5.2. Measuring intracellular lipid accumulation in macrophages with or without probucol. 
 
(A)THP-1 macrophages were grown on coverslips in 6 well sterile tissue culture plates. Wells were 
treated with LDL aggregated by sphingomyelinase (SMase-LDL) or α-tocopherol-enriched LDL 
aggregated by sphingomyelinase (200 μg protein/ml) for 24 h and after washing were further 
incubated for 7 days in fresh RPMI containing 10% (v/v) lipoprotein -deficient serum with or without 
probucol. After 7 days, cells were washed, fixed and stained with Oil Red O, and examined by light 
microscopy to demonstrate intracellular lipids.  (B) The bar chart shows the intracellular lipid 
accumulation in macrophages as a percentage of that incubated by SMase-LDL. A one-way ANOVA  
followed by Tukey's posthoc tests were significant (**P< 0.005, ***P<0.001, n= 4) compared to control 
LDL.  
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5.3.3 Measurement of ceroid formation in macrophages  
 
5.3.3.1 Measurement of ceroid formation in macrophages in the presence of 
tempol 
 
Foam cell lysosomes contain the peroxidised lipid-protein complex ceroid (Ball et al., 
1987). Ceroid is predicted to have detergent characteristics that liquefy membranes, triggering 
cell injury and necrosis, and initiating release of the toxic complex into the centre of the plaque. 
In tissues, it is identified histochemically by insolubility in lipid solvents and stainability with 
neutral lipid dyes (Di Guardo, 2015, Lang and Insull, 1970). Ceroid levels were increased in 
macrophages incubated with SMase aggregated-LDL or SMase aggregated α-tocopherol-
supplemented LDL (Figure 5.3).  This is consistent with the finding is not as effective an 
antioxidant for LDL at pH 4.5 as it is at pH 7.4,as shown in chapter 3. There was a significant 
decrease in the formation of ceroid with SMase LDL in the presence of tempol. Tempol 
addition to SMase -α- tocopherol enriched LDL did not protect cells from advanced LDL 
oxidation and therefore  ceroid formation.  
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Figure 5.3 Measuring ceroid formation in macrophages with or without tempol in macrophages 
 
(A) THP-1 macrophages were grown on coverslips in 6 well sterile tissue culture plates. Wells were 
treated with SMase-LDL and α-tocopherol enriched LDL (200 μg protein/mL) for 24 h and after washing 
were further incubated for 7 days in fresh RPMI containing 10% (v/v) lipoprotein-deficient serum, 
either alone or with 10 μM tempol. After 7 days, cells were treated with ethanol and xylene, followed 
by Oil Red O, and examined by light microscopy to demonstrate ceroid. (B) The bar chart shows the 
ceroid levels in macrophages as a percentage of that with SMase-LDL. A one-way ANOVA followed by 
Tukey's posthoc tests were significant (***P<0.001, n= 4) compared to the SMase-α-toc-LDL.  
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  5.3.3.2 Measurement of intracellular ceroid formation in macrophages with 
the presence of probucol 
 
In this study I investigated the effect of probucol on ceroid formation in macrophages (Figure 
5.4). Enriched LDL with α-tocopherol did not inhibit ceroid formationaccumulation. 
Surprisingly probucol alone increased the accumulation of ceroid in cells compared to control 
cells.  There was also more ceroid formation with native α-tocopherol-enriched LDL than 
native control LDL. In contrast, probucol, when it was combined with SMase-α-tocopherol-
enriched-LDL or SMase-LDL, showed inhibition effects. Thus, it appears that probucol can act  
as a pro-oxidant or an antioxidant, depending on the condition. The reasons for these complex 
and suprising effects are unknown. 
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Figure 5.4 Measuring ceroid formation in macrophages with or without probucol.  
 
(A)THP-1 macrophages were grown on coverslips in 6 well sterile tissue culture plates. Wells were 
treated with SMase-LDL and SMase α-tocopherol enriched LDL (200 μg protein/ml) for 24 h and after 
washing were further incubated for 7 days in fresh RPMI containing 10% (v/v) lipoprotein-deficient 
serum, either alone or with 5 μM probucol. After 7 days, cells were treated with ethanol and xylene, 
followed by Oil Red O staining, and examined by light microscopy to demonstrate ceroid. (B) The bar 
chart shows the intracellular ceroid accumulation in macrophages. A one-way ANOVA  followed 
byTukey's posthoc tests were significant (*P< 0.05, ***P<0.001, n= 4) compared to the SMase-α-
tocopherol- enriched LDL.  
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5.3.4 Monitoring of ROS production with the use of DHE 
 
I investigated the production of ROS by macrophages in the presence of oxidised LDL and if 
this would be decreased by antioxidants. 
Dihydroethidium (DHE) can be used to measure superoxide and hydrogen peroxide 
production, in intact macrophages  by  forming a fluorescent product (Zhao et al., 2012). The 
aim of this study  was to investigate antioxidants either individual or combination, to reduce 
ROS production in macrophages induced by oxidised LDL, which was produced by incubation 
with Cu2+ (5 μM).  There was a significant increase in reaction oxygen specious produced by 
the macrophages in the presence of α-tocopherol-enriched native LDL,oxidised LDL or 
oxidised α-tocopherol-enriched LDL, but not native control LDL. This study also evaluated the 
intracellular ROS formation induced by ox-LDL after incubating the cells with tempol (10 μM) 
only and untreated cells as a control and LDL and LDL enriched  with α -tocopherol by Cu 2+  
(5 μM) in the presence or absences of tempol (Figure 5.6 and 5.7). ROS formation increased 
in the cells which were treated with oxidised LDL and oxidised LDL enriched with α-
tocopherol, while in the presence of tempol or probucol there was significantly decreased 
generation of ROS. This suggests tempol and probucol can scavenger free radicals produced 
by the cells from oxidised LDL with or without additional α-tocopherol.  
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Figure 5.5  ROS formation in macrophages.  
 
(A) Control LDL and  LDL enriched with α-tocopherol LDL was oxidised by Cu2+(5 μM)  at  pH 4.5 for 24 
h.THP-1 macrophages were grown on coverslips in 6 well sterile tissue culture plates. Wells were 
treated with oxidised LDL or oxidised α-tocopherol enriched LDL (50 μg protein/ml) for 24 h. Untreated 
cells were taken as control and after washing, cells were further incubated for 15 minutes with 10μM 
DHE in fresh PBS in a non-CO2 incubator. Cells were washed with PBS, followed by staining the 
coverslips with DAPI, and examined by fluorescence microscopy to demonstrate DHE fluorescence.( 
B) The bar chart shows the fluorescence intensity of the  macrophages. A one-way ANOVA followed 
by  Tukey's posthoc tests were significant (***P<0.001, n= 3) compared to the control.  
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Figure 5.6   Detection  of ROS formation in macrophages with or without tempol 
 
(A) Control LDL and  α- tocopherol enriched LDL was oxidised by Cu2+(5 μM) at pH 4.5 for 24 h. THP-1 
macrophages were grown on coverslips in 6 well sterile tissue culture plates. Wells were treated with 
oxidised LDL or oxidised α-tocopherol enriched LDL (50 μg protein/mL) for 24 h either alone or with 
10 μM tempol. Untreated cells were taken as control and after washing, cells were further incubated 
for 15 minutes with 10μM DHE in fresh PBS in a non-CO2 incubator. Cells were then washed with PBS, 
followed by staining the coverslips with DAPI and examined by fluorescence microscopy to 
demonstrate DHE fluorescence. (B) The bar chart shows the fluorescence intensity of the 
macrophages. A one-way ANOVA followed by  Tukey's posthoc tests were significant (*P< 0.05, 
***P<0.001, n= 4) compared to the control.  
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Figure 5.7 Detection of  ROS formation in macrophages with or without probucol 
 
 
(A) Control LDL and α -tocopherol-enriched LDL was oxidised by Cu2+(5 μM) at pH 4.5 for 24 h. THP-1 
macrophages were grown on coverslips in 6 well sterile tissue culture plates. Wells were treated with 
oxidised LDL or oxidised α-tocopherol- enriched LDL (50 μg protein/mL) for 24 h either alone or with 
5 μM probucol. Untreated cells were taken as control and after washing, cells were further incubated 
for 15 minutes with 10μM DHE in fresh PBS in a non-CO2 incubator. Cells were washed with PBS, 
followed by staining the coverslips with DAPI and examined by fluorescence microscopy to 
demonstrate DHE fluorescence. (B) The bar chart shows fluorescence intensity of the macrophages. A 
one-way ANOVA  followed by Tukey's posthoc tests were significant (***P<0.001, n= 4) compared to 
the control.  
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5.3.5 Effect of α-tocopherol  and tempol on apoptosis of macrophages  
 
Macrophages are an important cell type in atherosclerotic lesions, and some of these cells 
become apoptotic, mainly in advanced lesions. Although they persist for a comparatively 
long time in a physiological situation, their death produced by such stimuli as cytokines, 
microbial invasion, or endoplasmic reticulum or ROS stress is frequently detected in 
pathological situations (DeVries-Seimon et al., 2005, Pan et al., 2010). Consequently, there 
is substantial clinical significance in reviewing macrophage cell death caused by ROS. Cell 
death is classically described either as apoptosis or necrosis. Since the consequences of 
apoptosis and necrosis are quite different for an entire organism, the investigation of the 
cell death mode has considerable clinical significance. Apoptosis followed by the 
phagocytosis of the apoptotic cells or cell fragments does not normally lead to 
inflammation, whereas necrosis causes inflammation (Lin et al., 2010). The objective of this 
study was to demonstrate  if α-tocopherol and tempol protect cells from apoptosis and 
necrosis induced by   oxidative stress (100 μM H2O2) by using the Annexin V and FITC .  
In this study, 100 μM H2O2 was used to induce apoptosis and we examined the antioxidant 
effect of α-tocopherol alone or in combination with tempol (10 μM) on THP-1 macrophages 
apoptosis. The α-tocopherol levels in the cells were increased by incubation with FCS enriched 
in α -tocopherol. We measured cell death by flow cytometry using annexin V binding, which 
measures the externalisation of phosphatidylserine and thus apoptosis, and propidium iodide 
binding to DNA, which measures membrane permeabilisation . An increase of both annexin V 
binding and propidium iodide binding measure secondary necrosis, i.e. membrane 
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permeabilisation following apoptosis. A plots were employed for gating cells and to recognise 
each change in the scattering features of the cells. Annexin V FITC-A vs Propidium Iodide-A 
plots from the gated cells show the populations conforming to viable (annexin V--PI--, lower 
left), apoptotic (annexin V+ PI--, lower right), dead (annexin V+ PI+, upper right) and necrotic 
(annexin V--PI+, upper left).  
There was a significant increase in apoptosis and secondary necrosis during treatment of 
normal cells with H2O2 (100 µM) ( Figure 5.8). Suprisingly, there was an increase in apoptosis 
and secondary necrosis when the cells were treated with α-tocopherol (Figure 5.8). 
Treatment with α-tocopherol and H2O2 increased apoptosis,but decreased secondary 
necrosis compared to cells incubated with α-tocopherol alone . There was no significant 
difference between control cells and cells treated with tempol, in terms of live, apoptotic and 
secondary necrotic cells except that there was a small increase in necrotic death percentage 
(Figure 5.9). Tempol had the ability to protect cells,with or without α-tocopherol treatment, 
almost totally from the toxic effect produced by hydrogen peroxide (Figure 5.8), α-tocopherol 
treatment increased the percentage of primary necrotic cells  in the presence of tempol. 
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Figure 5.8. Apoptosis detection in THP-1 cells by flow cytometry. 
 THP-1 cells were enriched with α-tocopherol for 24 h and then were treated with H2O2 (100 μM) 
and tempol (10 μM). The quadrants were set based on the population of healthy, unstained cells in 
untreated samples (control) compared to treated cells.  (A)  Representative figures showing 
population of unstained live (annexin V--PI--, lower left), apoptotic (annexin V+ PI--, lower right), 
dead (secondary necrosis) (annexin V+ PI+, upper right) and necrotic (annexin V--PI+, upper left) 
cells.( B) Bar chart represents the quantification of the all death cells induced upon treatment with 
H2O2 or without α-tocopherol and tempol. (C)  Repersentitve figure showing live ,apoptotic,dead and 
necrotic cells with tempol.(D) Bar chart showing quantative results of cell death in the presence of 
tempol.Data are expressed as mean± standard error of the mean (SEM), n = three. Statistical 
significance was estimated with respect to the control (untreated sample) by two-way ANOVA, 
followed by Tukey’s post hoc test (n = three,*, p < 0.05, **, p < 0.01, ***, p < 0.001). 
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5.4 Discussion 
Ceroid, a final product of LDL oxidation comprising of a compound of insoluble oxidised 
lipids and proteins, is found both intracellularly and extracellularly within atherosclerotic 
lesions (Mitchinson et al., 1985). Our laboratory has previously recognised that 
intralysosomal ceroid is formed in human macrophages when they are incubated with 
aggregated LDL (Wen and Leake, 2007) and it also observed lysosomal ceroid accumulation 
when  THP-1 macrophages were incubated with SMase-LDL. The aim of this part of the 
study was to investigate the effects of aggregated LDL oxidised under lysosomal conditions 
(which might released from macrophages) on macrophage characteristics and if 
antioxidants ceroid formation, ROS production and apoptosis. 
In the first part from this study, when control LDL  and LDL enriched with α -tocopherol and 
aggregated with sphingomyelinase was incubated with THP-1, the accumulation of  
intracellular lipid and ceroid formation, detected by oil red O,  were significantly increased 
compared to native LDL as expected. 
In the current study, tempol significantly decreased ceroid formation with SMase-LDL (but 
surprisingly not α-tocopherol-enriched LDL aggregated by secretory sphingomyelinase). 
Nitroxides are stable organic free radicals, and tempol has the greatest power of the 
nitroxides in protecting cells and tissues from the damaging effects of ROS (Czepas et al., 
2008, Tikhonov et al., 2015). Numerous mechanisms may explain the antioxidant activity of 
tempol, including the oxidation of reduced transition metals (Hyodo et al., 2006, Mitchell et 
al., 1990a). The inhibition of lipid peroxidation by nitroxides is believed to depend on their 
lipophilicity and chemical structure. This might possibly help to explain why tempol inhibited 
atherosclerosis in apo E knock-out mice (Cannizzo et al., 2014).  
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Probucol decreased lipid accumulation (detected by Oil Red O) with α-tocopherol-enriched 
LDL aggregated by sphingomyelinase (Figure 5.2). Yamamota et al. (Yamamoto et al., 1986) 
observed that probucol decreased lipid accumulation in U-937 macrophage-like cells 
incubated with acetylated LDL. The mechanism for the decrease remains unknown. 
Oxidative stress is the result of increased reactive oxygen species (ROS) or diminished 
antioxidant ability. ROS are chemically reactive materials that can react with cell constituents, 
causing cell injury (McMurray et al., 2016). The dihydroethidium (DHE) method is based on 
fact that dihydroethidium in the cytoplasm is colourless, but is converted to ethidium by O2•-
, which is trapped intracellularly  (Saenz-de-Viteri et al., 2014). LDL oxidised under lysosomal 
conditions (Cu2+ at pH 4.5) caused oxidation stress in macrophages (Figure 5.5). Surprisingly, 
oxidised α-tocopherol–enriched LDL caused more oxidative stress than oxidised LDL (Figure 
5.5). This, might be related to the creation of unstable α-tocopheroxyl radicals. 
Probucol decreased ROS in response to oxidised LDL (Figure 5.7), which might help to explain 
the anti-atherosclerotic effect of probucol in some but not all animal models (Xiao et al., 
2017).  
In this study, hydrogen peroxide (H2O2) was used to induce apoptotic cell death. It has been 
documented that exposure of specific cell types to low concentration of H2O2 can cause 
morphological alterations associated with apoptosis, while higher doses of H2O2 causes 
necrosis (Hampton and Orrenius, 1997, Krifka et al., 2012). α-Tocopherol enrichment of 
macrophages increased apoptosis, necrosis and secondary necrosis itself (Figure5.8). In the 
presence of H2O2, α-tocopherol had no effect on apoptosis but decreased secondary necrosis 
substantially. The mechanism by which α-tocopherol itself induces apoptosis is uncertain One 
of the possible explanations was that α-tocopherol adversely affected membrane structure 
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and function in the cells.  More research would be needed to identify the mechanisms 
involved.  
 Cells undergoing apoptosis from exposure to H2O2 showed a significant decrease in apoptosis 
when treated pre-incubated with tempol alone whereas there was an increase in apoptotic 
cells enriched with α- tocopherol treated with H2O2 plus tempol compared to cells that had 
not been enriched with α-tocopherol. The reasons for the apparently toxic effects of α- 
tocopherol are unknown.  Furthermore, several inhibitors of apoptosis have antioxidant 
properties or increase cellular antioxidant defence mechanisms. We used the nitroxide 
tempol as a radical scavenger for trapping superoxide anions (Monti et al., 2001). Tempol 
greatly increased cell viability in the presence of H2O2, decreasing both apoptosis and 
secondary necrosis (Figure 5.8).  This might help to explain why it has anti-atherogenic 
activity.Once it is delivered to the cells, α-tocopherol serves as an antioxidant, preventing free 
radical peroxidation and injury to cell membranes. However, α-tocopheroxyl radical (α-TO•), 
which might be generated during the apoptosis process, can act as a chain transfer agent of 
lipid peroxidation (Witting et al., 1997). Tempol might prevent the toxicity of the α-tocopherol 
radicals by acting as a co-antioxidant (Thomas et al., 1995). 
α-toc O•   +  tempol O•                       non-radical product 
The reason for the increase in primary necrosis by tempol in cells enriched in α-tocopherol is 
unknown (Figure 5.8). I expected to see the protective effects of α-tocopherol in the 
macrophages, but some toxic effects were seen. This might help to explain why the protective 
effects of α-tocopherol against the cardiovascular disease were not observed in the large 
clinical trials (Collins et al ., 2000). α-Tocopherol can sometimes inhibit the oxidation of LDL, 
but it has less antioxidant effect on LDL at lysosomal pH, as shown in chapter 3, and if it 
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increase cell death in macrophages (as shown in this chapter) this might outweigh its potential 
benficial effects. 
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Chapter 6 
 
 
Effect of LDL oxidised under lysosomal conditions on nitric 
oxide synthesis by endothelial cells 
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6.1 Introduction 
 
Nitric oxide is the supreme vasodilating molecule continuously produced by the endothelial 
constitutive isoform of nitric oxide synthase (eNOS or NOS III) under the stimulus of several 
neuro-humoral mediators, such as acetylcholine and circulating hormones, plasma 
constituents, platelet products and autacoids (Michel and Vanhoutte, 2010). In addition to 
vasodilatation, endothelium-derived NO has many pleiotropic vaso-protective, 
cardioprotective and anti-atherogenic properties, described in numerous review articles 
(Ungvari et al., 2010, Jin and Loscalzo, 2010, Bermudez et al., 2008).  
Endothelial nitric oxide synthase (eNOS) is a one of a group, which contain three mammalian 
nitric oxide synthase (“NOS”) isoforms that catalyse the oxidation of the terminal guanidino 
group of L-arginine to make NO and L-citrulline (Dudzinski et al., 2006, Forstermann et al., 
1998, Shaul, 2002). The N-terminus of eNOS shows homology mainly to the other NOS 
members, while the C-terminal has important sequence homology to cytochrome P450 
reductases. The NOS N-terminus binds with tetrahydrobiopterin (BH4) and heme. L-arginine 
binds with the enzyme in the active site near heme, while an oxygen molecule is bound to the 
ferrous heme iron. The binding sites for tetrahydrobiopterin and heme are restricted along 
the border of the monooxygenase domains of the dimeric, active form of NOS. Binding of 
heme and tetrahydrobiopterin, may be dynamic in inducing dimerization and NOS catalytic 
action. The C-terminal domain connects with NADPH, flavin adenine dinucleotide (FAD), and 
flavin mononucleotide (FMN) cofactors (Stuehr, 1997). Both N- and C-terminal domains are 
connected by a small sequence that binds calmodulin, an allosteric effector that is essential 
for full NOS activity. The complete NOS functions as a monooxygenase/ reductase enzyme 
and has the ability to produce a number of molecules besides NO, most remarkably 
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superoxide anions. In all NOS catalysis reactions, electrons inside the reductase domain flow 
from NADPH to FAD and finally to FMN. Calmodulin is thought to enable the movement of 
electrons from both the reductase zone to the monooxygenase area as well as from FAD to 
FMN. Because electrons seem to move from the reductase field of one NOS monomer to the 
oxygenase area of other NOS monomer, enzyme dimerization is essential for complete 
enzymatic activity (Balligand et al., 2009, Forstermann et al., 1998).  
Endothelial eNOS goes through a complex form of posttranslational regulatory alterations. 
These modifications trigger the active regulation of enzymatic activity in reaction to 
physiological alterations and pathophysiological environments (Dudzinski et al., 2006, 
Jagnandan et al., 2005, Sessa, 2004). The production of NO can be initiated or enhanced by 
several stimuli including shear stress (Kolluru et al., 2010b)  and acetylcholine, which acts on 
particular receptors on the endothelial cell membrane to increase the intracellular 
concentration of calcium, which binds to calmodulin and causes the activation of calmodulin-
binding domain of eNOS (Walch et al., 2001). This enables electron flux from the reductase to 
the oxygenase domains of the enzyme for NO production. On the other hand, 
phosphorylation of eNOS is also important for the activation of the enzyme because it 
facilitates the active flux of electrons from the reductase to the oxygenase domains (Sessa, 
2004) Phosphorylation is a post-translational alteration, which adds a phosphate group to 
eNOS by the kinases, the phosphate, in turn, is removed by phosphatases (Butt et al., 2000, 
Fleming et al., 2001). This modification alters the activity of eNOS and different sites of 
phosphorylation can have opposing effects (Kolluru et al., 2010a). Thus, for eNOS, Ser1177 
(or Ser1179 depending on the species) is an activation site and Thr495 is an inhibitory site. 
Protein kinase B activates eNOS by phosphorylating Ser1177 in response to various stimuli 
(Dimmeler et al., 1999). Increases in NO release induced by increases in haemodynamic shear 
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stress are mediated mainly through this calcium-independent pathway (Kuchan and Frangos, 
1994). Shear stress is accompanied by the elevation of intracellular calcium and the 
subsequent liberation of NO (Muller et al., 1999). The aims and objective of this study are to 
investigate if LDL oxidised by iron at lysosomal pH would decrease the generation of nitric 
oxide by endothelial cells and decrease vasodilatation. This is based on the hypothesis that 
LDL oxidised in the lysosomes of macrophages might become extracellular when the 
macrophages die by apoptosis or necrosis and the plasma membrane and lysosomal 
membranes lyse. Endothelial cells might be exposed to this oxidised LDL at their 
subendothelial surfaces. In order to achieved endothelial cells to LDL oxidised under 
lysosomal conditions and measure endothelial-depedent or endothelial-independent 
vasodilatation by a myography instrument, as well as to examine whether the type of 
endothelial cell affects the response to oxidised LDL. 
Objectives   
1. To see if incubating rat aortic rings in a myograph with LDL oxidised by iron at lysosomal pH 
would inhibit vasodilatation. 
2. To see if oxidised LDL caused gross changes to the aorta by histology and 
immunohistochemistry. 
3. To see if oxidised LDL increased ROS production from the aortic rings or cultured endothelial 
cells,  using DHE staining. 
4. To see if oxidised LDL increased the phosphorylaytion of eNOS by western blotting and 
immunocytochemistry. 
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6.2 Methods 
To test the effects of LDL oxidised under lysosomal conditions,  the following techniques were 
used. 
Exp.6.3.1: Rat aortic rings were incubated in a myograph with oxidised LDL, as described in 
chapter 2. 
 Exp.6.3.2 and 6.3.3: I then investigated the integrity of the aortic rings using histology and 
immunohistochemistry,as described in chapter 2. 
Exp.6.3.4 and 6.3.5: To try to explain the findings from experiment 6.3.1,  the effect of oxidised 
LDL, on reactive oxygen species generation by the aortic and cultured endothelial cells were 
investigated using dihydroethidium. 
Exp.6.3.6 and 6.3.7: To try to explain the effect of oxidised LDL on nitric oxide activity, the 
effects of oxidised LDL on eNOS phosphorylation were investigated in aortic rings and 
cultured endothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
 
   205 
 
 
 
6.3 Results 
6.3.1 Effect of oxidised LDL on the relaxation of aortic rings 
 
Atherosclerosis involves endothelial dysfunction and modifications in vascular reactivity, 
which can be studied by wire myography. The process allows vitro recording of the 
transverse isometric pressure developed by a vessel segment in response to various 
pathophysiological factors. I investigated the effect of LDL oxidised under lysosomal 
conditions (which might be released from lysed macrophages in atherosclerotic lessions) on 
the vasodilatation of rat aortic rings in a myograph. 
LDL was oxidised by FeSO4 (5 μM) for 24 h at pH 4.5 in sodium acetate buffer. Rat aortic rings  
with intact endothelial cells were contracted with phenylephrine (100nM) and increasing 
concentrations of acetylcholine and then they were washed several times by Krebs solution 
and incubated with oxidised LDL (50 μg protein/ml) for 60 min and then contracted with 
phenylephrine (100nM) and increasing concentrations of acetylcholine (10-9 to 3x10 -6 M) 
were added and the relaxations measured before and after incubation with oxidised LDL 
(Figure 6.1). The results indicated that aortic ring subjected to incubation with oxidised LDL 
showed significantly less relaxation to acetylcholine. It was reduced to 34%, while the control 
had a normal relaxation of 95%. Relaxation to sodium nitroprusside (SNP), which is converted 
directly to nitric oxide,was not significantly affected, showing that the smooth muscle cells 
were not damaged by the oxidised LDL. In conclusion, LDL oxidised at lysosomal pH inhibited 
endothelial-dependent-relaxation but not endothelial-independent relaxation.  
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Figure 6.1. Effect of LDL oxidised under lysosomal conditions on vasodilatation.  
LDL was oxidised by ferrous sulphate (5µM) for 24 hr at pH 4.5 at 37 
o
C.  Aortae were cut into rings 
(2mm width) and mounted on a wire myography setup for isometric tension recording. (A) Aortic rings 
were incubated for 1 h with or without oxidised LDL (50 µg protein/mL) and then pre-constricted with 
100nM phenylephrine and concentration-response curves to acetylcholine (1nM-3µM) were 
performed. Values are expressed as means ± SD (n = 5 independent experiments). Two way ANOVA, 
followed by Bonferroni post hoc test   ***P<0.001 compared to control. (B) Rings were also relaxed 
directly using SNP. 
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6.3.2 Evaluation of aortic wall structure 
 
H&E stain was used to evaluate the gross structure of the aorta after exposure to oxidised LDL 
in the myograph. There was no significant difference in wall thickness and lumen/outer 
diameter ratio of aortas incubated with or without oxidised LDL (Figure 6.2). The myography, 
which applied stretch forces, with or without the oxidised LDL, did not make any changes 
leading to gross damage in the tissue structure of the aorta. 
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Figure 6.2. Effect of LDL oxidised under lysosomal conditions on aortic structure. (A) Aortic rings, 
which were mounted in the myography for 1 h with or without oxidised LDL, were fixed with 4% 
paraformaldehyde for 24 h, dehydrated and embedded in OTC. Histological analysis was performed 
on serial cross-sections (10 μm) after staining with H&E to visualize whole aorta structure. (B) The bar 
chart shows no significant difference in aortic wall thickness between control and  aortic rings 
incubated with oxidised LDL, (t-test, n=5 independent experiments). (C) The bar chart shows no 
significant difference in the ratio of lumen/outer diameter between control and aortic rings incubated 
with oxidised LDL, (t-test, n=5 independents experiments). 
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6.3.3 Measurement  of endothelial integrity of aortic rings exposed to with 
oxidised LDL 
 
CD31 ( also known as PECAM-1) is an  endothelial marker. I  investigated the prescence of this 
marker on aortic rings incubated with oxidised LDL using immunohistochemistry. CD31-
positive cells were present in control aortic rings after being incubated in the myograph for 1 
h, but when they were incubated with oxidised LDL in the myography for 1 h CD31 staining 
was not observed (Figure 6.3). This suggests that the oxidised LDL caused the endothelial cells 
to detach from the aortic rings, but this finding needs to be confirmed by using another 
markers of endothelial cells or by electron microscopy. 
 
 
 
 
 
 
Figure 6.3.  Immunohistochemical staining for CD31 in rat aortic segments. 
Aortic sections were frozen in OCT embedding medium. The analysis was performed on serial 
cross-sections (10 μm) after staining with CD-31 primary antibody. Brightfield images were 
captured from immunostains of the aortic rings. CD31 staining is observed in the control 
section, whereas there is no staining in the aortic ring exposed to oxidised LDL (50 µg 
protein/ml) for 1h 
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6.3.4 Effect of oxidised LDL on reactive oxygen species in aortic ring 
 
Under physiological environments, ROS concentrations control important cellular roles and 
signalling stimulating pathways to support vascular homeostasis. Nevertheless, when 
endothelial cells are challenged to certein stimuli, such as hyperlipidaemia, extreme ROS 
level are produced and can cause oxidative modification on proteins and nucleic acids 
(Wang and Zou, 2018). The aim of this study was, to detect ROS formation in aortic rings 
after incubation with oxidised LDL. Throughout the past decade, numerous fluorescent dyes 
have been commonly employed to measure cellular O2•− and H2O2, for example by 
dihydroethidium (DHE) (Dikalov et al., 2007, Panth et al., 2016).  DHE can spontaneously 
permeate cell membranes and be oxidized by cellular O2•− to generate two red fluorescent 
substances, specifically ethidium (E+), which is classically produced by a general redox 
reaction, and 2-hydroxyethidium (2-OH-E+), a specific product of cellular O2•−. The 
fluorescent spectra of 2-OH-E+ (Ex 500–530 nm/Em 590–620 nm) and E+ (Ex 520 nm/Em 610 
nm) are quite similar. Therefore, exact detection of 2-OH-E+ is a challenge (Dikalov et al., 
2007, Munzel et al., 2002). In brief, tissue was incubated with DHE (10 μM) for 30 min. 
Fluorescence was measured with a fluorescence microscope and quantified using Image-J 
analysis software. The result showed oxidised LDL increased the intensity of DHE stain in the 
entire aorta wall compared to the control (Figure 6.4).  
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Figure 6.4 Effects of oxidised LDL on ROS formation from rat aorta. 
 (A) Rat aortic segments were frozen in OCT embedding medium. The analysis was performed on serial 
cross-sections (10 μm) after staining with DHE  and taking fluorescence images of the aortic tissue. 
Scale bars, 100 μm. (B) Quantification of DHE fluorescence image.  The bar chart show mean ± SEM of  
five independent experiments. Paired t-test. ***P < 0.001, n=5). 
A 
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6.3.5 Effect of oxidised LDL on reactive oxygen species formation by cultured 
endothelial cells  
 
I next investigated the effect of LDL oxidised under lysosmal conditions on cultured 
endothelial cells. Advanced atherosclerostic lesions have both large artery endothelial cells 
lining the lumen and microvascular endothelial cells in the neovessels at the base of the 
lesions. Human microvascular endothelial cells (HMEC) and Human aortic endothelial cells 
(HAEC) were incubated with LDL oxidised by iron at lysosomal pH for 24 and then washed by 
PBS. They were Incubated with DHE (10 μM) in PBS for 30 min and fluorescence was measured 
with a fluorescence microscope with wavelength 488nm and quantified using Image-J analysis 
software. LDL oxidised under lysosomal conditions increased reactive oxygen species 
generation in HMEC (Figure 6.5) and HAEC (Figure 6.6)  compared to the control LDL.  These 
results suggest that if LDL oxidised in the lysosomes of macrophages leaks out of damaged 
macrophages it might increase ROS generation by endothelial cells lining the lumen of the 
atherosclerotic lesion or in the neovessels in the base of the lesions. 
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Figure 6.5. ROS detection in HMEC. 
(A) Human microvascular endothelial cells were treated for 1 h with control LDL or LDL (50µg 
protein/ml) which had previously been oxidised with 5µM FeSO4
  
 for 24 h at pH4.5. Reactive oxygen 
species were measured using DHE. DAPI was used to stain the nuclei. (B) The bar chart shows the 
(mean ± SEM of 5 independent experiments. Two-way ANOVA, followed by Tukey’s post hoc test 
***P<0.001, n=5 
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Figure 6.6 ROS detection in HAEC. 
 (A) HAEC were treated for 1 h with control LDL or LDL (50µg protein/ml) which had previously been 
oxidised with 5µM FeSO4
  
 for 24 h at pH. 4.5. Reactive oxygen species were measured using DHE. 
DAPI was used to stain the nuclei. (B) The bar chart shows the mean ± SEM of  5 independent 
experiments. Two-way ANOVA, followed by Tukey’s post hoc test ***P<0.001, n=5). 
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6.3.6 Effect of oxidised LDL on eNOS phosphorylation in cultured endothelial 
cells measured by western blotting 
 
Phosphorylation eNOS serine 1179 (S1179) enhances eNOS enzymatic reactivity and NO 
release (Atochin et al., 2007). The vasorelaxation activity of acetylcholine (ACh) is mediated 
via muscarinic receptors that causes the liberation of calcium from intracellular stores. This 
permits calcium-calmodulin to bind to eNOS, relocating caveolin-1 and stimulating eNOS 
(Gratton et al., 2000).  The aim of this study was to detect whether LDL oxidised by iron at 
lysosomal pH leads to impaired endothelial nitric oxide synthase (eNOS)  activation by 
acetylcholine in different types of endothelial cells. Western blotting was performed 
according to standard methods using antibodies specific for total-eNOS, phosphorylated-
eNOS ( serine 1179) and β-actin and an HRP-conjugated secondary antibody. Quantitative 
analysis was performed using Image J. Western blot revealed clear 145 kDa bands in both 
HMEC and HAEC (Figure 6.7). Acetylcholine increased phosphorylated-eNOS, especially in 
HAEC. Phosphorylation of eNOS was decreased considerably by oxidised LDL alone in HMEC, 
but not in HAEC 
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Figure 6.7 Representative western blot analysis showing effect of LDL oxidised by iron at lysosomal 
pH on different type of endothelial cells   
 Bar charts displaying protein quantification of endothelial nitric oxide synthase (eNOS) and 
phosphorylated-eNOS(S1179). Endothelial cells were incubated for 24h with control LDL or LDL (50µg 
protein/ml) that had been oxidised by 5µM FeSO4
  
 for 24 h at pH. 4.5. Acetylcholine was added (3µM) 
for 8 min and the cells were then lysed and total and phosphorylated eNOS separated by SDS-PAGE 
followed by a polyvinylidene difluoride membrane before being probed for antibodies (western 
blotting). Protein levels are shown as mean ± SEM were and normalised to β-actin. The level of 
phosphorylated eNOS was expressed relative to the level of total eNOS. Illustrative western blots are 
shown. β-Actin was used as a loading control. The mean ± SEM 3 in depending experiments is shown. 
(One-way ANOVA, Tukey’s test (A) HMEC (B) HAEC *p ≤ 0.05 ***P<0.001). 
B (HAEC) 
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6.3.7 Effect of oxidised LDL on eNOS phosphorylation in cultured endothelial 
cells  measured by immunocytochemistry 
 
eNOS phosphorylation was also assessed by immunocytochemistry as well as western blotting. 
 Endothelial cells grown on glass coverslips were washed once with PBS and then incubated 
at 37 °C with oxidised LDL (50 μg protein/ml) for 60 min. Control and oxidised LDL treated 
cells in the presence or absence of  acetylcholine, permeabilised then incubated a primary 
antibody monoclonal antibody to phosphorylated eNOS (S1179) and then a secondary antibody  
and examined with  an epifluorescence microscope. Figure 6.8 shows the HMEC and HAEC 
had phosphorylated -eNOS expression in control cells and cells treated with control LDL while 
the cells treated with oxidised LDL had a somewhat decreased level of phosphorylated eNOS. 
Figure 6.8B shows HAEC with or without LDL or oxidised LDL (50 μg protein/ml) had 
increased phosphorylated eNOS after incubation with acetylcholine (3 μM) for 8 min.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   219 
 
 
 
 
 
 
 
 
 
A 
(HMEC) 
 220 
 
 
 
 
 
 
Figure 6.8 Representative eNOS immunofluorescences staining of HMEC and HAEC 
 
(A) HMEC were treated for 1 h with  control LDL (50µg protein/ml) or LDL which had previously been 
oxidised with 5µM Fe
2+  
 for 24 h at pH. 4.5. (B) HAEC cells were treated the same as in (A) but with or 
without acetylcholine (3µM) for 8 min. They were immunocytochemistry stained for phosphorylated 
eNOS and the nucleus stained for DAPI. The mean ± SEM three independent experiments are shown. 
Two-way ANOVA, followed by Tukey’s post hoc test ***P<0.001 test compared to the control.  
 
B 
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6.4 Discussion 
 I postulated that LDL oxidised in lysosomes of macrophages would be exposed to 
subendothelial surfaces of endothelial cells in atherosclerotic lesions when the macrophages 
die and lyse. Vasodilatation is normally measured by relaxation response curves to the 
vasodilator acetylcholine in vessel rings, pre-contracted with a vasoconstrictor 
(phenylephrine). In control aortic rings acetylcholine stimulates the release of nitric oxide 
(NO) from the endothelial cells, which spreads within the vessel wall and leads to 
vasodilatation by inducing the relaxation of smooth muscle cells, while in the presence of LDL 
oxidised by iron there is a reduction in relaxation compared with the control (Figure 6.1A). In 
contrast, the endothelium-independent vasorelaxation was measured by addition of sodium 
nitroprusside (SNP) to pre-contracted aortic rings (Figure 6.1B) and was not significantly 
different between the control and oxidised LDL (control: 99.4%, oxidised LDL: 93.5% for 
maximum relaxation). This suggests that the effect of oxidised LDL on the aortic ring 
relaxation is due to its effects on the endothelium and agree with many studies, which 
suggested that oxidised LDL can impair endothelium relaxation (Hein et al., 2000, Kugiyama 
et al., 1990). 
There were no significant differences in wall thickness or lumen diameter in histological 
sections of the aortic rings (Figure 6.2). I examined the presence of endothelium after 
incubation for 1hr with LDL that had previously been  oxidised by iron (5 μM) for 24 hr at 
lysosomal pH by using CD31 as a marker for endothelial cells. Endothelial cell damage shows 
a key role in the pathogenesis of atherosclerosis, in which the endothelial cells are unable to 
regulate appropriate lipid homeostasis, resistance and inflammation (Peng et al., 2014, Sun 
et al., 2011, Leppanen et al., 2005, Foteinos et al., 2005, Barton et al., 1998, Szmitko et al., 
2003, Hedner et al., 2000). Indicators of endothelial cells are employed by clinical 
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histopathologists to recognise these cells in tissue sections, the best commonly utilized 
marker is CD31 (Szekanecz et al., 1995). The proportion of luminal surface of aortic rings 
containing endothelium was inspected and suggest that the low CD31 detection results from 
a decreased endothelial cell number in aortic rings that had been incubated with oxidised LDL 
for 1hr compared to the control, but this needs to be confirmed and quantified. This agreed 
with several studies (Liu and Shi, 2012, Fornasa et al., 2010, Pusztaszeri et al., 2006). 
While oxidised LDL is a product of oxidative stress, it can also exert pro-oxidant effects by 
inducing ROS generation (Heinloth et al., 2000). It is commonly found that oxidation of LDL 
increases its ability to increase O2.− formation; native lipoproteins produce no or merely weak 
effects on ROS production. Freshly prepared dihydroethidium (DHE, 10 μM) was added to the 
aortic rings sections for 30 min at 37 °C (Figure 6.4). There was a significant increase between 
aortas incubated with oxidised LDL compared to the control. In the control rings, most  of the 
fluorescence was due to the endothelial cells, but in the rings exposed to oxidised LDL, it was 
mainly produced by the smooth muscles cells in the whole aorta, in agreement with other 
studies (Kugiyama et al., 1999, Ohara et al., 1994).  The questions arise here of which 
components of the oxidised LDL increased ROS. It might have been lysophosphatidylcholine 
(LPC), aldehydic lipid peroxidation products, oxidised fatty acids produced by phospholipase 
A- like activity or oxysterol (Parthasarathy et al., 1985, Yokoyama et al., 1990, Esterbauer et 
al., 1987).  
In addition to the whole aorta, two types of endothelial cells were used to detect ROS after 
incubation with oxidised LDL by iron for 24 hr (Figure 6.5 &6.6). The result show there was no 
significant difference between the controls and the cells treated with native LDL, but an 
increase with cells treated with oxidised LDL. Increased ROS might help to explain the reduced 
vasodilatation as ROS might inactivate NO•  
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O2•−      + NO•                                 ONOO-       
 High level of ROS not merely modify signal transduction mechanisms but also disturb cellular 
processes, such as ubiquitination necessary for cyclin functions, and both protein and lipid 
oxidation. In these conditions, cells can be detained in all stages of the cell cycle, and then 
lead to apoptosis, or, in extreme cases, may lead to necrotic cell death (Boonstra and Post, 
2004, Aronis et al., 2005).  
To examine the endothelial dysfunction caused by oxidised LDL, we measured the 
phosphorylation of eNOS. Treatment of HMEC with oxidised LDL resulted in a significant 
decrease in the phosphorylation of eNOS in the absence of acetylcholine compared to the 
control cells or cells incubated to the control LDL (Figure 6.7).  Oxidised LDL did inhibit the 
phosphorylation of eNOS in HMEC, but not HAEC, in the presence of acetylcholine as shown 
by western blots  ( Figure 6.7). Immunocytochemistry showed that oxidised LDL decreased 
phosphorylated eNOS in HMEC (Figure 6.8A), in agreement with the western blots.  
Early atherogenesis is accompanied by weakened endothelial NO production in reaction to 
extracellular inducements, even though the ability for maximal NOS enzyme activation and 
the breakdown of NO are not affected (Katusic and Austin, 2014). As the disease develops 
inhibition of NO bioavailability happens, which is at least partially due to the higher block of 
NO by superoxide anions (Flavahan, 1992). Oxidised LDL  has been reported to reduces 
cholesterol in the plasma membrane, changing the location of eNOS from caveolae to an 
intracellular membrane and  to block acetylcholine-induced eNOS activation (Uittenbogaard 
et al., 2000, Cominacini et al., 2001).  In conclusion, these results  show that LDL oxidised 
under lysosomal conditions decreases vasodilatation in our experiments. The fundamental 
molecular mechanisms have not been totally clarified, but might involve  a decrease in eNOS 
phosphorylation. 
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7.0 General discussion  
 
This thesis covers a number of related possible roles of lysosomally–oxidised LDL in the field 
of atherosclerosis.  
 
The main findings of the research presented in this thesis can be basically summarized as 
follows.  
 
• α-Tocopherol is less antioxidant at pH 4.5 than 7.4 and can even be prooxidant with 
Fe3+ (2, 5 or 20 µM) and 2 µM Fe 
2+
.  
• α-Tocopherol enrichment of LDL increased the rate of conversion of Fe
3+ 
to Fe 
2+
 and 
Cu 
2+
 to Cu,
+ 
which have pro-oxidant effects. 
• Tempol does not inhibit the initial oxidation (possibly the cholesteryl  ester core) of 
control or α-tocopherol-enriched LDL, but inhibits the late oxidation (possibly the 
phospholipid monolayer) with Fe
2+
 and Cu
2+ 
but does not inhibit either the early or 
late oxidation of LDL by Fe
3+
 at pH 4.5. This suggests the chemistry of LDL oxidation by 
Fe 
2+
 and Fe 
3+
 is different. 
• Probucol inhibited the later oxidation of control or α-tocopherol-enriched LDL by 
Fe2+ more effectively than the initial oxidation at pH 4.5. 
 
 226 
• Incubation of human THP-1  macrophages with SMase-LDL or SMase- α-tocopherol-
enriched LDL leads to intralysosomal ceroid generation, which is inhibited by the 
antioxidant probucol. Tempol inhibited ceroid formation with SMase-LDL but not 
with SMase- α-tocopherol-enriched LDL. 
 
 
• α-Tocopherol enrichment of  THP-1 macrophages did not protect the cells from 
apoptosis induced by H2O2. 
 
• Endothelium-dependent relaxation, but not endothelium-independent relaxation, is 
impaired by LDL oxidised by iron at lysosomal pH. Therefore LDL oxidised in 
lysosomes when released from dying cells in an atherosclerotic lesion might 
adversely affect endothelial function.  
 
Recent research has shown that atherosclerosis is not just an unavoidable development of 
advanced age, but also a process with several modifiable factor, such as LDL. Many studies 
suggest that oxidised LDL is a key factor in atherosclerotic disease (Toshima et al., 2000, 
Faviou et al., 2005, Meisinger et al., 2005), but this is a controversial topic.  Some nutrients 
have antioxidant characteristics, which decreases lipid peroxidation and LDL oxidation in 
vitro (Basu et al., 2010). α-Tocopherol is the most plentiful type of vitamin E in plasma, and 
vitamin E might have numerous biological roles, including regulation of cell survival (de 
Nigris et al., 2000). Some research has proposed that all of the biological roles of α-
tocopherol are actually a result of its antioxidant activity (Blum et al., 2008). Long-term α-
tocopherol administration is related to higher proportions of heart failure and 
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hospitalisations for heart failure (Lonn et al., 2005), but there were no significants  effects 
on myocardial infarctions or stroke (Yusuf et al., 2000). No particular mechanism has been 
suggested to clarify these observations on heart failure, however, it  was proposed that α- 
tocopherol may have pro-oxidant properties in vitro models (Bowry et al., 1995, Thomas 
and Stocker, 2000, Miller et al., 2005). The failure of α-tocopherol supplementation to 
decrease cardiovascular disease (Eidelman et al., 2004) and possibly the increased heart 
failure in those with a high risk of cardiovascular events (Lonn et al., 2005), has led some to 
question the importance of oxidised LDL in atherosclerosis.  
This study suggests that LDL enriched with α-tocopherol is a generally valid model to 
describe the molecular events occurring during lipoprotein lipid peroxidation in lysosomes 
of pH about 4.5 with different oxidative stresses. The concentration of iron in some 
lysosomes of rat liver endothelial cells has been reported to be about 16 µΜ (Petrat, 
2002),but very widely depending on the type of cells and size of lysosome. The 
concentration of copper in lysosome is unknown .  α-Tocopherol is probably mainly in the 
surface monolayer of LDL,  as it contains a hydrophilic hydroxcyl group. α-Tocopherol is not 
antioxidant at pH 4.5 (Figure 3.4) with a low concentration (2 µΜ) of FeSO4 while it was 
antioxidant with 5 or 20 µM FeSO4 (Figure 3.5 and 3.6). The classical action of α-tocopherol 
is that of a chain-breaking antioxidant that reflects its capability to respond quickly with the 
chain-propagating lipid peroxyl radical (LOO•).  Alternatively, α-tocopherol may directly 
scavenge the radical that initiates peroxidation.  In both situations, the relatively 
nonreactive α-tocopheroxyl radical is generated. This finding agreed with other studies 
(Hodis et al., 2002, Stampfer et al., 1993, Hodis et al., 1995, Stephens et al., 1996, Yusuf et 
al., 2000), reporting that α-tocopherol appeared  to have pro-oxidant properties with  low 
levels of oxidative stress. This might have counteracted the antioxidant effect of α- 
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tocopherol, resulting in no antioxidant effect. There was no antioxidant effect of α- 
tocopherol on LDL oxidation by any concentration of Fe3+ or Cu2+ at lysosomal pH, but there 
was a good antioxidant effect with Cu2+ at pH7.4. 
  A pro-oxidant effectof α -tocopherol was detected under mild oxidative environments in 
extremely diluted (150-fold) plasma and in isolated LDL (Kontush et al., 1996).  The 
lipoprotein’s concentration of α-tocopherol and the rate of oxidation are an important 
marker to distinguish whether the vitamin exhibits anti- or pro-oxidant activity (Thomas and 
Stocker, 2000). We do not know what the pro-oxidant effects of α -tocopherol at pH 4.5 are, 
but propose that the hydroperoxyl radical converts α -tocopherol to its radical, which then 
attacks lipids. 
α -toc OH  +  HO2•                        α -toc O•   + H2O2 
α -toc O•   +  LH                         α -toc OH  +   L• 
 
The aim of the next part of the study was to evaluate the antioxidant and/or prooxidant 
activities of hydrophilic and lipophilic antioxidants in combination with α- tocopherol, which 
needs to be explored in more detail with a special focus on the nature of the products of 
LDL oxidation when oxidised by different oxidative stresses. 
 Tempol is a stable nitroxide radical that can freely permeate biological membranes and 
protect mammalian cells from oxidative stress (Bonini et al., 2002, Offer et al., 2000). It has 
a substantial preventative outcome related to decreased oxidative damage and stress in 
Atm−/− mice in vivo (Schubert et al., 2004). Tempol protected important organs, such as the 
heart and brain, from ischaemia-reperfusion injury and it has been active in protecting 
numerous aspects of oxidative stress and inflammation that underlie many of the diseases 
associated with ageing like atherosclerosis (Wilcox, 2010). Probucol inhibits LDL oxidation 
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effectively at pH7.4 (Parthasarathy et al., 1986), but did not decrease femoral 
atherosclerosis in patients (Walldius et al., 1994). 
Adding tempol or probucol to control LDL or LDL enriched with α-tocopherol inhibited the 
later oxidation (maybe phospholipids) more than the early oxidation (maybe cholesteryl 
esters) by iron at lysosomal pH. This might be because tempol and probucol, being 
amphipathic reside in the surface phospholipid monolayer of LDL. 
 Studies which test foam cell development by the incubation of macrophages with altered 
monomeric LDL, like oxidised LDL  formed at pH 7.4 do not completely reflect the in vivo 
environment, as the common form of the LDL in atherosclerotic plaques is recognised as an 
aggregated form and bound to subendothelial matrix (Boren et al., 2000). LDL captured by 
extracellular matrix, mainly by proteoglycans, is susceptible to hydrolysis by different 
enzymes such as lipases and proteases. It has been shown that secretory sphingomyelinase 
(SMase), is proficient in aggregating LDL to make it an atherogenic LDL type that is swiftly 
internalized by macrophages (Fenske et al., 2008, Deevska et al., 2009). Here in this study, 
tempol and probucol decreased ceroid formation when it was incubated with THP-1 
macrophages after treatment with SMase -LDL or α-tocopherol-enriched SMase LDL. 
Tempol and probucol reduced ROS formation in the cells when incubated with LDL or α-
tocopherol-enriched LDL  oxidised by Cu2+  at pH 4.5.   Tempol greatly protected 
macrophages against apoptosis induced by H2O2, whereas α-tocopherol treatment of the 
macrophages surprisingly increased cell death, either in the presence or absence of tempol. 
This may possibly relate to α-tocopherol having the ability to prevent cell proliferation in 
cancer cells (Neuzil et al., 2001). 
Previous data caused great interest in the evaluation of antioxidants as potential anti-
atherosclerotic agents. One such antioxidant is probucol. The capability of probucol to 
 230 
protect against atherosclerosis in rabbits was a cornerstone of the oxidative theory of 
atherosclerosis, which proposed that the oxidation of LDL is an early event in, and 
participates in, atherogenesis (Steinberg et al., 1989). Probucol has varied pharmacological 
effects with respect to its therapeutic properties on the cardiovascular systems (Yamashita 
and Matsuzawa, 2009). However,it lowers serum HDL-C and causes QT prolongation (Guo et 
al., 2007). Consequently, probucol was withdrawn in most of the Western countries after 
statins entered the market in 1987 in the USA and in 1989 in Japan.  
Although probucol totally inhibited conjugated diene formation with copper at pH7.4 
(Figure 4.15), it only partially inhibited LDL oxidation by iron at pH 4.5 (figure 4.9, 4.11 
&4.13). This might help to explain why it did not protect against femoral atherosclerosis in 
patients (Walldius et al., 1994). 
Endothelial dysfunction is related to an augmented risk of cardiovascular events and a 
vasoconstrictor reaction to acetylcholine shows the incidence of endothelial dysfunction 
(Ludmer et al., 1986). As the endothelium is the main source of NO in the vasculature, 
damage of usual cellular function might lead to altered eNOS action and NO synthesis. 
Numerous evidence shows that endothelium-dependent vascular relaxation is decreased in 
cholesterol-fed animals (Kojda et al., 1998). Oxidized LDL relocates eNOS from caveolae by 
connection to endothelial cell CD36 receptors and by reducing caveolae cholesterol, leading 
to the interruption of eNOS stimulation (Blair et al., 1999, Feron et al., 1999). Therefore, LDL 
has powerful effects on eNOS,s role in caveolae through activities on both membrane 
cholesterol stability and on the enzyme activity level. OxLDL adversely influences the 
endothelium by inducing the expression of cellular adhesion molecules, stimulating 
apoptosis after long-term exposure, and impairing vasodilatation (Kamiyama et al., 2009, Ou 
et al., 2006). Investigational evidence proposes that oxLDL may modify many signalling 
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pathway, such as PKC, MAPK, SAPK, tyrosine kinases, and the sphingomyelin/ceramide 
pathway, and many transcription factors, namely AP1, NF-κB, and STATs, all of which are 
potentially involved in atherosclerotic development (Auge et al., 2000, Napoli et al., 2000). 
Understanding the mechanisms of the recovery from endothelial dysfunction by 
antioxidants might result in effective therapeutic interventions for the prevention of CHD.  
LDL oxidised in lysosomes of macrophages might be exposed to endothelial cells when the 
macrophages die and their plasma membranes and lysosomal members rupture. Therefore, 
this study examined the effects of LDL oxidised at lysosomal pH on endothelium-dependent 
vasodilatation.     
Rat aortic rings exposed to LDL oxidised by iron ions at lysosomal pH, showed reduce 
relaxation to acetylcholine but not reduced relaxation to sodium nitroprusside. This finding 
agreed with studies with other forms of oxidised LDL (Giardina et al., 2001, Galle et al., 
2003). Iron–oxidised LDL increased reactive oxygen species formation by the aortic rings and 
cultured endothelial cells, which might help to explain the decreased activity of nitric oxide.  
In summary, the data presented in this thesis have identified the potentially atherogenic 
effects of LDL oxidised in lysosomes and the complex effects of various antioxidants on this 
oxidation. 
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7.1 Suggestions for future experiments 
1. Antioxidant targeted to lysosomes could be used to see if they inhibit atherosclerosis 
in LDL-receptor deficient mice or WHHL rabbits. This size of  the atherosclerotic 
lesions could possibly measured using the Vivo micro-ultrasound imaging system. 
2. Different antioxidants, combined or alone would be  evaluated to see if they 
decrease the inhibition of vasodilatation caused by LDL oxidised under lysosomal 
conditions using rat or rabbit aortic rings.  
3. Substances extracted from plants could be used to try to  inhibit LDL oxidation, 
under lysosomal conditions,  measured by spectrophotometry and evaluating 
oxidative products by HPLC. 
4. Antioxidants could  be tested to see if they can reduce apoptosis in cultured cells,  
exposed to LDL oxidised under lysosomal conditions.   
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